Optimisation of immune effector function within the tumour microenvironment by Byrne, William L.
Title Optimisation of immune effector function within the tumour
microenvironment
Author(s) Byrne, William L.
Publication date 2013
Original citation Byrne, W. L. 2013. Optimisation of immune effector function within the
tumour microenvironment. PhD Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2013. William L Byrne
http://creativecommons.org/licenses/by-nc-nd/3.0/
Item downloaded
from
http://hdl.handle.net/10468/1309
Downloaded on 2018-08-23T19:38:57Z
1 
 
 
Ollscoil na hÉireann, Corcaigh 
THE NATIONAL UNIVERSITY OF IRELAND, CORK 
 
Coláiste na hOllscoile,  
Corcaigh 
UNIVERSITY COLLEGE CORK 
 
Cork Cancer Research Centre 
 
 
Optimisation of immune effector function within the tumour 
microenvironment 
 
Thesis presented by 
William L Byrne, BPharm., MPSI 
Under the supervision of 
Dr. Mark Tangney 
for the degree of 
Doctor of Philosophy 
April 2013 
 
 
2 
 
Abstract .................................................................................................................... 7 
Declaration ............................................................................................................... 9 
Acknowledgements ................................................................................................ 10 
Abbreviations ......................................................................................................... 11 
 
Chapter 1: ................................................................................................................... 14 
Literature Review ....................................................................................................... 14 
1.1 Tumour Immune Suppression .......................................................................... 15 
1.1.1 The immune system and cancer ................................................................ 15 
1.1.1.1 The rationale for Immune Therapy of Cancer.................................... 15 
1.1.1.2 Immune Suppression by TRegs ............................................................ 17 
1.1.2 Targeting regulatory T cells for therapy ................................................... 18 
1.1.2.1 Current approaches to TReg modulation .............................................. 18 
1.1.2.2 Novel approaches to TReg modulation ................................................ 24 
1.1.3 Tumour-Associated Macrophages ............................................................ 26 
1.2 RNA interference ............................................................................................. 28 
1.2.1 Background - the promise of RNAi .......................................................... 28 
1.2.2 The endogenous RNAi pathway ............................................................... 29 
1.2.3 Exploiting RNAi ....................................................................................... 30 
1.2.4 Barriers to development of RNAi therapeutics ......................................... 35 
1.2.4.1 Delivery .............................................................................................. 35 
1.2.4.2 Saturation of endogenous pathway .................................................... 36 
1.2.4.3 Off-target effects ................................................................................ 37 
1.2.4.4 Stimulation of immune responses ...................................................... 38 
1.2.5 RNAi mediators as therapeutics ................................................................ 39 
1.3 Microbial gene therapy vectors ........................................................................ 42 
1.3.1 The promise of gene therapy ..................................................................... 42 
   
3 
 
1.3.2 Vector types .............................................................................................. 46 
1.3.2.1 Non-microbial gene delivery.............................................................. 48 
1.3.2.2 Viral gene delivery ............................................................................. 48 
1.3.2.3 Bacterial gene delivery ....................................................................... 51 
1.3.3 Lentivirus as a targeted gene therapy vector ............................................. 52 
1.3.4 Bacteria as a targeted gene therapy vector for cancer ............................... 54 
1.4 Use of optical imaging to progress novel therapeutics to the clinic ................ 56 
1.4.1 The benefits of harnessing optical imaging .............................................. 56 
1.4.2 The physics of optical imaging ................................................................. 58 
1.4.3 The biology of optical imaging ................................................................. 60 
1.4.3.1 Bioluminescent Imaging (BLI) .......................................................... 60 
1.4.3.2 Fluorescence Imaging (FLI) ............................................................... 61 
1.4.4 Use of Optical Imaging in the clinic ......................................................... 64 
1.5 Conclusion ....................................................................................................... 68 
1.6 Bibliography ..................................................................................................... 69 
 
Chapter 2: ................................................................................................................... 91 
Identification of an RNAi mediator against mouse FOXP3 ...................................... 91 
2.1 Abstract ............................................................................................................ 92 
2.2 Introduction ...................................................................................................... 93 
2.3 Study Aim ........................................................................................................ 94 
2.4 Materials & Methods........................................................................................ 95 
2.4.1 Bioinformatics ........................................................................................... 95 
2.4.2 Cloning miR-31 into pAAV-MCS ............................................................ 95 
2.4.3 Cell culture ................................................................................................ 95 
2.4.4 RNAi mediators against mFOXP3 ............................................................ 95 
2.4.5 Co-transfection of plasmids & detection of FOXP3 knockdown ............. 96 
   
4 
 
2.4.6 Validation of miRNA delivery and expression - Detection of mature miR-
31 ........................................................................................................................ 96 
2.4.7 Validation of siRNA delivery (siGLO) ..................................................... 97 
2.4.8 Knockdown of reporter gene (EGFP) ....................................................... 98 
2.4.9 Testing candidate RNAi molecules against mFoxp3 ................................ 98 
2.4.10 Confirmation of the specificity of mimic #2 and mimic #4 .................... 99 
2.4.11 FACS analysis ......................................................................................... 99 
2.4.12 Statistical analysis ................................................................................... 99 
2.5 Results ............................................................................................................ 100 
2.5.1 Bioinformatic validation that miR-31 targets mFoxp3 ........................... 100 
2.5.2 Validation of miR-31 delivery and expression ....................................... 102 
2.5.3 Assessment of miR-31 knockdown of mFOXP3 .................................... 104 
2.5.4 Validation of siRNA delivery ................................................................. 106 
2.5.5 Knockdown of a reporter gene (EGFP) .................................................. 108 
2.5.6 siRNA Knockdown of mFOXP3 ............................................................ 111 
2.5.7 Target-specificity of RNAi mediators against mFOXP3 ........................ 116 
2.6 Discussion ...................................................................................................... 119 
2.7 References ...................................................................................................... 122 
 
Chapter 3: ................................................................................................................. 125 
Lentivirus as a vector for artificial miRNAs ............................................................ 125 
3.1 Abstract .......................................................................................................... 126 
3.2 Introduction .................................................................................................... 127 
3.3 Study Aim ...................................................................................................... 128 
3.4 Materials & Methods...................................................................................... 129 
3.4.1 Design and testing of new SCR siRNA .................................................. 129 
3.4.2 Incorporating siRNA sequences into pre-microRNA cassettes .............. 129 
   
5 
 
3.4.3 Cloning pre-microRNA cassettes and lentiviral vector production ........ 132 
3.4.4 Lentiviral vector experiments on HeLa cells .......................................... 135 
3.4.5 Tumour induction & monitoring ............................................................. 135 
3.4.6 In vivo administration of lentiviral vector ............................................... 135 
3.4.7 Whole animal imaging ............................................................................ 135 
3.4.8 Processing of tumour samples for FACS analysis .................................. 136 
3.4.9 Quantifying TReg infiltration and T cell subsets ...................................... 136 
3.4.10 Analysis of in vivo cytokine profile ...................................................... 137 
3.4.11 Statistical analysis ................................................................................. 138 
3.5 Results ............................................................................................................ 139 
3.5.1 Development of a scrambled siRNA for DNA-based construct ............. 139 
3.5.2 Optimisation of lentiviral vector expression in vitro .............................. 141 
3.5.3 Lentiviral vector-mediated RNAi silencing of mFOXP3 ....................... 146 
3.5.4 Lentiviral vector gene delivery in vivo.................................................... 150 
3.5.5 Determination of the optimal time to target intra-tumoural TRegs ........... 152 
3.5.6 The effect of Lenti miR 4 treatment on tumour cytokine profile ............ 154 
3.5.7 Lenti miR 4 treatment effects on T cell populations ............................... 157 
3.6 Discussion ...................................................................................................... 160 
3.7 References ...................................................................................................... 165 
 
Chapter 4: ................................................................................................................. 168 
Tumour-associated macrophage targeting with a bacterial vector ........................... 168 
4.1 Abstract .......................................................................................................... 169 
4.2 Introduction .................................................................................................... 170 
4.3 Study Aim ...................................................................................................... 171 
4.4 Materials & Methods...................................................................................... 172 
4.4.1 THP-1 cell culture ................................................................................... 172 
   
6 
 
4.4.2 Differentiation of THP-1 monocytes ...................................................... 172 
4.4.3 Generation of bacterial vectors ............................................................... 172 
4.4.4 Preparation of bacteria for in vitro and in vivo gene delivery ................. 173 
4.4.5 Bacterial gene delivery to differentiated THP-1 cells ............................. 173 
4.4.6 Tumour induction and bacterial delivery in vivo .................................... 174 
4.4.7 Monitoring bacteria within a growing tumour ........................................ 174 
4.4.8 Detection of gene delivery ...................................................................... 174 
4.4.9 Assessing cytokine profile ...................................................................... 174 
4.4.10 Monitoring tumour progression ............................................................ 174 
4.4.11 Statistical analysis ................................................................................. 175 
4.5 Results ............................................................................................................ 176 
4.5.1 E. coli MG1655 mediates gene delivery to macrophages in vitro .......... 176 
4.5.2 Analysis of intra-tumoural viable bacterial vector in vivo ...................... 179 
4.5.3 Gene Delivery in vivo.............................................................................. 182 
4.5.4 Influence of in vivo therapeutic gene delivery on intra-tumoural cytokine 
profiles.............................................................................................................. 185 
4.5.5 Influence of in vivo therapeutic gene delivery on tumour growth .......... 189 
4.6 Discussion ...................................................................................................... 191 
4.6 References ...................................................................................................... 198 
 
Chapter 5: ................................................................................................................. 200 
Conclusions and Future Directions .......................................................................... 200 
Abstract publications & poster presentations ....................................................... 204 
 
   
7 
 
Abstract  
 
Cancer represents a leading of cause of death in the developed world, inflicting 
tremendous suffering and plundering billions from health budgets. The traditional 
treatment approaches of surgery, radiotherapy and chemotherapy have achieved little 
in terms of cure for this deadly disease. Instead, life is prolonged for many, with 
dubious quality of life, only for disease to reappear with the inevitable fatal outcome. 
“Blue sky” thinking is required to tackle this disease and improve outcomes. The 
realisation and acceptance of the intrinsic role of the immune system in cancer 
pathogenesis, pathophysiology and treatment represented such a “blue sky” thought. 
Moreover, the embracement of immunotherapy, the concept of targeting immune 
cells rather than the tumour cells themselves, represents a paradigm shift in the 
approach to cancer therapy. 
The harnessing of immunotherapy demands radical and innovative 
therapeutic endeavours – endeavours such as gene and cell therapies and RNA 
interference, which two decades ago existed as mere concepts. This thesis straddles 
the frontiers of fundamental tumour immunobiology and novel therapeutic 
discovery, design and delivery. The work undertaken focused on two distinct 
immune cell populations known to undermine the immune response to cancer – 
suppressive T cells and macrophages. Novel RNAi mediators were designed, 
validated and incorporated into clinically relevant gene therapy vectors – involving a 
traditional lentiviral vector approach, and a novel bacterial vector strategy. 
Chapter 2 deals with the design of novel RNAi mediators against FOXP3 – a 
crucial regulator of the immunosuppressive regulatory T cell population. Two 
mediators were tested and validated. The superior mediator was taken forward as 
part of work in chapter 3. 
Chapter 3 deals with transposing the RNA sequence from chapter 2 into a 
DNA-based construct and subsequent incorporation into a lentiviral-based vector 
system. The lentiviral vector was shown to mediate gene delivery in vitro and 
functional RNAi was achieved against FOXP3. Proof of gene delivery was further 
confirmed in vivo in tumour-bearing animals. 
Chapter 4 focuses on a different immune cell population – tumour-associated 
macrophages. Non-invasive bacteria were explored as a specific means of delivering 
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gene therapy to this phagocytic cell type. Proof of delivery was shown in vitro and in 
vivo. Moreover, in vivo delivery of a gene by this method achieved the desired 
immune response in terms of cytokine profile. 
Overall, the data presented here advance exploration within the field of 
cancer immunotherapy, introduce novel delivery and therapeutic strategies, and 
demonstrate pre-clinically the potential for such novel anti-cancer therapies. 
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1.1 Tumour Immune Suppression 
 
1.1.1 The immune system and cancer 
The immune system and cancer are inextricably linked. Most tumours develop in the 
face of normal immune function and anti-tumour responses of varying strength 
result. A strong immune response against the primary tumour is associated with 
clearance and induced dormancy of metastatic cancer cells, with a resulting 
enhanced prognosis. Conversely, global immune deficiencies secondary to disease or 
therapy are thought to be associated with an increased frequency, earlier recurrence, 
more rapid progression of tumours and poorer prognosis 
1
. Responses to 
chemotherapy and oncolytic virotherapy may in part be immune-determined and 
there is persuasive evidence that an intact immune system, specifically determined 
by CD4
+
 T cells, is required for sustained tumour regression following oncogene 
inactivation therapies 
2
. 
Immune evasion is now considered a hallmark of cancer that results from 
both passive and active tolerising conditions which subvert anti-tumour immune 
responses 
3
. Passive tolerisation may result from down-regulation of MHC Class I 
expression on the tumour cells and/or low antigenicity secondary to immune editing 
and selective cell growth. Other tolerising mechanisms involve inhibition of immune 
cells in the tumour domain by depletion of tryptophan by the enzyme 2, 3 
indoleamine dioxygenase (IDO). Active tolerisation involves suppression of anti-
tumour cell-mediated responses by tumour infiltrating regulatory T cells (TRegs) and 
myeloid derived suppressor cells 
4
.  
Surmounting the immune suppression that exists within solid tumours would 
break the body‟s immune tolerance of the cancer, and, either alone or in combination 
with immuno-stimulatory strategies, improve patient outcomes. 
 
1.1.1.1 The rationale for Immune Therapy of Cancer 
There is renewed optimism that many cancers can be cured or forestalled by 
immune-based therapies, used either alone or as part of multimodal programmes. 
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This originates from an improved understanding of tumour immune interactions and 
the availability of gene, cell and ligand-based technologies which promote effector 
anti-tumour responses. The majority of immune therapy strategies for cancer seek to 
mobilise the adaptive arm of the immune system either directly by manipulating T or 
B lymphocytes or indirectly by undermining suppressive components within the 
immune system. The rational for such strategies derives from the adaptive anti-
tumour immune responses that result. These responses are both tumour antigen-
specific and durable. 
Adaptive anti-tumour immune responses are acquired through the integrated 
intercellular responses of the innate and adaptive immune systems 
5
 (figure 1.1, 
centre). Tumour infiltrating T cells, especially CD8
+ 
cytotoxic T lymphocytes 
(CTLs) and IFNγ-secreting CD4+ (Th1) cells, are central to effective immune 
containment. Adaptive immune responses are initiated when cells of the innate 
immune system (NKT, γδ T, NK and macrophages) are recruited to the tumour 
microenvironment - the continued process of tumour remodelling results in the 
shedding of cancer cells and debris with a consequent induction of inflammatory 
signals. The production of IFN-γ (initially from NK and NKT cells) appears critical 
as it creates a positive feedback loop by inducing some tumour cell death, the further 
activation of NK cells and macrophages and the production of chemokines and 
cytokines which are also tumouricidal and anti-angiogenic. Immature dendritic cells 
(DCs) are activated following uptake of tumour debris/antigens and migrate to the 
regional lymph nodes where they present the tumour antigens to naive T cells, which 
can differentiate into Th1, Th2, Th17 or regulatory T cells (TRegs) depending on the 
cytokine environment. Th1 cells can license DCs to induce tumour-specific CTLs by 
cross presentation of antigen on MHC class I. Antigen-specific CD8
+
 T cells traffic 
to the tumour where cell-mediated killing of tumour cells is augmented by Th1 and 
Th17 derived cytokines.  
However these effector responses can be inhibited by TRegs, and tumour-
associated macrophages (TAMs), induced by or recruited to the growing tumour 
6
. 
This thesis review focuses on these two cell types, TRegs and TAMs, which act as 
mediators of tumour immune suppression. 
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1.1.1.2 Immune Suppression by TRegs 
TRegs are considered to be the most powerful inhibitors of anti-tumour immunity and 
the greatest barrier to successful immunotherapy 
7
. In the early stages of cancer, 
TRegs are concentrated in the tumour mass, resulting in concomitant immunity, 
whereby the primary tumour can progress due to local inhibition of effector immune 
responses, but metastatic cells are eliminated by uninhibited systemic anti-tumour 
immune responses. In advanced stage disease or for poorly immunogenic cancers 
there are increased TRegs systemically and absence of concomitant anti-tumour 
immunity 
8
. While a correlation between increased TReg number and survival, either 
negative or positive, remains equivocal, the ratio of TReg to Teffector cells in the tumour 
mass seems to have greater prognostic significance 
9
.  
There are a number of subtypes of TReg 
9
, including natural CD4
+
 TRegs 
(nTRegs) which originate in the thymus, express CD25, FOXP3, CTLA-4, LAG3 and 
GITR and suppress innate and adaptive immune cells. Induced CD4
+
 TRegs (iTRegs) 
control immune responses to tissue antigens, including tumour antigens and include 
CD4
+
 nTReg-like, Tr1 and Th3 cells that suppress through production of IL-10 and 
TGF-β. The iTRegs develop in the periphery following engagement of the TCR of 
naïve T cells and under the influence of innate IL-10 and TGF-β. Their cell-surface 
markers are often indistinguishable from those of nTRegs and they differ principally in 
their mechanism of suppression. Although less well characterised, there are also 
populations of natural and induced CD8
+
 TRegs. 
While the field is still in its infancy, evidence is emerging that inhibition of 
TRegs may help in tumour containment, especially when combined with appropriate 
immunotherapies that activate effector T cells. Systemic TReg depletion in patients 
induced regression of melanoma metastases 
10
 and in mice when combined with 
immunogene stimulation of intra-tumoural immune effector cells resulted in cure of 
90% of animals who had large and weakly immunogenic sarcomas 
11
. The clinical 
objective will be to provide sustained reduction of TReg function, particularly in the 
tumour environment, allowing enhancement of anti-tumour effector functions and 
with minimal risk of developing systemic autoimmune diseases. 
 
   
18 
 
1.1.2 Targeting regulatory T cells for therapy 
1.1.2.1 Current approaches to TReg modulation 
Regulatory T cell depletion (figure 1.1 A) 
Depletion strategies are not T cell subset-specific but have a selective advantage 
when the TReg accumulation provides functional dominance in the tumour 
environment. TReg depletion strategies have focused on monoclonal antibodies or 
ligand-directed toxins targeted to a TReg cell surface receptor such as CD25 (IL-2 
receptor α chain). Daclizumab and basiliximab are anti-CD25 antibodies which 
invoke cell death by cytokine deprivation (IL-2) and also by triggering antibody-
dependent cell-mediated cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC). Results from an ongoing clinical trial have shown that 
Daclizumab reduces TRegs and thereby enhances cytotoxic T lymphocyte responses to 
tumour antigen induced by vaccination
12
. 
Denileukin diftitox (Ontak
®
) is a fusion protein of human IL-2 and the 
enzymatically active and membrane-translocating domains of diphtheria toxin. After 
binding to CD25 and internalisation, release of the toxin is cytocidal. Clinical data 
on the use of Ontak
® 
for alternative indications has led to its application for CD25 
targeting of TRegs and the emergence of similar CD25-targeted immunotoxins LMB-2 
and RFT5-SMPT-dgA. With one exception, Ontak
®
 depleted TReg numbers, albeit 
transiently, with TReg nadirs persisting for less than 3 weeks 
12
. The TReg elimination 
was mirrored by a concomitant increase in the prevalence of IFN-γ+CD3+ T cells in 
the blood and de novo appearance of melanoma antigen-specific CD8
+
 T cells 
10
. 
However the clinical benefits were modest. Regression of melanoma metastases in 
five out of sixteen patients represents the most promising outcome 
10
. Consistency of 
response is an issue as two patients who developed antigen-specific T cells failed to 
show any tumour regression and another study in melanoma patients failed to yield a 
single objective clinical response 
12
. 
Ontak
® 
is the subject of numerous clinical trials but to date fails to realise its 
clinical promise. Since CD25 is also expressed on activated Teffector cells, Ontak
® 
may also restrain protective anti-tumour immune responses. Ontak
®
 transiently 
depleted various T subsets including tumour antigen-specific CD8
+
 T cells 
10
. Its 
indiscriminate effects on CD4
+
CD25
-
cells are difficult to rationalise. 
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Low-dose oral metronomic cyclophosphamide induced a profound, selective 
reduction in TRegs and restored T and NK cell function in advanced cancer patients 
13
. 
This invoked temporary disease stabilisation in a number of patients without clinical 
improvement. The mechanism underpinning its selective toxicity towards TRegs is 
unexplained. Metronomic cyclophosphamide also has anti-angiogenic and direct 
cytotoxic effects, which contribute to tumour stabilisation or shrinkage. 
Depleting TRegs may have further consequences aside from an unintended 
treatment-mediated elimination of activated Teffector cells 
14
. Their depletion leads to 
an increase in tumour-mediated Teffector to TReg conversion with a diminution in anti-
tumour immune responses. This does not seem to occur with the other TReg 
modulation approaches. 
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Figure 1.1: Targeting regulatory T cells in cancer. The central schematic depicts the main 
events involved in mounting an immune response to a tumour. Cells of both the innate and 
adaptive systems contribute (further details are provided in the text). TRegs offer substantial 
resistance to this immune assault and thus four different approaches for reducing their 
immunosuppressive contribution are advanced (A, B, C and D); depletion, inhibition of 
function, blockade of trafficking and modulation of T cell plasticity. Within each approach 
numerous existing and novel options for therapeutic manipulation are forwarded. Ab – 
antibody; DC – dendritic cell; IDO - indoleamine 2,3-dioxygenase; MDSCs – myeloid-
derived suppressor cells; TReg – regulatory T cell. (From 
15
). 
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Suppression of TReg function (figure 1.1 B) 
Similar to CD25, CTLA-4 is not exclusively expressed on TRegs – it is also found on 
activated CD4
+
 and CD8
+
 T cells 
9
. CTLA-4 inhibits antigen priming of Teffectors by 
competing with CD28 for the costimulation of CD80/CD86 on APCs. Furthermore, 
it induces IDO in DCs 
16
. The consequent depletion of tryptophan and production of 
tryptophan metabolites, such as kynurenines and picolinic acid, inhibit Teffector 
proliferation and function. The anti-CTLA-4 antibodies ipilimumab (MDX-010) and 
tremelimumab (CP-675206) are currently undergoing clinical evaluation. 
Ipilimumab, as monotherapy or in combination with peptide vaccination improved 
survival in patients with previously treated metastatic melanoma 
17
. Tremelimumab 
promotes anti-tumour responses but recently these have been shown to result from 
Teffector activation rather than TReg modulation 
18
. This may also be true of Ipilimumab 
as its clinical mode of action has yet to be fully defined and could be ascribed to 
direct effects on either TRegs, Teffectors or a combination. 
The glucocorticoid-induced TNF receptor (GITR) is constitutively expressed 
on TRegs but also at lower levels on activated Teffectors. Intra-tumoural injection of an 
agonistic antibody to GITR (DTA-1) invoked potent anti-tumour immunity and 
eradicated established tumours in mice 
19
. The exact mechanism by which this 
approach achieves its effects is controversial. One study showed that the benefit of 
DTA-1 was TReg-mediated, facilitated by their selective modulation 
20
. However a 
more recent study suggested Teffector costimulation as the predominant outcome 
21
. 
Regardless of mechanism of action, GITR approaches have yet to recapitulate these 
promising findings in humans. Receptor activator of nuclear factor-kβ (RANK) 
ligand (RANKL) expression on TRegs engages the RANK receptor on cancer cells 
and promotes metastases 
22
. Inhibitors of RANK signalling, such as the anti-RANKL 
antibody denosumab, already used against osteoclastic-mediated bone resorption, 
may block direct TReg-induced metastases of certain cancers. 
Targeting FOXP3, the essential transcription factor of TRegs, by RNA 
interference (RNAi) could also modulate their function. Lentiviral-mediated delivery 
of miR-31 (a negative regulator of FOXP3) to TRegs abolished their suppressor 
capability 
23
. Translation to clinical application is challenging, as miR-31 would 
need to be delivered specifically to TRegs because FOXP3 is also transiently 
expressed on activated human Teffectors. FOXP3 is also expressed (both mRNA and 
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protein) in numerous cancer cell lines 
24
 but the effects of its down-regulation are 
unknown and could even be counterproductive.  
Further options for disrupting TReg function include Toll-like receptor (TLR) 
modulation, OX40 stimulation or interference with the adenosinergic pathway. 
Exposure of TRegs to the TLR8 ligand, poli-G10 abolished their suppressive influence 
on CD8
+
T cells, leading to improved anti-tumour immunity 
25
. More recently a 
synthetic TLR1/TLR2 agonist, an analogue of bacterial lipoprotein, mediated a dose-
dependent tumour regression and a long-lasting protective response against tumour 
rechallenge through a reciprocal down-regulation of TRegs and up-regulation of CTL 
function 
26
. These findings suggest that TLR signalling is a worthwhile pursuit but 
caution is advised as TLR agonists can promote regulatory as well as effector 
responses 
27
. Stimulation of OX40 (a co-stimulatory member of the TNF receptor 
family) inhibits the suppressive function of TRegs in vitro (by down-regulation of 
FOXP3) and abolishes protection against graft-versus-host disease in mice 
14
. The 
paradoxical stimulatory effects on Teffectors make it an enticing target for cancer 
immunotherapy. Another potential target on TRegs is ectonucleotidase activity which 
facilitates local generation of adenosine which has immunosuppressive capability. 
Ectoenzyme inhibitors such as ARL67156 and other modulators of the adenosinergic 
pathway, such as inhibitors of the A2A adenosine receptor, have been shown to 
block TReg-induced immunosuppression 
28
. 
 
Disrupting Tumoural Homing of Regulatory T Cells (figure 1.1 C) 
Chemokine-chemokine receptor and integrin-integrin ligand interactions attract TRegs 
to the tumour, a phenomenon first observed for the CCL22-CCR4 interaction in 
ovarian cancer 
29
. Importantly CCL22 expression was not confined to tumour cells 
but also included bystander cells such as tumour-associated macrophages. Further 
chemokines/integrins have been implicated in the selective recruitment and retention 
of TRegs at tumour sites including CXCR4, CD103 and CCR2 
9
. Because 
chemoattraction is ubiquitous in the immune system efforts to block TReg recruitment 
to the tumour mass may be limited by the concurrent effects on Teffectors. 
Nevertheless, disruption of CCR5/CCL5 signalling blocks TReg migration to tumours 
and inhibits pancreatic tumour growth in mice 
30
. Methyl gallate has also recently 
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been shown to inhibit infiltration of TRegs into tumours resulting in reduced tumour 
growth and prolonged survival rates 
31
.  
Immuno-stimulatory therapies may inadvertently promote tumoural homing 
of TRegs. Therapy with IL-2 can enhance CCR4 expression on TRegs, which stimulates 
their migration to the tumour mass and an up-regulation of CXCR4, the receptor for 
CXCL12, a chemokine linked to development of organ-specific metastases 
9
. These 
findings endorse a more prudent use of IL-2 or perhaps its use in combination with 
agents such as AMD-3100 which antagonise the CXCR4-CXCL12 interaction. 
 
Exploiting T cell plasticity (figure 1.1 D) 
The origins of iTRegs within the tumour microenvironment are diverse as varying 
degrees of plasticity exist within the helper CD4
+
 T cell population (TRegs, Th1, Th2, 
Th17, Tfh) 
32
; Pre-differentiated TRegs may migrate under the influence of 
chemokines 
29
, TRegs may arise from de novo generation via differentiation and 
expansion or may derive from conversion of CD4
+
CD25
-
 T cells. The plasticity 
inherent in each of these processes is a potentially exploitable therapeutic niche.  
IL-6 is central to T cell plasticity 
32
. It helps to convert FOXP3
+
 TRegs into IL-
17 secreting T cells (Th17). It potently abolishes conversion of conventional T cells 
into iTRegs and in its absence no other cytokine can substitute for this inhibition. 
Thus, IL-6 merits further investigation as a therapeutic for cancer. TGF-β acts at the 
axis between TReg and Th17 differentiation, enhancing the function of FOXP3 and 
inhibiting the function of RORγt, their essential transcription factors respectively. 
TGF-β-induced FOXP3 expression is inhibited by proinflammatory cytokines (IL-6 
and IL-21 for example) in a Stat-3-dependent manner. Thus Stat-3 may also 
represent a therapeutic option – indeed forced expression of Stat3 augmented IL-17 
production, most likely through increased RORγt expression 32. Re-directing 
differentiation towards a Th17 phenotype might also be achieved by direct 
introduction of RORγt, as this has been shown to induce IL-17 expression upon 
transduction of naive CD4
+ 
T cells 
32
. Conversely, selective methylation at the 
FOXP3 locus would likely hinder differentiation along a suppressor pathway. Aside 
from the epigenetic level, targeting FOXP3 at the mRNA and protein levels would 
also be worthwhile. Other approaches include antagonists for retinoic acid receptors 
which facilitate differentiation into Th17 cells over TRegs 
32
. TReg differentiation can 
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be redirected towards lineages other than Th17. Specific inactivation of the 
transcription factor interferon regulatory factor 4 (IRF-4) elevates Th2 cytokine 
production while IL-4-driven growth factor independent 1 (Gfi-1) facilitates optimal 
Th2 differentiation 
32
.  
Blocking TReg proliferation is an obvious goal. This can be achieved by either 
direct inhibition of TGF-β, inhibition of indoleamine 2,3-dioxygenase (IDO) directly 
with 1-methyl-D-tryptophan or indirectly by CTLA-4 blockade. Aside from directly 
stimulating TReg expansion, COX-2-derived PGE2 facilitates tolerogenic APC-led 
TReg recruitment and is itself a functional instrument of TRegs in certain tumours 
9
. 
Thus, use of COX-2 inhibitors like celecoxib may be justified. Alternatively, 
bevacizumab or blockade of PD-L1 on TRegs with MDX-1106 (Phase II) may halt 
TReg proliferation.  
Inhibiting the peripheral conversion of CD4
+
CD25
-
 T cells into CD4
+
CD25
+
 
TRegs may be a useful therapeutic approach. The TGF-β-blocking antibody, 1D11 
abolished this conversion and reduced tumour burden in mice. Subsequently other 
TGF-β-modulators including antibodies, soluble TGF-β receptors and the antisense 
oligonucleotide AP-12009 have reached Phase I/ II clinical trials. However systemic 
TGF-β-blockade may carry the risk of developing autoimmune disorders. 
Furthermore, under sub-immunogenic conditions T cell conversion can occur in the 
absence of TGF-β; IL-10 and IDO have also been shown to promote induction of 
TRegs 
9
.  
 
1.1.2.2 Novel approaches to TReg modulation 
The multitude of strategies discussed in this review deliver only marginal efficacy. 
While some strategies have lacked potency the majority flounder on specificity. This 
dearth of specificity is understandable given the intersecting differentiation pathways 
shared by all cells of the T cell lineage. Selective approaches to TReg modulation are 
warranted. Simple depletion of TRegs maybe naive and the benefit short-lived, while 
inhibiting their migration to the tumour ignores the in situ generation of these cells. 
Thus strategies focused on negating TReg function or reprogramming their functional 
phenotype would seem more meritorious.  
A unique cell surface marker which facilitates selective targeting of TRegs has 
yet to be uncovered. Thus targeting CD25 or CTLA-4 has been encumbered by a 
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concomitant effect on Teffectors. Introducing a second layer of specificity, so called 
dual specificity, to receptor targeting would likely be synergistic. This is a strategy 
under investigation in our laboratory whereby a relatively TReg-specific gene therapy 
approach is coupled to ligand selectivity. 
A global TReg modulation is undesirable as it may increase susceptibility to 
autoimmunity. Tumour-TRegs could be targeted via their antigen-specific T cell 
receptors (TCRs); antigen-specific TRegs engaged melanoma-expressed CTAG2 
(Cancer/testis antigen 2) and ARTC1 (Antigen recognised by TReg cells 1) 
33
 and in 
colorectal cancer patients CEA (carcinoembryonic antigen), telomerase, HER2/neu 
(human epidermal growth factor receptor 2) and MUC-1 (mucin 1) reactive TRegs 
were detected in the peripheral blood 
34
. On a practical level this could be achieved 
by harnessing tetramer technology; Saporin-coupled MHC class I tetramers 
specifically ablated IGRP (islet-specific glucose-6-phosphatase catalytic subunit 
related protein)-autoreactive T cells and delayed diabetes in NOD (non-obese 
diabetic) mice 
35
. Identification of CD4
+
 TRegs specific for a given tumour antigen 
would facilitate their targeting with MHC class II tetramers by similar means.  
While such agents would be specific for a given subset of TRegs they would 
also target other CD4+ helper cells expressing the same antigen specificity – CD8+ 
cells would be unaffected. To circumvent this issue the effector component attached 
to the tetramer could be modified to confer another level of specificity. It could be 
miR-31 as 100% of target cells internalise the tetrameric complexes 
35
. Although the 
consequence of FOXP3 knockdown in non-TRegs is unknown TCR engagement in 
these cells may simply lead to activation – further augmenting the immune effector 
response. 
Alternatively one could target tumour-TRegs indirectly by modulating 
dendritic cell activation. This could be achieved by blockade of DC p38 MAPK, 
COX-2 or PI3K which inhibits innate production of TGF-β and IL-10 and thereby 
suppresses induction of TRegs. Such strategies enhance the efficacy of TLR (toll-like 
receptor) agonists or HSPs (heat shock proteins) as immunotherapeutics or adjuvants 
for DC vaccines and permit an un-restrained development of protective Th1 and 
Th17 cells 
27
. 
In conclusion, TReg inhibition in the cancer environment would permit an 
anti-tumour immune effector competency with containment or elimination of 
   
26 
 
disease. Such responses would be tumour specific and durable and should be 
effective against systemic disease, particularly micrometastases. There is clinical 
potential for TReg inhibitory strategies as part of multimodal programmes or 
combined with targeted therapies or local immunogene stimulation of anti-tumour 
immune effector cells. The objective should be to selectively modulate TRegs within 
the tumour microenvironment rather than their global depletion in order to minimize 
the risk of autoimmune manifestations. Strategies targeting TReg function or 
differentiation seem currently to be the best option as they are less susceptible to 
compensatory mechanisms. Emerging technologies such as tetramer or RNA 
interference approaches should improve specificity and efficacy and thus favour the 
preferential inhibition of TRegs within the tumour environment. 
 
 
1.1.3 Tumour-Associated Macrophages 
Macrophages represent innate immune cells with an inherent adaptive component as 
evidenced by a variety of polarised responses 
36,37
. Adaptive responses or 
reprogramming of macrophages occur following exposure to environmental signals 
from microbes, damaged tissues and lymphocytes. The diversity and plasticity of 
macrophages is perhaps most evident in solid tumours 
38
.  
 The different polarised states can be defined by their activation stimuli, their 
phenotype in terms of cytokines/chemokines secreted, and their function 
39,40
. M1 or 
classically activated macrophages, derive from polarisation by bacterial moieties 
such as LPS and the TH1 cytokine IFN-γ. They secrete high levels of IL-12 but low 
IL-10 and express the TH1-attracting CXCL9 and CXCL10. M1 macrophages are 
involved in killing of intracellular pathogens and tumour destruction, but can also 
lead to tissue damage 
38
. In contrast, M2 or alternatively activated macrophages are 
polarised by the TH2 cytokine IL-4 
41
 and secrete low levels of IL-12 with high IL-
10. They express chemokines CCL17, CCL22 and CCL24 
42
. They are involved in 
parasite clearance, tumour progression and have immunoregulatory functions. 
Importantly, the different polarised states do not represent distinct phenotypes, as 
overlapping characteristics exist 
43,44
. M1 and M2 macrophages are probably best 
looked upon as being at opposite ends of a spectrum of functional activation 
45
. 
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 Within the tumour microenvironment, M2-like macrophages generally 
predominate where they play a part in tumour immune evasion 
38,46
. Indeed, for the 
majority of human tumours, increasing TAM numbers negatively correlates with 
prognosis 
47
. They release angiogenic growth factors including IL-8, VEGFA, 
VEGFC and EGF, which support development of a new blood and lymph system for 
the emerging tumour 
48,49
. M2 macrophages also recruit pro-tumourigenic TRegs and 
TH2 cells through expression of chemokines CCL17, CCL22 and CCL24 which are 
chemotactic for these lymphocyte subsets 
37
. They further drive the differentiation of 
CD25
+
GITR
+
FOXP3
+
 TRegs 
50
.  
 The macrophage polarisation state that predominates within the tumour is 
influenced by their interaction with lymphocytes, especially TRegs. While TRegs 
directly undermine anti-tumour immunity (see previous), they also have an indirect 
effect through their manipulation of macrophage plasticity. The interaction between 
TRegs and macrophages is best described as bi-directional as macrophages attract 
TRegs to the tumour (see above) where they are then influenced by the TRegs 
themselves. Human monocytes have been observed to differentiate into M2-like 
macrophages when cultured in the presence of TRegs 
51
, while addition of TRegs to the 
peritoneal cavity of SCID mice polarized the resident macrophages to an M2-like 
phenotype 
52
. Furthermore, TRegs but not effector T cells, have been shown to induce 
B7-H4 expression in a variety of APCs including macrophages 
7
. Significantly, in 
that study, normal macrophages were refractory to stimulation of B7-H4 expression 
while ovarian-TAMs were not. B7-H4
+
 macrophages have been shown to inhibit T-
cell mediated anti-tumour responses 
53-55
. Moreover, TReg-derived IL-10 induces 
expression of the PD-L1 receptor on TAMs, which also inhibits T cell mediated 
immunity 
56
. 
 Based on the evidence presented, efforts to eradicate or re-programme TAMs 
would seem meritorious.  
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1.2 RNA interference 
 
1.2.1 Background - the promise of RNAi 
RNA interference (RNAi) is an evolutionary conserved regulatory mechanism, 
common to most eukaryotic cells, that uses small RNAs to orchestrate homology-
dependent control of gene activity 
57
. Currently, more than 1000 microRNAs 
(miRNAs) have been identified which are thought to regulate expression of greater 
than 30% of human genes 
58
. Given their abundance, it is unsurprising that miRNAs 
play a crucial role in the maintenance of health. As a corollary, one would predict 
that when the RNAi pathway runs awry, through over or under expression of RNAi 
mediators for example, disease would result. Given the regulatory control afforded to 
the RNAi pathway and the potential that this control mechanism is subverted in 
disease, the opportunity for a novel category of RNAi therapeutics is self evident. 
 RNAi-based therapeutics promise many advantages over conventional 
treatment modalities 
59
. Principal among these is the potential to reach all targets, 
including previously “undruggable” targets, since in theory, any transcript that 
encodes a protein linked to a disease can be targeted 
60
. For example, in diseases 
which derive from a single nucleotide polymorphism (often dominant negative 
genetic disorders) it is very challenging to design effective small molecule and 
biological therapies (proteins or antibodies) as there is insufficient structural 
difference between the normal and disease-causing variant. RNAi mediators 
surmount this issue with single nucleotide selectivity. Furthermore, RNAi mediators 
can easily be combined to reach multiple targets simultaneously making them more 
suitable for treatment of polygenic diseases. The time taken from target identification 
to therapy development is comparatively much shorter for RNAi molecules also. 
Often this can result from being able to use a single RNAi drug candidate all the way 
through the development process where the molecule displays cross-species 
reactivity 
61
.  
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1.2.2 The endogenous RNAi pathway 
Endogenous RNAi is mediated by miRNAs and siRNAs which, although distinct 
entities, follow a converging biogenesis pathway (Table 1.1 and figure 1.2). miRNAs 
are embedded in the host genome and transcribed as part of a long primary transcript 
(pri-miRNA) from pol II promoters 
62
. The pri-miRNAs are processed within the 
nucleus to ~70 nucleotide precursor stem-loop RNA (pre-miRNA) by the 
microprocessor complex consisting of Drosha and DGCR8 (DiGeorge syndrome 
critical region gene 8) 
63,64
. Pre-miRNAs are exported to the cytoplasm by exportin-5 
where the stem-loop is removed by the actions of the RNAse III Dicer. The miRNA 
duplexes that result are structurally similar to siRNAs 
65
 and are loaded into the 
RNA-induced silencing complex (RISC). Either strand of the duplex can carry out 
gene silencing, but many miRNAs show asymmetry, whereby one “guide” strand is 
preferred and the passenger strand is then discarded.  
Within RISC, the mature miRNA associates with an Argonaute protein 
family member, of which there are four (AGO 1-4) 
66,67
; the majority of miRNAs 
imperfectly match their target mRNA strand and thus engage with AGO 1. The guide 
strand generally guides the RISC to the 3‟ untranslated region (3‟-UTR) of the target 
mRNA where imperfect complementarity leads to translational repression 
68
, mRNA 
destabilisation or both 
69
.  
In the absence of total complementarity, perfect alignment in the seed region 
(nucleotides 2-8 from the 5‟ end of the miRNA) is seen as crucial to the specificity 
and function of miRNAs 
70
. The guide strand stays within the RISC where it can 
turnover and enable repeated binding and perpetuate the silencing of the target 
mRNA. This leads to long term silencing of the target gene 
71,72
. It is important to 
note that similar to siRNAs, some miRNAs are (near) perfectly complementary and 
bind to AGO 2 where they promote mRNA cleavage (see below) 
73
. 
siRNAs are produced from cleavage of longer dsRNA precursors by the 
direct actions of Dicer. One strand is referred to as the “guide” strand and directs 
silencing. Cleavage of the other, “passenger” strand is necessary to facilitate 
assembly of the guide strand into the AGO 2-containing RISC 
74,75
. Strand selection 
is determined by the thermodynamic properties of the siRNA duplex 
76
. In contrast 
to miRNAs, most siRNAs share 100% complementarity with their target mRNA. 
This permits interaction with AGO 2, the only member of this protein family with 
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cleavage capability 
77
. The end result is cutting of the mRNA strand at position 10-
12 (from the 5‟ end of the guide strand) 78. 
 
Table 1.1: Differences between endogenous miRNA and siRNA 
 
 
1.2.3 Exploiting RNAi 
The natural phenomenon that is RNAi can be exploited to answer fundamental 
biological questions about gene function and also for therapeutic endeavour (figure 
1.2). The three principle approaches are to use siRNA (an RNA-based approach), 
short-hairpin RNA (shRNA) or miRNA (both DNA-based strategies). Their terminal 
mode of action is largely similar but they differ widely in the stage at which they hi-
jack the endogenous pathway, their mode of delivery and duration of activity. In the 
simplest classification, recombinant inhibitory RNAs are designed to mimic primary 
miRNAs (in the case of artificial or exogenous miRNAs) or precursor miRNAs (in 
the case of shRNAs) or the products of Dicer processing (in case of chemically 
synthesised RNA duplexes) 
79
. Each strategy has advantages and disadvantages and 
often the choice of mediator depends on the target gene to be silenced and the 
planned phenotypic alteration.  
Exogenously produced siRNAs were the first approach to exploiting RNAi. 
Synthetic siRNAs of ~21 bp with 2-nt 3‟ overhangs were designed to mimic the 
natural Drosha/Dicer cleavage products 
80
. These siRNAs were mainly designed to 
share perfect complementarity with their target mRNA and thus effect cleavage 
through an interaction with AGO 2. Early approaches focused solely on sequence 
alignments with the target mRNA but subsequent design strategies sought to 
introduce functional asymmetry to the synthesised duplexes. Backbone and terminal 
nucleotide modifications, such as 2‟-O-Me or locked nucleic acids, destabilised the 
5‟-end of the siRNA duplex which favoured loading of the guide strand into the 
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RISC with concomitant destruction of the passenger strand 
81
. Such modifications 
had a number of advantages; they minimised sequence-dependent off-target effects 
by the passenger strand, improved efficacy of the guide strand and increased the 
likelihood of avoiding Toll-like receptor responses 
82
. 
siRNA as an approach to RNAi has two major drawbacks 
83
; 1) delivery: 
Unformulated siRNA molecules do not readily permeate the cell membrane due to 
their negative charge and size. Furthermore these 22 bp duplexes cannot be delivered 
by viral vector delivery systems in their native form. As a result siRNA delivery is 
largely dependent on non-viral gene therapy strategies which to date have lagged 
behind viral vectors in terms of efficiency of delivery. Many researchers have sought 
to encapsulate siRNA molecules in cationic liposomes and polymers which have 
yielded some success in mice 
84,85
 but many lipid based systems are rapidly cleared 
by the liver. Other in vivo delivery strategies have included cholesterol conjugated to 
the siRNA 
86
, antibody-protamine fusions to bind the siRNA 
87
, cyclodextrin-based 
encapsulation 
88
 and aptamers as targeting moieties for the siRNA 
89
. All these 
approaches brought an element of specificity to the delivery but the efficiency 
remained limited. Indeed the first display of siRNA silencing in humans used 
nanoparticles guided by transferrin-receptor ligands to specifically enhance uptake 
by cancer cells 
90
. 
2) short half-life: the chemical nature of siRNA duplexes renders them 
susceptible to degradation by RNase A-type nucleases in serum. Some progress has 
been made in this area whereby RNA backbone modifications such as 2‟F, 2‟O-Me 
and 2‟H substitutions have increased serum stability 82. However even within the cell 
siRNAs are readily degraded and their concentration decreases with every cell 
division leading to a transient silencing effect. Silencing can be as short as three to 
five days for transiently transfected cells in vitro but may be several weeks in non-
dividing cells 
91
. However for both dividing and non-dividing cells in an in vivo 
setting this transient silencing would probably mandate repeated administrations 
which could prove cost-prohibitive. In summary siRNA may be more suitable for in 
vitro proof of principle to verify silencing of a target gene at a sequence level. They 
can readily be introduced to growing cell cultures with various commercial 
transfection reagents where transient silencing is generally sufficient for validation. 
Translation into an in vivo setting seems challenging thus far.  
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shRNAs are DNA-based RNAi triggers that when introduced into cells are 
transcribed as sense and antisense sequences connected by a loop of unpaired 
nucleotides. They are designed to mimic pre-miRNAs. However shRNA transcripts 
often do not reflect the Drosha cleavage products they were designed to mimic 
92
. In 
many instances they lack the 3‟ dinucleotide overhang which impairs their transport 
by exportin 5. The subsequent nuclear accumulation of hairpins can be toxic to cells. 
However a bigger issue with shRNAs has been the RNA polymerase III-based 
promoter systems into which they are incorporated. The U6 promoter has been a 
common choice given its natural function in the generation of small cellular 
transcripts 
93
. These strong Pol III promoters drive massive over-expression and 
saturate the endogenous pathway leading to severe toxicity 
94-96
. The toxicity has 
been shown to correlate with both shRNA expression levels and an accumulation of 
unprocessed shRNAs. Many solutions have been postulated to overcome the 
saturation problem and these are discussed below (Section 1.2.4.2). Of note artificial 
miRNAs do not appear to saturate the endogenous miRNA pathway 
92,95
 and as such 
represent an advancement on shRNAs.  
Artificial microRNAs are also DNA-based triggers of RNAi and are designed 
to mimic pri-miRNAs. In this approach a perfectly complementary siRNA is 
embedded within a miRNA-scaffold derived from an endogenous miRNA. To date 
the best characterised pri-miRNA backbones are based on miR-30 and miR-155 
97
. 
The miRNA mimics that result, are thought to enhance RNAi via more efficient 
interactions with the RNAi processing machinery 
64
. One study demonstrated 
artificial miRNAs to be superior to shRNAs both in vitro and in vivo when knocking 
down the same target gene 
98
. Artificial miRNAs are usually transcribed using a Pol 
II promoter in keeping with the natural promoter for the majority of miRNA genes 
99
. Compatibility with Pol II promoters offers the researcher several well 
characterised inducible systems and tissue specific promoters allowing for greater 
temporal and spatial control of expression.  
Crucially artificial miRNAs appear devoid of the saturating toxicity 
associated with shRNAs. Incorporation of a saturating shRNA into an artificial 
miRNA-30 scaffold attenuated its toxicity and knockdown efficiency was 
maintained 
95
. This can be attributed to the lower steady-state levels of the mature 
antisense RNAs from artificial miRNAs and hence failure to overload the machinery. 
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This theory is supported by competition studies showing that two co-transfected 
shRNAs compete with each other and that shRNAs compete with both artificial and 
endogenous miRNAs 
92,100
. In the same studies no competition was seen between 
two co-transfected artificial miRNAs or between artificial miRNAs and the 
endogenous miRNA pathway. Taken en masse the evidence would suggest that the 
artificial miRNA approach is more suitable as a therapeutic strategy for inducing 
RNAi.  
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Figure 1.2: The endogenous RNAi pathway and opportunities for exploitation. The left 
hand side shows the endogenous origin of mature RNAi mediators from either miRNAs 
embedded in the host genome or siRNAs produced from cleavage of long dsRNA 
precursors. The right hand side shows options for harnessing the endogenous pathway for 
therapeutic endeavour using DNA-based (red) or RNA-based (blue) approaches (From 
71
). 
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1.2.4 Barriers to development of RNAi therapeutics 
1.2.4.1 Delivery 
At its simplest interpretation exploiting RNAi for therapeutic endeavour is another 
form of gene therapy where the goal is to deliver nucleic acids to cells specifically 
and efficiently. Thus it is unsurprising that development of RNAi as a therapy has 
been hampered by a difficulty common to the entire gene therapy field – delivery. A 
wide variety of gene/RNAi delivery strategies are available including non-microbial 
(physical and chemical strategies) and microbial systems such as viral and bacterial 
vectors (reviewed in section 1.3.2). 
RNAi mediators by their nature are difficult to deliver; they are highly 
negatively charged which repels them from the cell surface – this makes the use of 
some type of encapsulation or targeting moiety almost essential. They are also large 
molecular weight molecules – a typical siRNA is greater than 13 kDa for example. 
Given their potency within the cell targeted delivery is paramount. A myriad of 
strategies have been trialled in an effort to enhance efficiency and specificity of 
siRNA delivery (reviewed in 
101
). Proof of principle has been demonstrated for many 
in animal studies but the efficiency is often poor. Furthermore many involved focal 
delivery such as direct injection to the eye or tumour which some may consider 
clinically unworkable.  
That said two studies using siRNA are noteworthy. One group used an 
aptamer targeting the prostate specific membrane antigen receptor to carry an siRNA 
capable of inducing cell death in a xenograft tumour model. They succeeded in 
impeding tumour growth 
89
. A project that has progressed further is now in clinical 
trials for patients with refractory solid tumours, involves cyclodextrin nanoparticles 
coated with transferrin carrying an siRNA selectively to tumour cells 
(www.clinicaltrials.gov). Although proof of principle has been demonstrated for 
siRNA approaches their effect is transient with repeat administrations likely for a 
sustained alteration of disease phenotype. Such dosage schedules, given that oral 
formulations are unlikely in the near future, may be the undoing of the siRNA 
apporoach.  
shRNAs and artificial miRNAs on the other hand have more potential given 
that they are plasmid-based and hence poised to take advantage of the advances in 
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viral vector technology. They hold the promise of bettering the delivery and short 
duration of action of siRNAs. With the appropriate virus the RNAi mediator can 
potentially be stably integrated into the target cell and thus mediate sustained gene 
silencing with a single administration. Viral vectors have a tremendous propensity 
for specificity when combining transductional and transcriptional targeting; 
Transductional targeting can be conferred through capsid or envelope protein 
engineering and pseudotyping whereby foreign proteins from a different virus are 
used to alter the tropism of the core virus carrying the therapeutic gene 
(transductional targeting of lentivirus vectors is reviewed in section 1.3.3). 
Transcriptional targeting involves the use of inducible or tissue-specific promoters 
whereby expression of the therapeutic gene is controlled by exogenously introduced 
agents (e.g. tetracycline antibiotic) or agents unique to the specific target cell/tissue 
respectively. It must be noted however that some concerns remain around the use of 
viruses, particularly surrounding insertional mutagenesis.  
1.2.4.2 Saturation of endogenous pathway 
Excessive delivery and/or over-expression of an RNAi mediator can overload the 
processing machinery with potentially fatal consequences 
94
. Toxicity was shown to 
correlate with vector dose. Such saturation is possible with siRNA and shRNA based 
systems but artificial miRNAs avoid this complication as previously outlined 
(section 1.2.3). An obvious solution to the problem is to transpose the mature RNAi 
sequence from siRNA and shRNA molecules into artificial miRNA scaffolds, which 
has been shown to be effective 
95
.  
 However other potential solutions, particularly for shRNA-mediated 
saturation have been explored (reviewed in 
65
). One could simply lower the dose of 
vector administered – depending on the target disease this may 94 or may not 95 be 
tolerated as this will also reduce the percentage of cells transduced. Alternatively for 
shRNAs, one could substitute a weaker Pol III promoter. The U6 promoter has been 
frequently associated with saturation but changing to the weaker H1 (or 7SK) can be 
acceptable in certain scenarios 
102
. A further option is to drive expression of the 
shRNA with a Pol II promoter but this may not always be successful. Pol II 
promoters often have poorly defined transcriptional start sites. This can be 
problematic downstream as the RNAi machinery needs to engage with the first base 
of the shRNA for correct processing 
103
. A more elaborate method of dealing with 
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the saturation is to concomitantly overexpress the processing proteins with the 
shRNA. Extra copies of Exportin-5 and argonaute proteins have been delivered to 
animals 
104
 but this approach may not be clinically acceptable in the absence of a 
robust cell-specific delivery platform.  
 
1.2.4.3 Off-target effects 
Off-targeting can be defined as the silencing of unintended mRNA sequences. 
Despite the early promise of exquisite specificity associated with RNAi this has not 
been realised at a practical level. Off-targeting was first reported in vitro from 
microarray analysis following siRNA-transfection of HeLa cells 
105
. Indeed a more 
recent in vitro study showed that one third of randomly selected siRNA had an 
unintended negative effect on cell viability 
106
. This highlighted the potential of off-
targeting to invoke cellular toxicity. Off-targeting has also been verified in vivo in a 
mouse model of Huntington‟s disease 107. The consequences of off-target effects are 
potentially very serious as the silencing of any gene by RNAi will undoubtedly have 
knock-on effects on other genes and perturb a complex gene network 
108
. Given that 
many gene networks have yet to be elucidated the cellular phenotype that may 
manifest is largely unpredictable.  
 Off-target effects manifest predominantly from three scenarios; 1) Sequences 
in the mature RNAi mediator are identical to seed regions of an endogenous miRNA 
(nucleotides 2-8 from the 5‟end of the guide strand) 109. The siRNA then partly pairs 
with a weakly complementary sequence in the 3‟UTR region of an unintended 
mRNA. When this happens the siRNA can mimic the actions of the endogenous 
miRNA leading to silencing. Screening out sequences that match human or cross-
species specific miRNA seed sequences using BLAST will minimise this problem. 
Where the RNAi mediator is a chemically-synthesised siRNA addition of an O-
methyl group to the second nucleotide of the guide and passenger strands further 
helps reduce indiscriminate silencing effects 
105
. This option is however not available 
to plasmid-based RNAi induction approaches. 2) Incorrect processing of the RNAi 
mediator such that an altered sequence is loaded into RISC. This represents a less 
common cause of off-targeting but sequencing of the processed product is essential 
to identify the correct mature silencing RNA and spurious RNAs that result from 
cleavage sites moving one or more nucleotides. 
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 3) The incorrect strand of the mature duplex is incorporated into RISC. 
Careful design of the RNAi mediator will improve strand selectively and disfavour 
loading of the passenger strand 
71
. For example introduction of a thermodynamic 
differential between the 5‟ ends of the guide and passenger strands favours loading 
of the strand with the lower pairing energy 
76
. Also deliberate mismatches at 
appropriate sites on the passenger strand will limit its involvement and greatly 
enhance the overall efficiency of gene silencing. When developing an RNAi 
mediator it is important to ascertain which strand is loaded into RISC. A number of 
methods are suitable for this including northern blots, small RNA PCRs and 
luciferase-based reporter plasmids where targets for either the guide or passenger 
strand are placed in the 3‟UTR of the luciferase gene 79. 
 
1.2.4.4 Stimulation of immune responses 
An immune reaction to double-stranded RNA represents an innate mechanism of 
defence against invading viral pathogens. However in the context of siRNA delivery 
for therapeutic gain such immune responses compromise the benefits bestowed 
through harnessing the endogenous RNAi pathway. siRNA molecules stimulate an 
interferon response through interaction with toll-like receptor 3 (TLR 3) on the cell 
surface. This response can be rather easily abrogated by shielding the siRNA with a 
carrier molecule such as a lipid bilayer or cholesterol 
86,110
 
 A bigger issue which may extend to all RNAi mediators including shRNAs 
and artificial miRNAs is the activation of TLR 7 and 8. DNA-based approaches to 
RNAi may not directly engage these receptors as they subtly enter the endogenous 
pathway and mimic naturally occurring miRNAs 
111
. However it is possible that 
following expression and export from the nucleus such mediators may be recognised 
by cytoplasmic pattern recognition receptors which may also trigger an interferon 
response 
112
. Engagement of TLR 7 and 8 has been shown to be sequence-specific 
113,114. GU rich motifs such as 5‟-UGUGU-3‟ or 5‟-GUCCUUCAA-3‟ have been the 
main culprits. An obvious means of preventing interferon responses is to screen out 
mediators bearing such “danger” sequences. Given that for many target mRNAs 
several candidate RNAi sequences are available such exclusion should not offer a 
significant impediment to the development of RNAi therapeutics. Alternatively 
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certain chemical modifications such as inclusion of at least one 2‟-OMe in either 
strand of the siRNA duplex can abrogate the interferon response 
115
. 
 
1.2.5 RNAi mediators as therapeutics 
In spite of the aforementioned barriers to RNAi therapy development RNAi 
molecules have reached clinical trial stage (reviewed in 
116
). However as of yet there 
remains no RNAi mediator on the market, perhaps reflecting the complexity of such 
medicines. As for other therapeutic categories the route from bench to bedside is 
long and arduous. A schematic representation of the RNAi drug design workflow is 
presented below (figure 1.3). 
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Figure 1.3: The steps involved in the rational design of an RNAi therapeutic (From 
59
). 
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As of August 2013 a database search of clinical trials under “RNA interference” 
returns just 5 studies (www.clinicaltrials.gov). “siRNA” as a search term yielded 31 
results, “shRNA” had just 7 results and “miRNA” had 157. Based on this analysis 
several conclusions can be drawn; the high number of “miRNA” trials is misleading 
in this context as the majority of such studies involved miRNA expression profiling 
and/or biomarker discovery. Most did not involve evaluation of a therapeutic 
(artificial) miRNA. Most therapeutic evaluations of RNAi mediators involved 
synthetic siRNA molecules. This can be attributed to their relative ease of design and 
lower cost of production – Indeed one siRNA entity, bevasiranib made it to Phase 3 
trials but was withdrawn due to insufficient efficacy. It is worth noting that most 
trials to date have involved non-viral delivery, often to readily accessible tissues 
such as the eye and solid tumours which can be reached by direct injection and hence 
circumvent the problems attached to systemic delivery. The scarcity of studies 
involving therapeutic use of artificial miRNAs perhaps reflects their more recent 
discovery. Given their enhanced safety features and equal if not superior knockdown 
efficiency over shRNAs (see above) it is likely that future interest may focus more 
on artificial miRNAs. Furthermore recent advances in viral vector technology 
involving specific cellular targeting and improved safety should also propel the field 
of DNA-based RNAi delivery.  
 Some optimism for the future of RNA-based medicines comes from 
Pegaptanib (Macugen
®
) which was licensed for use in the USA in 2004 and Europe 
in 2006. Although its mode of action does not involve RNAi it represents an RNA 
molecule that is successfully and safely delivered to patients. Pegaptanib, an 
aptamer, is a pegylated modified RNA oligonucleotide that binds with high 
specificity and affinity to extracellular Vascular Endothelial Growth Factor 
(VEGF165) inhibiting its activity (www.medicines.ie). Its physicochemical 
characteristics are such that Pegaptanib must be delivered directly to the eye by 
intra-vitreal injection, generally at six week intervals. Pegaptanib is licensed for the 
treatment of age-related macular degeneration – the greatest cause of vision loss in 
elderly patients in the Western world. By selectively inhibiting the “165” isoform of 
VEGF Pegaptanib prevents pathological ocular neovascularisation while sparing 
normal vasculature (www.ema.europa.eu/). 
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1.3 Microbial gene therapy vectors 
1.3.1 The promise of gene therapy 
Despite the advances in modern medicine, even in the developed world there 
remains many diseases for which there is an unmet therapeutic need – diseases for 
which cure is unheard of and palliation is the best on offer as the inevitable 
succumbent to disease approaches. Still for many other diseases, treatment is 
available which prolongs life and may even be curative but few treatments are 
devoid of side effects which impinge upon quality of life. Furthermore, the “one size 
fits all” approach that shrouds the majority of medicines in regular use today, offers 
little regard to the individual intricacies that constitute a person‟s genetic makeup. In 
many instances, this predisposes recipients to potentially fatal idiosyncratic drug 
reactions. The holy grail of disease management is a therapeutic entity which is both 
curative and tailored, but also tolerable to the patient. Existing small molecule 
entities and protein-based therapies (e.g. monoclonal antibodies) deliver huge 
benefits to patients, but many sufferers continue to die prematurely as a result of 
their disease. Thus, novel therapeutic approaches are mandated. Gene therapy 
represents one approach and carries tremendous potential to revolutionise modern 
therapeutics with enormous benefits for patients. 
 At its broadest, “gene therapy” could be defined as the exploitation of genetic 
material for therapeutic endeavour. The term would encompass in vivo and ex vivo 
manipulations of DNA and RNA and the introduction, modification or removal of 
genetic material. Gene therapy represents an umbrella term for a range of different 
strategies. The simplest and most commonly attempted involves gene addition 
whereby a missing or functionally inept protein is supplied. Gene knockdown is also 
routinely attempted in the form of RNA interference whereby DNA encoding 
siRNAs or miRNAs or the RNA molecules themselves are delivered to cells to 
facilitate post-transcriptional gene silencing 
79
. A more novel approach involves 
direct correction of the mutated gene using zinc finger nucleases in conjunction with 
DNA recombination technologies 
117
. Paradoxically, the same approach can be 
employed to create mutations in certain beneficial scenarios. Emerging gene therapy 
strategies include the use of non-coding RNA molecules to alter protein function by 
interfering with splicing – through exon skipping for example 118 or to upregulate 
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gene expression 
119
 or to function as aptamers where they function independently or 
guide other therapeutics to enable selective delivery 
120
. 
 Despite the promise of gene therapy and the enormous amount of research on 
this topic, few gene-based therapeutics are in routine clinical use today. Indeed last 
year (2012) yielded the first licensing of a gene-based therapy in the western world -
EU EMA licensing of Glybera
®
 - an AAV vector engineered to express lipoprotein 
lipase in the muscle 
121
. Previously two gene-based therapies have been licensed for 
use in China; Gendicine
®
 - a recombinant adenovirus carrying the tumour suppressor 
gene p53 was granted approval in 2003 for the treatment of head and neck squamous 
cell carcinoma 
122
 while in 2005 Oncorine
®
 - a type 5 adenovirus defective of the 
E1B-55 kDa molecule was licensed, also for head and neck cancer treatment 
123
.  
The field has suffered some noteworthy setbacks however; in 1999 a clinical 
trial participant died following an adenoviral vector-induced fatal immune response 
124
; the following year apprehension surrounding this novel field was compounded 
with reports that a γ-retroviral vector successfully restored X-SCID patients‟ immune 
systems but also caused leukaemia in several of these patients 
125
. Despite these 
reports gene therapy clinical trials have a good safety record – indeed the above 
mentioned fatal outcome in response to adenovirus represented the first death in 
nearly 400 gene therapy trials involving over 4000 patients 
126
. 
The above notwithstanding, many barriers to successful gene therapy have 
emerged over the years. In the first instance making sufficient quantities of the 
chosen vector (in particular viral vectors) at a realistic cost remains challenging. 
Furthermore, the nature of the diseases being targeted by gene therapy (often rare, 
“orphan” diseases) hampers recruitment of sufficient subjects for clinical trials.  
 This is before one even considers the in vivo concerns of which four 
predominate 
127
 (figure 1.4); 1) Delivery – efficient delivery of the nucleic acid 
therapeutic (although still an issue for many non-viral vectors) is not on its own 
sufficient, as specific delivery is also mandated to avoid off-target effects; 2) Vector 
persistence – depending on the vector used, the transgene will remain episomal or be 
integrated into the host chromosome. Either outcome can be useful depending on the 
turnover kinetics of the target cells and the disease being treated. However 
chromosomal integration at the wrong location carries the added risk of malignant 
transformation while episomal existence may warrant repeat administration which 
   
44 
 
may be precluded by immune responses (see below); 3) Duration of transgene 
expression – depending on the target disease, a continued therapeutic response may 
be required. Often this continuity can be extinguished by epigenetic interference with 
the vector genome; 4) The host immune response – this unwanted reaction can be to 
the vector (although less problematic with non-viral vectors) or to the transgene 
itself. If severe enough, such an immune response can be fatal (see above) or in 
milder cases therapeutic efficiency is lost and/or repeat administration is prohibited.  
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Figure 1.4 Issues to consider for successful gene therapy. Depicted are 4 crucial 
steps faced by a gene therapy vector (either microbial or non-microbial) as it 
attempts to mediate successful delivery and expression of its transgene within the 
target cell population. Further details are provided in the text. CTL, cytotoxic T 
lymphocyte; MHC, major histocompatibility complex; TCR, T cell receptor (From 
127
). 
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1.3.2 Vector types 
A major hurdle in the advancement of gene therapy has proven to be the 
development of a delivery vector that is efficient, non-toxic and has ease of 
application. There are a number of properties that the ideal vector for cancer gene 
therapy should possess; i) it should be amenable to commercial production and 
processing; ii) on delivery, the vector should be capable of sustained expression of 
the genetic material, ideally in a regulatable fashion; iii) the vector should also be 
immunologically inert; iv) a vector that specifically targets certain cells or tissues is 
highly desirable, particularly where the target cells are dispersed throughout the body 
or where the cells are part of a heterogeneous population; v) there should be no 
constraint on the size of the transgene; vi) the vector should be capable of 
transfecting both dividing and non dividing cells 
128,129
. While some of these 
properties exist in various classes of vectors, to date, all of these properties have not 
been found in any one vector. It is feasible that the optimal delivery modality for 
different diseases and anatomical locations and/or tissue types will vary. The 
delivery systems currently being used for gene therapy can be divided into two 
distinct groups- microbial and non- microbial gene delivery systems (Table 1.2). 
Each of these groups has its own advantages and disadvantages, while the key 
element for any vector strategy involves the balance between efficacy and safety. 
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Table 1.2 Gene delivery methods 
Modality Benefits Drawbacks Reference 
Viral High efficiency 
Nuclear entry 
Self delivery 
Systemic 
administration 
suitability 
Safety Concerns  
Anti-vector immune 
response 
130,131
 
Bacterial Self delivery 
Systemic 
administration 
suitability-Targeting 
to tumours 
Cell or gene therapy 
Potential for oral 
delivery 
Immune responses 
Low-medium 
transfection efficiency 
132,133
 
Physical Techniques 
Electroporation 
Sonoporation 
Microinjection 
Particle bombardment 
Laser Irradiation 
Magnetofection 
Site specific 
Safety of plasmid-
based approach 
Limited tissue 
accessibility  
Tissue damage 
Low transfection 
efficiency  
134,135
 
Chemical Techniques 
Cationic polymers, 
peptides, lipids 
(liposomes) aka 
Nanoparticles  
Self delivery 
May have nuclear 
entry 
Systemic  
Safety of plasmid-
based approach 
Low transfection 
efficiency 
136,137
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1.3.2.1 Non-microbial gene delivery  
Non-microbial gene delivery systems normally involve the transfer of genes carried 
on plasmid DNA. Plasmids do not generally replicate in mammalian cells. Plasmid 
DNA is a relatively safe alternative to viral vectors. The toxicity is generally very 
low, and large-scale production is relatively easy. Plasmid delivery systems involve 
the use of chemical or physical means to mediate cellular entry of the plasmid 
molecules. The use of chemical means to carry DNA into cells involves cationic 
polymers, cationic peptides and cationic lipids (liposomes) 
137
. Mechanical or 
physical techniques include the application of energy waves to cells to create 
transient pores in the cell membrane, thereby permitting entry of plasmid without 
killing the cell. Cell „poration‟ systems include electroporation 134,138 and 
sonoporation 
135
. Overall, while the safety profile of non-microbial vectors is 
attractive, the efficiency of current non- microbial approaches is considerably below 
that observed with viral vectors 
139
. 
 
1.3.2.2 Viral gene delivery 
By virtue of their natural life cycle, pathogenic viruses possess an innate ability to 
effectively invade human cells and express their genes within the cell. Gene 
therapists have harnessed the capacity of viruses to package DNA, transfer it to a 
cell, and produce proteins within it. Engineered viral gene delivery systems are 
typically rendered replication deficient by replacing those regions of the virus that 
are essential for viral propagation with the genetic sequence of a therapeutic gene. In 
this way, infectious progeny viruses are not produced from these viral vector 
particles, and hence are no longer pathogenic. Viral vectors have the advantage that 
their efficiency as delivery vehicles has evolved naturally 
131
. The most commonly 
used viral gene transfer systems are derived from adenovirus (Ad), adeno-associated 
virus (AAV), lentivirus, retrovirus, herpes simplex virus (HSV) and semliki forest 
virus (SFV). These can be categorized into integrating and non-integrating vectors. 
In the normal virus life cycle AAV, retrovirus and lentivirus are able to integrate 
their viral genome in to the chromosomal DNA of the host cell. Ad and HSV 
however deliver their genomes to the nucleus of the host cell and remain episomal. 
Vectors derived from adenovirus represent the most widely used class of viral vector 
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for prostate and other cancers, and have shown great promise at clinical trial level 
130,140
. 
 However, several problems exist with current viral gene therapies. In terms 
of practicality of usage, there are associated difficulties in production, size 
restrictions on transgenes in some viral vectors, anti-vector immunological responses 
limit their usage to a single application, while several human cancers are devoid of 
viral receptors and are not transducable by viral vectors 
141-145
. Many viruses are 
toxic and elicit systemic inflammatory reactions – one such immune response was 
fatal following use of an adenoviral vector 
124
.  Although confined to retroviral 
vectors random vector integration (which has resulted in cases of leukaemia
125
) has 
raised safety concerns. It should be noted however that newer, non-integrating 
lentiviral vectors (NILV) do not integrate and are hence devoid of this risk (see 
below) 
143
. While vector promiscuity is also a concern perhaps the greatest 
limitations are the immunogenicity of the vector and the potential for insertional 
mutagenesis. Strategies are under development to overcome these limitations. 
Vector immunogenicity Inactivation of the delivery vector by the same 
immune responses that eliminate wt viruses poses a significant problem. A number 
of approaches have been adopted in order to overcome this limitation. 
Ad vectors have been used extensively in cancer immunotherapy; they are 
easy to propagate enabling high titre viral stocks to be generated; they have a broad 
host range and are capable of infecting both dividing and non-dividing cells 
146,147
; 
they can be manipulated relatively easily to accommodate large DNA cassettes. 
However Ad vectors are the most immunogenic of all the viral vector groups, 
inducing strong cellular and humoural immune responses 
148-150
 and this limitation 
resulted in the first fatality in clinical trials 
124,151
. The humoural response involves 
the secretion of antibodies against the Ad vectors resulting in its elimination whilst 
the cellular immune response involves the activation of cytotoxic T cells, 
macrophages and natural killer cells that result in the destruction of the virally 
infected cells. For this reason, a gutless Ad vector was developed. This vector is 
deprived of nearly all viral genes, retaining only the viral ITRs and packaging signal. 
These vectors are helper dependent, demonstrate less immunogenicity and persist 
longer in animals 
152-154
. The vector exists episomally and does not integrate into the 
host genome, therefore the expression of the transgene has been found to be at best 
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transient 
155
, which depending on the therapeutic strategy, presents an increased 
safety profile, but possibly reduced efficacy. Induction of humoural responses has 
been demonstrated to vary depending on the antigen, the processing and presentation 
of the antigen and the route of administration.  
 Wild-type (wt) viruses can be recognised by the innate immune system 
resulting in antiviral immune responses. Receptors of the innate immune system 
recognize specific molecular patterns that are conserved in viruses but absent in the 
host. In a bid to overcome the innate immune response, „cloaking‟ of the viral vector 
by encapsulating the vector or conjugating a protective substance to the viral capsid 
is under investigation. These approaches have focused mainly on Ad vectors, being 
the most immunogenic of the viral vector systems, but have also been studied for 
AAV vectors 
156
. Strategies for adenoviral vectors include encapsulating the vector 
with cationic liposomes 
157
 or conjugating polyethylene glycol (PEG) onto the viral 
capsid 
158-161
. Croyle et al 
158-160
 have shown that pegylation of both E1-deleted Ad 
and helper dependent Ad resulted in prolonged transgene expression following a 
reduction in cellular immune responses against transduced cells. However re-
administration of these vectors results in a decrease in transgene expression, which 
may be due to an immune response against viral gene products. 
Integration The initial promise of an integrating viral vector for gene 
therapy strategies meant that repeated administration of the vector would no longer 
be required in order to sustain the therapeutic effect. However, the first clinical trial 
using an integrating retroviral vector for the treatment of severe combined immune 
deficiency (SCID) took a tragic turn for the worse when 3 of the patients developed 
leukaemia following the activation of the LMO-2 proto-oncogene following 
integration of the vector 
162-164
. Despite the potential that RV offers for gene therapy 
the problems associated with integration need to be resolved before these vectors can 
again be considered for the treatment of most diseases. Vectors derived from LV 
offer the same efficiency for gene transfer and also integrate randomly, but NILVs 
have been identified which overcome this issue. NILVs were identified as by-
products of integration during wt HIV infection and following transduction with 
other retroviruses 
165-167
. On binding of the wt virus to the cell, the LV genome enters 
the cell where the viral RNA undergoes reverse transcription in the cytoplasm prior 
to nuclear entry. Three forms of lentiviral DNA exist: double stranded linear, circular 
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with a single long terminal repeat (1-LTR) and circular with two LTRs (2-LTR) 
168
. 
The linear form integrates into the host genome, whilst the 1-LTR and 2-LTR exist 
episomally, yet transgenes can be actively transcribed from all three 
169
. Vector 
development has shown that LV vector integration can be blocked by mutating the 
viral integrase while all other functions can be maintained 
170-173
. Integration can also 
be blocked by pharmacological agents, such as diketo acids 
174,175
.  
 
1.3.2.3 Bacterial gene delivery 
Interest in bacterial gene therapy vectors increased following safety concerns over 
viral vectors. While being potentially safer than viral delivery platforms, bacterial 
vectors retain many attributes of a biological agent. They are versatile in that any 
therapeutic encoded by nucleic acid can be delivered. This paves the way for a 
variety of strategies including direct cell killing (e.g. by toxin delivery), anti-
angiogenic therapy and immunotherapy 
176
. Many successful applications of bacteria 
as tumour-specific delivery vectors have emerged, e.g. Salmonella Typhimurium 
delivered mouse GM-CSF and IL-12 to tumours which induced regression in mice 
bearing lewis lung carcinomas 
177
. Like other gene delivery modalities, bacteria can 
also be employed in vaccination strategies, e.g. an attenuated Listeria 
monocytogenes was used to deliver the HPV16 E7 antigen as part of a Phase I 
clinical trial for metastatic cervical cancer. Tumour reduction and prolonged survival 
were achieved 
178
. 
 Bacteria are not without their limitations as gene therapy vectors however. 
Many strains are pathogenic and carry toxins and thus need to be attenuated before 
use as a vector to avoid complications associated with systemic infection. Moreover, 
as vectors for cancer, full penetration of the primary tumour mass and reaching 
distant metastases is not always achievable due to their variable constitution 
179
. The 
transfection process faces additional obstacles in terms of plasmid release from the 
phagolysosome following cellular internalisation of bacteria. The efficiency of this 
release is poor for most species with the exception of Listeria monocytogenes which 
produces listeriolysin O, an enzyme that disrupts the phagolysosomal membrane 
180
. 
Fortunately the hlyA gene which codes for listeriolysin O can be incorporated into 
other bacteria for therapeutic improvement 
181
. Even after release of the plasmid into 
the cytosol, it must still enter the nucleus in order to facilitate transcription of its 
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therapeutic entity. Like other „non-viral‟ or plasmid-based modalities, this step may 
be boosted by incorporation of nuclear localisation sequences on the plasmid itself. 
 These limitations notwithstanding, bacterial mediated gene delivery offers 
many unique advantages which may be highly applicable in appropriate strategies. 
 
1.3.3 Lentivirus as a targeted gene therapy vector 
HIV-based lentiviral vectors represent a promising candidate for gene delivery as 
they are relatively non-immunogenic, capable of transducing both dividing and non-
dividing cells and they maintain long-term transgene expression 
182-184
. Current state-
of-the-art vectors are pseudotyped with the glycoprotein of the vesicular stomatitis 
virus (VSV-G) in an effort to achieve maximal production yield. However such 
pseudotyping mediates non-selective cell entry into virtually any cell type of mouse, 
rat or human origin. Further refinement of such vectors is clearly desirable to 
improve the efficacy and safety of transgene delivery. Ideally, transgene expression 
would be restricted to only the cell type relevant for a particular therapeutic 
application. Strategies to achieve this selectivity include the use of tissue-specific 
promoters and switching off gene expression in irrelevant cells by incorporation of 
target sequences for tissue-specific miRNAs 
185
. However, the preferred approach to 
selectivity would be to limit transgene expression at the step of cell entry using cell-
specific delivery vectors. In light of this several strategies have emerged for 
engineering targeted lentiviral vectors including novel pseudotyping viruses, use of 
adaptors or bridging molecules and the genetic incorporation of cell-specific ligands 
or combination approaches (reviewed in 
186
). Here we review advances in targeted 
lentiviral gene therapy.  
 An early approach by the Chen group involved pseudotyping HIV-1 
lentivirus with the envelope of the Sindbis virus 
187
. By inserting the Fc binding 
domain of protein A (ZZ) into the E2 region of the Sindbis virus, it was possible to 
couple any targeting antibody of choice. By coupling antibodies specific for HLA 
and CD4 a significant enhancement in delivery specificity was achieved in vitro. 
However two limitations exist with this approach; 1) the non-covalent coupling of 
the antibody means that in an in vivo setting the targeting antibody may become 
dislodged by endogenous antibodies in the circulation – this could lead to 
unpredictable and dangerous off-target effects; 2) the requirement for the target 
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cellular receptor to be endocytosed following vector engagement – this is necessary 
in order to activate the membrane fusion function of the Sindbis glycoprotein by low 
pH. Furthermore a residual non-specific tropism for the liver and spleen attributed to 
the ZZ Sindbis glycoprotein was subsequently detected in vivo 
188
. The same 
research team improved upon this promiscuity by identifying a modified ZZ Sindbis 
envelope (designated m168) which was used in conjunction with an anti p-
glycoprotein antibody to successfully retarget lentivirus to metastatic melanoma cells 
following systemic administration 
189
. Alternative approaches that do not involve 
antibodies have also been explored in the Chen lab including insertion of integrin-
targeting peptides into the envelope 
190
 and modification of N-linked glycans in the 
envelope proteins for lectin-mediated targeting 
191
. 
 Wang and Baltimore took a different approach to engineering targeted 
lentiviral particles and developed a system that involved separating the cell 
recognition and fusion functions of the Sindbis glycoprotein. They used the same 
binding-deficient, fusion competent Sindbis glycoprotein as the Chen group (except 
the ZZ domain was replaced with a 10-residue tag sequence) but the targeting 
antibody was incorporated as a distinct molecule on the lentiviral surface. Their first 
report provided proof of concept by displaying receptor-specific delivery via CD20 
to B cells 
192
. They further directed lentivirus specifically towards dendritic cells for 
in vivo immunisation by manipulating the natural tropism of the Sindbis virus– this 
natural tropism relies on the widely distributed heparan sulphate receptor and the 
more restricted expression of DC-SIGN (CD209) which is only found on subsets of 
dendritic cells. By mutating the heparan sulphate binding domain on the Sindbis 
virus glycoprotein transduction was exclusively confined to DC-SIGN-expressing 
cells. This immunisation strategy successfully protected against the emergence of 
nascent tumours and induced regression of established tumours in antigenically-
defined OVA tumour models 
193
.  
 While Wang and colleagues initially relied upon the natural fusogenic 
capability of the Sindbis virus, they later sought to improve this crucial fusion step - 
introduction of mutations in the loop region of the fusogen molecule enhanced 
delivery efficiency 
194
. In a further improvement of their original conceptual paper 
192
 they introduced single chain antibodies (as opposed to their full-sized 
counterparts) as the targeting entities on the lentiviral surface 
195
. The Wang lab has 
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continued to pioneer targeted lentiviral-based platforms culminating in particles 
pseudotyped with a CD4 receptor and fusogenic protein (derived from Sindbis) 
capable of specific delivery to HIV-1 envelope-expressing cells in culture 
196
.  
 The Buchholz lab sought to use a similar pseudotyping strategy to target 
lentiviral particles to cells of choice but employed Measles virus glycoproteins, 
namely haemaglutinin (H) which is responsible for receptor recognition and the 
fusion protein (F). They built upon earlier work which endeavoured to redirect 
Measles virus itself 
197
 – the natural tropism of Measles had been ablated by 
mutations in the H protein 
198
 and a single chain antibody had been fused to its 
ectodomain 
199
. Buchholz and colleagues identified cytoplasmic tail variants of H 
and F with these features which could efficiently pseudotype HIV-1 vector particles 
200
. Proof of concept was demonstrated by incorporation of an anti-CD20 single 
chain antibody – the resultant particles had high target versus non-target cell 
discrimination when added to a mixed cell population. 
 Using Measles over Sindbis glycoproteins should be advantageous in that H 
and F mediate cell entry directly at the cell membrane in a pH-independent manner 
without the requirement for the target receptor to be endocytosed 
201
. The Buchholz 
group advanced Measles-pseudotyped lentiviral delivery into animals where they 
achieved greater than 94% specificity for gene delivery to neurons in the adult 
mouse brain 
202
. This strategy was also successfully adopted for specific gene 
delivery via MHC II to antigen presenting cells with the generation of robust 
immunity 
203
.  
 
1.3.4 Bacteria as a targeted gene therapy vector for cancer 
A preferential growth of bacteria within tumour tissue as distinct from healthy tissue 
has long been recognised 
204
. However, the basis for this selectivity remains to be 
determined with many theories being furthered; the original suggestion that the 
hypoxic nature of solid tumours provides a niche for bacteria 
205
 over-simplifies 
matters. It now appears this phenomenon may be independent of the tumour type and 
the bacterial type (in terms of oxygen requirements). Other factors common to most 
tumours, such as the provision of cancer-derived purine nutrients to promote 
bacterial growth 
206
 and secretion of chemo-attractant molecules (e.g. aspartate, 
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ribose or galactose) 
207
 are now thought to play an important role. It is prudent to 
also consider the contribution of the chaotic and leaky vasculature which 
predominates in the tumour. Indeed the leaky blood vessel theory is supported by 
parallel evidence from wound-healing studies 
208
. The inertia of the immune system 
within the tumour microenvironment has been well espoused previously and this 
clearly fosters a bacteria-friendly sanctuary 
209
. Given their inherent tumour tropism 
it seems a logical extension to seek to use bacteria as selective gene delivery vectors. 
 While capable of delivering any nucleic-acid based therapeutic to tumours 
(section 1.3.2.3), the use of bacteria to deliver prodrug-converting enzymes, so-
called “BDEPT”, represents a particularly interesting strategy. The selective 
localisation of the bacteria within the tumour succeeds in converting a systemically-
applied prodrug into a toxic agent while negating harmful effects to non-tumour 
healthy tissue. Several enzyme/prodrug combinations have been successfully trialled 
using a variety of different strains including cytosine deaminase (CD) with 5-
fluorcytosine, nitroreductase with CB1954 and HSV-thymidine kinase with 
ganciclovir 
179
.  
 To date the majority of bacterial strains chosen as delivery vectors for cancer 
have been invasive with the goal of invading tumour cells and subsequent production 
of tumouricidal toxins or immuno-stimulatory cytokines. The target is the tumour 
cells themselves with cellular entry hinging on the natural properties of the 
bacterium. A novel slant on bacterial gene delivery involves using non-invasive 
strains that are captured by phagocytic cells such as dendritic cells and macrophages. 
This “passive” delivery mechanism recapitulates the normal functioning of the 
immune system as might occur in the context of a bacterial infection for example. 
The concept of directly targeting immune cells represents a paradigm shift in our 
approach to cancer therapy driven largely by advances in our understanding of the 
dynamic interplay that exists between the tumour and the immune system.  
 Overall, bacteria show great, but as yet unfulfilled promise as a gene delivery 
vector for cancer.  
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1.4 Use of optical imaging to progress novel therapeutics to the clinic 
 
1.4.1 The benefits of harnessing optical imaging 
The rationale for the development of novel therapeutics in the form of gene and cell-
based therapies has already been espoused in this review. Such treatment modalities 
are not in routine clinical use, but rather on the cusp of clinical translation. A 
significant impediment to their advancement to the clinic is a paucity of knowledge 
surrounding their in vivo characteristics and an inability to convert promising 
preclinical data into positive patient outcomes. Methodologies to track therapeutics 
and their efficacy/effect in vivo have not kept pace with the design and experimental 
testing of novel therapeutics in vitro. This underdevelopment is acknowledged by the 
call from the NIH Recombinant DNA Advisory Committee (RAC) for improved 
assays to measure transgene expression in cells and tissues 
210
. Existing clinical 
approaches to monitoring of biological therapeutics are unfit for this purpose. These 
involve biopsies and serial specimen sampling, supported by various nucleic acid 
and protein assays. Such approaches are retrospective rather than real-time, as well 
as being invasive and time-consuming, impinging on patients‟ quality of life. Putting 
the impracticality of repeated biopsies to one side, sampling at multiple sites cannot 
accurately track transgene expression kinetics and levels or recapitulate the disease 
phenotype within an entire organ or tissue. Issues arise as to the stability of samples 
and delays between sampling and testing. The nature of gene and cell-based 
therapies is such that real-time and continuous monitoring is necessary as transgene 
expression, and hence therapeutic response, can fluctuate according to design (e.g. 
with regulatable promoters) and physiological conditions. Furthermore, traditional 
approaches generally require a terminal assay to macroscopically assess an organ of 
interest – an option which is rarely clinically appropriate. Thus, novel, innovative 
monitoring strategies are mandated. 
 The benefits promised by superior monitoring technologies are far reaching. 
In many instances, gene and cell-based therapies are experimentally tested in a small 
cohort of patients, whereby appropriate monitoring can lead to i) optimisation of 
route and timing of administration, ii) determine whether repeat administration is 
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warranted or safe and iii) provoke manipulation of pharmacokinetic and 
pharmacodynamic properties of the therapeutic. The more powerful the monitoring 
technology, the more information can be gleaned from a small number of subjects. 
Appropriate monitoring is paramount to facilitate a continuum in the drug discovery 
pathway as minor tweaks in formulation and utilisation take place iteratively from 
bench to bedside and back to bench again. Data generated from improved monitoring 
shortens time-to-market for these medicines which can be life-prolonging or even 
curative 
211
. 
 Optical imaging (OI) has been at the forefront of preclinical testing of 
therapeutics in this field, but has struggled somewhat in terms of clinical utility. It 
does, however, promise many benefits over other imaging modalities. Firstly, in the 
pre-clinical setting, utilisation of OI is facile and inexpensive while being amenable 
to high-throughput work, whereby multiple subjects can be imaged simultaneously 
212
. In terms of safety and costs for clinical translation, no radiation is required and 
single cell sensitivity can be achieved at a low cost level 
213
. That said, OI is not 
without its limitations; as a result of light scattering and absorption, OI is difficult to 
directly quantify, the resolution for whole body imaging is inferior to Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI), but with a higher 
resolution at depths of 0-1.0 cm and the penetration depth of imaging is still 
somewhat limited to max 1.5 cm compared with CT, MRI and Positron Emission 
Tomography (PET), although novel developments like optoacoustics might 
outperform current reflectance based optical imaging modalities 
214
. These barriers to 
clinical translation are slowly being overcome and many impressive examples of OI-
driven advancement of novel therapies exist (see below). Novel combination 
approaches involving OI such as photoacoustic imaging partially overcome the depth 
limitations associated with more traditional approaches (bioluminescent and 
fluorescent imaging) facilitating imaging up to several centimeters of tissue in 
patients 
215
. The attributes of rival and often complementary technologies such as 
PET, CT and MRI-based imaging are reviewed elsewhere 
216,217
. Section 1.4 
highlights the use of OI strategies in the clinical arena. A detailed review of how OI 
has advanced early stage and pre-clinical drug discovery is beyond the scope of this 
thesis – the interested reader is referred to 218. 
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1.4.2 The physics of optical imaging 
As a functional imaging modality, OI serves a similar role to PET imaging in its 
ability to track and monitor biological activity in vivo. OI involves detecting visible 
wavelength light emitted from biomarkers; Bioluminescence imaging (BLI) hinges 
on the liberation of light energy by a reporter luciferase gene which oxidises a 
substrate in an energy-dependent (ATP or FMNH2) manner 
219
. Fluorescence 
imaging (FLI) is based on excitation of a fluorophore (generally a protein or 
chemical dye) using an external light source. However, unlike PET scans in which 
the high energy gamma-ray photons emanating from the site of the radio-labelled 
probe traverse tissue essentially unencumbered before reaching the imaging 
detectors, the visible wavelength photons of OI are at much lower energies and are 
subject to scatter and absorption in the tissue.  
While photon scatter by tissue structures such as mitochondria and cell nuclei 
can be of large angle, the scattering is primarily in the forward direction.  Eventually 
the multiple scattering events cause the photon direction to become randomized. For 
weakly anisotropic media such as tissue, the distance at which the directional 
distribution becomes approximately isotropic is 1/s for visible wavelengths, where 
s is the reduced scattering coefficient. Absorption of photons by endogenous 
chromophores in tissue, such as oxy- and deoxy-hemoglobin, water, melanin and fat 
can also be problematic. Fortunately, the discovery of the near infra-red window 
(600-900 nm) negates this problem as absorption by these physiologically abundant 
molecules is reduced to the minimum at such wavelengths 
220,221
. The photon 
absorption length, 1/a, refers to the distance at which the number of photons has 
dropped to ~1/e due to absorption, where e refers to the mathematical constant.  The 
fraction of the photons which can eventually reach the imaging subject surface is 
dependent on these tissue optical properties, s and a, and the distance to the 
surface 
222
. 
The light intensity that reaches the surface is usually below the ambient light 
necessary to visualize the imaging subject. This is particularly true for in vivo 
bioluminescence imaging.  In order to detect the light which originates from the 
luminescent biomarker, the in vivo OI instrument for small animals typically consists 
of a light-tight dark box mounted with a charge coupled device (CCD) camera, 
cooled to prevent thermal electronic noise from dominating the signal 
223
. CCDs with 
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high quantum efficiency of photon conversion to electronic signal are especially 
advantageous for optical imaging of these types of reporters in vivo. The dark box is 
also useful for fluorescence imaging of weak or deep fluorophores.  However, 
fluorophore brightness is also dependent on the excitation source power density, and 
therefore for superficially located fluorophores that have a sufficiently high quantum 
yield, and use of proper filtering methods, fluorophore detection can be achieved in 
the presence of ambient light.    
 Two-dimensional optical imaging involves collection of the light emission 
from the animal surface onto the pixel array of the CCD chip, allowing for 
immediate interpretation of the image data for gross biomarker localization and 
concentration. Although a greater issue when imaging deeper tissues multiple 
scattering and absorption of the photons can lead to a diffuse pattern of emission. 
This makes it difficult to determine the origination location of the emitted light as the 
emission pattern at the surface appears diffuse and unfocused. This explains why 
optical images, typically rendered in pseudocolour, will appear in broad patterns for 
deep sources and narrow peaks for shallow sources. When imaged longitudinally, 
efficacy of therapeutics or disease progression can be inferred from temporal 
decrease or increase in detected signal intensity.  
However, the signal intensity at the animal surface is dependent on the 
underlying thickness of tissue through which the photons must travel, and therefore 
is dependent on the luminescent biomarker source depth. Conclusions drawn from 
two-dimensional OI longitudinal studies rest on the assumption that luminescent 
biomarker depths in tissue are invariable throughout the time frame of the study. The 
attenuation of the light signal which tissue mass imposes can be excluded from the 
measurement of source strength by modelling the light propagation through the 
tissue. Photon propagation in tissue can be modelled by stochastic methods which 
consider the probability of photon scatter, scattering angle, and absorption for each 
incremental step of the photon path 
224,225
. Other methods include solving the 
radiative transport equation for a finite element mesh representation of the tissue 
volume 
226,227
. Finally, the photon fluence rate can be approximated by the diffusion 
equation for tissue in which s>>a, and given specific boundary conditions; 
expressions which relate the source strength to surface signal can be analytically 
derived 
228
. 
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With the ability to model the photon propagation in the animal body, the 
unaltered source strength and location can be established in three-dimensions with 
numerical techniques which aim to minimize the difference between the simulated 
data and the measured signal at the animal surface 
229
. In order to accomplish this, 
the animal surface should be defined for appropriate treatment of the boundary 
between tissue and air. Animal surfaces have been approximated as slabs, where the 
animal is placed into a chamber giving it a bulk slab shape. Animal surfaces have 
been more accurately measured with structured light methods 
230
, silhouette back-
projection methods 
231
, or segmentation of CT images 
232
.  
Resolution in 3D optical imaging is largely limited by the tissue optic 
properties and the wavelength band used for detection 
233
. Prudent selection of data 
is important to minimise the effect of unknown parameters on the overall imaging 
success. In bioluminescent 3D imaging, acquiring image data at discrete spectral 
bands over a wider bandpass which encompasses strong changes in optical properties 
is advantageous for resolution 
230,234
. In fluorescence 3D imaging, in addition to 
relevant wavelengths, the selection of excitation light irradiance pattern on the 
animal surface can be crucial for resolution 
235
 (see below). 
 
1.4.3 The biology of optical imaging 
Targeted OI has only very recently had its first clinical application (see below). 
Thus, most arguments endorsing OI are based on pre-clinical evaluations with novel 
therapeutics. The improvements in technology and labelling required to make OI a 
routine companion for novel therapeutic translation and utilisation are also 
predominantly pre-clinically based. The vast majority of OI encompasses 
exploitation of visible light from two different phenomena; bioluminescence and 
fluorescence. 
 
1.4.3.1 Bioluminescent Imaging (BLI) 
Bioluminescence hinges on the liberation of light energy by a reporter luciferase 
gene which oxidises a substrate in an energy-dependent (ATP or FMNH2) manner 
219
. Importantly, no external light source is required for the reaction. Various 
luciferase genes have been trialled, including firefly (Fluc), Click Beetle (CBluc), 
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Renilla (Rluc), Gaussia (Gluc) and the bacterial luciferase gene cassette/operon (lux) 
236-238
. Of these, Fluc is the most widely used. The oxidation of D-Luciferin by Fluc 
or CBluc is exemplified below; 
 
 
 
Although not yet licensed for human use, D-luciferin has not exhibited toxicity in 
pre-clinical animal studies. Its small molecular size makes it an ideal in vivo reporter 
substrate with the capability to penetrate many anatomical barriers, including the 
placenta and blood-brain-barrier 
239
. 
 BLI has been explored as an imaging modality for many types of gene and 
cell therapies in a variety of disease settings (reviewed in 
212
) – a testament to its 
broad appeal. BLI is routinely used pre-clinically as an initial screening methodology 
to assess the delivery capacity and in vivo dissemination of novel gene therapy 
vectors, including cellular therapies 
240,241
. It represents an efficient and affordable 
technology for most laboratories, as the required instrumentation and consumables 
are relatively inexpensive, the imaging methodology is easy to learn, and 
interpretation of the data requires little technical expertise BLI generally reflects the 
product of both delivery and expression of the transgene. In this context, BLI is well 
suited to optimising both the transduction/transfection 
242
 and 
transcription/translation 
243
 steps involved in therapeutic development. By improving 
the efficiency of these steps, BLI is enabling novel therapeutics to reach patients and 
improve outcomes. 
 
1.4.3.2 Fluorescence Imaging (FLI) 
Fluorescence imaging (FLI) is based on excitation of a fluorophore (generally a 
protein or chemical dye) using an external light source. As the excited electron in the 
fluorophore transitions to a lower state, light of a different wavelength (fluorescence) 
is emitted and can be detected. When deciding on a fluorophore, many 
characteristics must be considered such as the suitability of the excitation and 
emission wavelengths, photostability, brightness, and maturation speed 
244,245
.  
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Fluorescent proteins The original and perhaps the most commonly utilised 
fluorescent probe to date is the green fluorescent protein (GFP) derived from the 
jellyfish Aequorea Victoria. Technical issues quickly emerged with GFP use, 
however, as spectral wavelengths in the green range have limited penetration in vivo 
(1–5 mm in mammalian tissues for example) 246. This issue inspired the development 
of a range of optimised and stabilised mutants of this gene emitting blue, cyan or 
yellow light. Moreover, novel sources of fluorescent proteins emitting light at the 
other end of the spectrum (orange, red and far-red) emerged 
247
. With such a diverse 
collection of fluorescent proteins (each with unique emission wavelengths) available, 
the modern researcher is capable of simultaneously monitoring multiple targets. 
 A further issue with GFP is autofluorescence whereby molecules such as 
flavins, lipofuscin, NAPDH, collagens and elastins of connective tissues and the 
animal's food also fluoresce following application of an external light source. This 
confuses the output data. Autofluorescence undermines the signal-to-noise ratio with 
resultant poor quality imaging
248
. Moving to the far-red and near-infrared spectrum 
promises to ameliorate both the tissue penetration and autofluorescence limitations. 
Proteins that emit at longer wavelengths such as the DsRed derivative, mCherry and 
tdTomato, derived from Discosomastriata, are desirable as red light penetrates 
tissues more efficiently than green 
249
. Further refinements geared towards in vivo 
imaging include the brighter mKate2 
247
 and further red-shifted iRFP 
250
. Indeed, the 
use of iterated somatic hyper-mutation to optimise monomeric red fluorescent 
proteins may advance FLI to the clinic 
251
. 
Fluorescent dyes and Quantum dots Alternative options to fluorescent 
proteins include fluorescent dyes and quantum dots. Fluorescent dyes can be 
categorised as non-targeted or targeted probes 
213
. Non-targeted probes are generally 
more amenable to tracking cellular therapies as they bind indiscriminately to the 
cellular membrane (phospholipid bilayer) when added to cells in suspension – 
efficacy has been demonstrated both in vitro and in vivo in conjunction with OI 
252
. 
Targeted probes can be subdivided into simple targeting probes, cross-linking probes 
and enzyme-activatable, so-called “smart” probes. Targeted probes are more 
selective with fluorescence emanating only from defined cell populations that carry a 
specific functionality. Consequentially many targeted probes have derived from 
diagnostic endeavours 
253
. 
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 Various inorganic and organic fluorophores for have been developed. 
Wavelength, quantum yield, photo- bleaching resistance, aggregation, stability, cell 
penetration, biocompatibility and toxicity are important criteria to consider. 
Quantum dots (QD) are robust, exhibit a large stokes shift and can emit at tuneable 
wavelengths. They are composed of fluorescent semiconductor cores (Au, Cd, Zn) 
embedded within an outer coating that defines their surface chemistry 
254
. QDs offer 
many advantages over fluorescent proteins and dyes; autofluorescence is less of a 
concern and they permit greater sensitivity enabling single molecule detection. Due 
to their continuous broad absorption spectrum, multiplexing is possible whereby a 
single light source can be used to track multiple QDs 
255,256
. Photobleaching is less 
problematic which gives rise to enhanced stability – QDs can remain fluorescent in 
vivo for months
257
. QDs are not without concerns however, particularly in terms of: 
1) cytotoxicity as their heavy metal cores can oxidize and 2) tissue absorption of the 
excitation light which reduces the detectable fluorescence. An elegant solution to this 
latter issue has recently emerged however. It involves the use of “self-illuminating” 
QDs whereby the light source to excite the QD is in situ in the form of Renilla 
luciferase 
258
. To offset toxicity, Li et al have recently produced photostable 
fluorescent organic dots with aggregation induced emission 
259
. These dots contain a 
propeller shaped dye, non-emissive in solution, but highly fluorescent upon 
aggregation. When conjugated to the TAT cell penetration peptide, C6 tumour cells 
could be traced for 21 days in vivo. 
 While QDs may well be superior to fluorescent proteins and dyes, the poor 
signal-to-noise ratio remains the Achilles tendon of FLI, particularly in deeper tissue 
as the emergent signal fades. However plans are apace to overcome this limitation; 
the advent of “spectral unmixing” enables detection of separate wavelengths from 
different sources and thus minimisesautofluorescence 
260
. Moreover newer imaging 
approaches such as fluorescence-mediated tomography make deep tissue imaging 
more plausible 
261
. This uses fluorophores to create a volumetric model of an organ 
through reconstruction of multiple images formed from light transmitted through and 
scattered from the organ. While still in its infancy this approach shows promise in 
many contexts 
262
. 
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1.4.4 Use of Optical Imaging in the clinic 
While the use of OI to advance novel therapies to the clinic has largely focused on 
pre-clinical work, robust examples of the use of OI in the clinical setting have 
emerged (figure 1.5). A multitude of studies have reported on the use of 
fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) for resection of 
malignant gliomas (reviewed in 
263
). 5-ALA is a non-fluorescent prodrug that 
facilitates the accumulation of fluorescent porphyrins within malignant glioma cells. 
While 5-ALA had been granted orphan drug status as far back as 2002 it was not 
until 2007, when the positive results of a Phase III clinical trial emerged, that it was 
granted full authorisation under the tradename Gliolan
®
. This pivotal trial showed 
that complete resection of tumour was much more readily achievable with 5-ALA 
versus white light 
264
. Furthermore 6-month progression free survival was 
significantly enhanced in the 5-ALA cohort (41% versus 21%). 
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Figure 1.5: Fluorescence imaging from patient to surgeon to pathologist. After detection 
of a tumour with conventional imaging a biopsy of the tumour is taken. Expression of 
tumour-specific targets for molecular imaging can be determined by immunohistochemistry 
on the biopsy. Since targeted fluorescence tracers can have a long tissue stability without 
bleaching (simulated in this figure), the same tracer can be used for preoperative, 
intraoperative as well as postoperative localization of tumour cells, ranging from macro- to 
microscopic investigation of the tumour process. After formaldehyde tissue fixation the 
targeted fluorescent tracer is still visible for the pathologist for validation of pre- and intra-
operative fluorescence imaging.  
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Troyan et al. undertook a first-in-human clinical trial using the FLARE 
intraoperative near-infrared (NIR) fluorescence imaging system 
265
. This represented 
a significant advancement on previous studies which had used the same NIR 
fluorophore (indocyanine green) 
266-271
 as it permitted simultaneous visualisation of 
the surgical anatomy and used an improved fluorophore formulation. In the context 
of the underlying goal, to map sentinel lymph nodes in breast cancer patients, NIR 
fluorescence imaging was comparable to the current standard of care, 
99m
Tc- 
lymphoscintigraphy. Following intra-tumoural injection of indocyanine green 
dissolved in human serum albumin no adverse effects were observed. This OI 
approach paves the way for greater clarity surrounding sentinel lymph node 
detection while avoiding use of ionising radiation. 
 Van Dam et al. employed intra-operative tumour-specific fluorescence 
imaging whereby a folate-FITC conjugate molecule was used to target folate-
receptor-α which is over-expressed in epithelial ovarian cancer 272. OI produced 
superior outcomes in terms of detection of tumour deposits with surgeons identifying 
a median of 34 deposits using fluorescence in contrast to a median of just 7 deposits 
by standard visual observation. In this context OI paves the way for enhanced 
surgical debulking and more accurate staging of disease with subsequent better 
patient outcomes. The intra-operative fluorescence imaging was consistent with ex 
vivo analysis of tissue sections. This study provides an important proof of principle 
regarding the monitoring of therapeutic interventions in humans. Not alone can 
surgical interventions be monitored, this identical approach lends itself to assessing 
efficacy of other therapeutic modalities such as chemotherapy and molecular based 
therapies. Furthermore by targeting different cellular receptors with a similarly 
designed ligand-fluorophore combination OI could be used to follow interventions in 
other cancer types and indeed other disease settings. Moreover the versatile and non-
invasive nature of this approach could permit labelling of therapeutic entities such as 
monoclonal antibodies directly with FITC or similar molecules. This would provide 
invaluable data surrounding in vivo pharmacokinetics and pharmacodynamics and 
pave the way for iterative optimisation of such novel therapeutics.  
In summary, OI has made a significant contribution to the advancement of 
novel therapeutics to the clinic. While both FLI and BLI are forms of optical 
imaging, the potential to translate these techniques (and the therapies they support) 
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to the clinic differs. FLI certainly has a place in advancing novel therapies to the 
clinic, but perhaps more in the pre-clinical stage as high background levels and poor 
tissue penetration of both input and output light sources restrict efficacy in vivo. In 
contrast, autoluminescence is almost nonexistent for BLI approaches leading to 
superior sensitivity. As few as 1-100 FLuc2–expressing cells can be detected in vivo 
whereas a minimum of 10,000 fluorescent cells are required 
273
. Nevertheless, the 
need to genetically encode the bioluminescent source certainly hinders translation 
into the clinic. On the other hand FLI is substrate independent, a major advantage in 
the context of potential for clinical translation. Limitations aside, given the pace of 
advancements in the field, FLI could yet overtake BLI en route to the clinic.  
The use of OI as an aid to surgical intervention continues to grow with the 
promise of greater acceptance and embracement of this non-invasive monitoring 
modality in clinical circles. Perpetual improvements in optical contrast agents 
paralleled with innovations in imaging technologies pave the way for the widespread 
utilisation of OI in the clinical drug discovery process. Indeed the possibility of 
harnessing OI to titrate the dose of novel gene and cell therapies safely and in real 
time in patients is no longer an intangible goal. 
 
 
1.5 Conclusion 
This thesis review explores the interaction between the immune system and cancer. 
A focus is placed primarily on two suppressive immune cell types - TRegs and TAMs 
that undermine anti-tumour immunity and the rationale for targeting these cells in 
cancer is outlined. The merits of a novel, emerging therapeutic modality (RNAi) are 
discussed and the potential use of viral and bacterial gene therapy vectors in cancer 
is highlighted. Finally the potential role of optical imaging in advancing 
revolutionary novel therapies to the clinic is explored. Throughout the review future 
developments are hypothesised upon and clinical translatability is emphasised.  
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Identification of an RNAi mediator against 
mouse FOXP3 
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2.1 Abstract 
RNAi is a useful experimental tool on the cusp of clinical translation into a new 
therapeutic modality. RNAi-based therapeutics have the potential to improve on 
existing small molecule and antibody/protein-based therapeutics, for various 
strategies, including tumour immunotherapy. TRegs are recognised as the predominant 
cell mediating suppression of anti-tumour immunity, and mouse FOXP3 (mFOXP3) 
has been identified as a central target for their manipulation in the mouse. In this 
chapter, mFOXP3 was targeted by RNAi with the long term goal of abrogating the 
suppressive contribution of TRegs within the tumour microenvironment and enhancing 
anti-tumour immunity.  
An in vitro mFOXP3 expression assay was developed and optimised. 
Examination of an endogenous miRNA (miR-31), which was previously shown to 
knockdown expression of the human version of this gene, failed to knockdown 
mFOXP3 expression. Attention was then focused on the design and validation of a 
novel RNAi mediator against mFOXP3. Various candidate RNAi mediators were 
designed and tested, and two candidates confirmed to significantly silence mFOXP3. 
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2.2 Introduction 
TRegs are considered the most powerful inhibitors of anti-tumour immunity and the 
greatest barrier to successful immunotherapy 
1
.The primary goal of this project was 
to abrogate the suppression of anti-tumour immunity mediated by TRegs. Various 
strategies exist for TReg modulation 
2
. Simple TReg ablation strategies have been 
shown to be ineffective as TReg numbers are quickly replenished by conversion of 
effector CD4
+
 cells 
3
. Thus a therapeutic modality which does not destroy this subset 
but rather induces a functional dormancy while leaving the cells in situ is desirable. 
RNA interference fulfils these criteria. 
RNAi has been previously explored as a method to manipulate TRegs (both 
mouse and human) via a variety of targets. Silencing of tumour necrosis factor-α 
induced protein 8 like-2 (TNFAIP8L2, TIPE2) in naturally occurring TRegs isolated 
from murine spleens led to downregulation of FOXP3 and CTLA-4 as well as a 
reduction in secreted cytokines (TGF-β and IL-10)4. Subsequently, T-cell 
proliferation and differentiation were boosted. Elsewhere, silencing of Eos in TRegs 
abrogated their ability to suppress immune responses and endowed them with partial 
effector function 
5
. Eos, a zinc-finger transcription factor, was found to interact 
directly with FOXP3, inducing chromatin modifications that result in gene silencing 
in TRegs and leading to their suppressive phenotype. 
FOXP3 has been previously referred to as a master regulator of TRegs
6,7
. 
Indeed, high level overexpression of FOXP3 has been shown to confer suppressive 
capacity to human T cells 
8
. Furthermore, numerous reports have attested that 
inhibition of FOXP3 abolishes the suppressor phenotype of both mouse and human 
TRegs. Lentiviral vector delivery of an artificial miRNA construct against FOXP3 to 
primary human TRegs in culture reversed their anergic/suppressive phenotype as 
measured by mixed leukocyte reaction 
9
. More recently, human TReg inhibition using 
a morpholino oligomer targeting FOXP3 was shown to enhance generation of 
antigen-specific T cells in response to peptide stimulation 
10
. Similar evidence exists 
for mouse TRegs, where lentiviral-mediated FOXP3 RNAi was shown to hinder 
growth of a regulatory T cell-like leukaemia cell line 
11
. This suppression of growth 
was shown to be an indirect effect as the RNAi-treated leukaemia developed at the 
same pace in an immuno-deficient animal. It is suggested that silencing of FOXP3 
reduces secretion of suppressive cytokines which facilitates an enhanced immune 
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response. This evidence supported the selection of FOXP3 as a target gene for 
RNAi-mediated TReg inhibition. 
In the human setting, an endogenous miRNA has previously been shown to 
silence hFOXP3. miRNAs are indispensable for the correct development and 
function of TRegs 
12
. Abolition of Dicer, the RNAse III enzyme that generates 
functional miRNAs abrogates their suppressive capability and leads to autoimmune 
pathology 
13,14
. Ideally, the chosen miRNA would function specifically in TRegs 
without modulating other cell populations. A previous miRNA signature for human 
TRegs identified miR-31 to be expressed at much lower levels in TRegs relative to other 
CD4
+
 T cells 
15
. Moreover, a functional target site for miR-31 was identified in the 
3‟UTR of human FOXP3 mRNA and miR-31 was confirmed to silence human 
FOXP3 expression. 
 
2.3 Study Aim 
The aim of this study was to identify and validate an RNAi mediator capable of 
specific silencing of mFOXP3. 
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2.4 Materials & Methods 
2.4.1 Bioinformatics 
Two independent bioinformatic databases were explored to verify an interaction 
between miR-31 and mFOXP3. They included the recently developed miRanda-
mirSVR algorithm (www.microRNA.org) 
16-19
 and DIANA-microT 
20
. 
 
2.4.2 Cloning miR-31 into pAAV-MCS 
The original strategy for this thesis work involved adeno-associated virus (AAV) as 
the delivery vector. Thus, to facilitate production of AAV particles carrying miR-31 
the sequence was cloned into the pAAV-MCS plasmid (Stratagene – Agilent 
Technologies). pAAV-miR-31 was generated as follows; the miR-31 fragment was 
amplified from the parent plasmid, pCDH-CMV-MIR31-EF1-copGFP (Systems 
Biosciences) using two primers: miR-For (5‟-AGCAGCATCGATGAATTC-3‟) and 
miR-Rev (5‟- AGCAGCGGATCCAGCGA-3‟). The miR-31 fragment was gel 
extracted using the QIAquick Gel Extraction Kit (Qiagen) and purified using the 
QIAquick PCR Purification Kit (Qiagen). The 518 bp miR-31 fragment was digested 
with ClaI and BamHI and subcloned into the pAAV-MCS plasmid which had been 
digested with the same enzymes.  
 
2.4.3 Cell culture 
HeLa cells were maintained in RPMI 1640 medium (Sigma-Aldrich) supplemented 
with 10% v/v fetal bovine serum and 2mM L-glutamine in a 37
0
C incubator with 5% 
CO2. 
 
2.4.4 RNAi mediators against mFOXP3 
pCDH-CMV-MIR31-EF1-copGFP carrying pre-microRNA-31 (pmiR-31) and its 
backbone equivalent (pCDH-CMV-EF1-copGFP) (pmiR-BB) were both purchased 
from Systems Biosciences. Novel RNAi mediators targeting mFOXP3 mRNA 
transcript variant 2 (Accession # NM_054039.2) were designed using the Block-
iT
TM
 miR RNAi Select Tool (Invitrogen). The mature miR sequence for each 
candidate RNAi mediator was discerned and a 3‟ “G” (derived from native miR-155) 
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was added (see section 3.4.2). The mature miR sequence and its complementary 
strand were synthesised as a 22 bp duplex siRNA (Qiagen). The two candidates were 
designated mimic #2 and mimic #4 to acknowledge their derivation from the longer 
pre-microRNA oligos. The mimics had the following sequences;  
mimic #2: 5‟ AATTCATCTACGGTCCACACTG 3‟ 
mimic #4: 5‟ AAACTCTTCTGGCTCCTCGAAG 3‟ 
 
2.4.5 Co-transfection of plasmids & detection of FOXP3 knockdown 
No suitable cell line that stably expressed mFOXP3 was available. Thus, to facilitate 
development of an expression assay, both the target FOXP3 gene and miR-31 were 
artificially introduced by transfection. HeLa cells were co-transfected with a miRNA 
3' UTR target clone for FOXP3 (either mouse or human) in a Firefly luciferase 
reporter vector (Genecopoeia) and either pmiR-31 or pmiR-BB. 2.5x10
6 
cells in 10 
ml media were seeded in a 58 cm
2
 tissue culture plate 24 h prior to transfection. 10 
µg each plasmid was diluted in serum-free media and incubated with 20 µl 
Turbofect™ (Fermentas) for 15 min. 1 ml of transfection mixture was then added to 
the cells. After 24 h of culture, cells were lysed using 2 ml reporter lysis buffer 
(Promega). 100 µl cell lysate was mixed with 100 µl luciferin substrate (Promega) 
and luminescence read using a luminometer. Knockdown of FOXP3 could be 
detected as a reduction in luminescence. 
 
2.4.6 Validation of miRNA delivery and expression - Detection of mature 
miR-31 
To verify that the pmiR-31 plasmid was functional and that the pre-microRNA was 
correctly processed intra-cellularly, mature miR-31 was detected by RT-PCR. Total 
cellular RNA was extracted using the miRNeasy Mini Kit (Qiagen) and subjected to 
on-column DNase treatment with the RNase-Free DNase Set (Qiagen). cDNA 
synthesis was performed with 1µg of total RNA using the miScript Reverse 
Transcription Kit and PCR detection carried out using the miScript SYBR Green 
PCR Kit combined with miScript Primer Assays (all Qiagen). cDNA synthesis was 
assumed to be 100% efficient such that 1µg of RNA yielded 1µg  of cDNA. 15 ng of 
cDNA template in a 20 µl volume was used per PCR reaction under the following 
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conditions; 15 min pre-incubation at 95
0
C, followed by 50 cycles of 15 s at 94
0
C, 30 
s at 55
0
C, 30 s at 70
0
C. 15 ng of RNA template was also subjected to PCR 
amplification as a control for amplification of genomic DNA. Water template served 
as a negative control while a miScript miRNA Mimic of miR-31 (Qiagen) served as 
a positive control for the PCR reaction. All samples were normalised against the 
widely used endogenous house-keeping miRNA RNU6B 
21
. 
Quantitative PCR was carried out using the “Delta-Delta” mathematical 
technique as previously described 
22
. This technique involves normalising the 
amount of transcript of interest (miR-31 in this case) against an internal control 
transcript (RNU6B in this case) for each sample. This controls for variations in the 
amount of template between different samples. Following this internal normalisation 
each treatment sample (“backbone plasmid” or “miR-31 plasmid” in this experiment) 
was normalised against a control sample (“untransfected”) to indicate the fold 
change in expression as a consequence of the different interventions. To carry out 
these calculations the crossing point (Cp) was determined for each transcript using a 
Lightcycler machine (Roche). Cp represents the point at which fluorescence 
increases above background noise – the Cp value is inversely proportional to the 
amount of a specific mRNA/miRNA species in the sample from which the cDNA 
was derived. The following formula was employed to determine the fold change in 
miR-31 expression between the “miR-31 plasmid” and “untransfected” samples and 
represents an example; 
 
Expression ratio = 2 
– [ΔCp “miR-31 plasmid” (Cp miR-31-Cp RNU6B) – ΔCp “untransfected” (Cp miR-31-Cp 
RNU6B)] 
where 2 = the efficiency of the PCR reaction. 
2.4.7 Validation of siRNA delivery (siGLO) 
To confirm transfection of various siRNAs and miRNA mimics an siGLO
®
 
transfection indicator (Thermo Scientific) was used. 1x10
5 
HeLa cells were seeded 
per well of a 24-well plate 24 h in advance of transfection. 1 µl Lipofectamine 
(Invitrogen) was diluted in 50 µl serum-free media and an appropriate volume of 
siRNA was diluted to 50 µl with serum-free media in a separate tube. The tubes were 
incubated at room temperature for 5 min, combined and incubated for a further 20 
min. The 100 µl mixture was then added to the well to be transfected. The final 
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concentration of siRNA per well was 50 nM. After 24 h transfected cells were 
viewed under an inverted fluorescent microscope as a qualitative indicator of 
siGLO
®
 delivery. Fluorescence-activated cell sorting (FACS) was performed using a 
BD LSR II instrument (BD Biosciences) to determine quantitatively the transfection 
efficiency. The siGLO
®
 transfection indicator could be detected in the green 488-2 
channel.  
 
2.4.8 Knockdown of reporter gene (EGFP) 
As a positive control for the in vitro system the gene encoding the enhanced green 
fluorescent protein (EGFP) was silenced using a commercially available siRNA. 
pIRES2-EGFP-mFOXP3 (pFOXP3) (generated by Dr Garret Casey, Cork Cancer 
Research Centre) was transfected using Turbofect™ (Fermentas) as outlined above 
and provided the target EGFP gene. GFP-22 siRNA was purchased from Qiagen 
along with a negative control siRNA (Allstars Negative Control siRNA). Both 
siRNAs were delivered using Lipofectamine (Invitrogen) as previously outlined. 
Cells were prepared for FACS where EGFP expression was detected at 509 nm (488-
2 channel). Data was presented as the total number of cells expressing the relevant 
protein. To allow for the fact that gene silencing is not an absolute phenomenon (i.e. 
cells are not just positive or negative for protein expression) knockdown data was 
also presented as a tiered level of expression; high, medium and negative.  
 
2.4.9 Testing candidate RNAi molecules against mFoxp3 
Mimic #2 and mimic #4 were introduced into HeLa cells using Lipofectamine as 
previously described. To maintain consistency and to harness the benefits of an 
optimised transfection protocol, the same plasmid (pFOXP3) used as the source of 
EGFP (section 2.4.8) was used as the source of mFOXP3. The IRES sequence within 
pFOXP3 afforded the opportunity to observe gene knockdown by detection of either 
mFOXP3 (with a conjugated antibody) or EGFP (directly). As the long term goal 
was to investigate endogenous mFOXP3 in vivo it was deemed prudent to develop a 
direct mFOXP3 protein detection assay from the outset and to use in this in vitro 
assay. pFOXP3 was transfected using Turbofect™. Knockdown efficiency was 
determined by FACS at 578 nm (PE channel) using a PE-conjugated anti-mouse/rat 
   
99 
 
FOXP3 antibody (clone FJK-16a) (0.5 µg/test) and a PE-conjugated Rat IgG2a 
isotype control (clone eBR2a) (both eBioscience). 
 
2.4.10 Confirmation of the specificity of mimic #2 and mimic #4 
To show that the two RNAi candidate molecules were target specific they were 
assessed on their ability to silence expression of an irrelevant target gene – the EGFP 
reporter. pIRES2-EGFP was used to supply the EGFP target, GFP-22 siRNA as a 
positive control and Allstars Negative Control siRNA. All nucleic acids were 
delivered as previously outlined and EGFP expression was determined by FACS as 
before.  
 
2.4.11 FACS analysis 
For FACS analysis all cells were trypsinised, washed once and resuspended in PBS. 
All cells were then fixed in a 2% para-formaldehyde solution for a minimum of 1 h 
on ice. For detection of EGFP, cells were recovered and resuspended in 200 µl of 
PBS. For detection of non-fluorescent intracellular proteins (e.g. FOXP3) cells were 
washed once in permeabilisation buffer (0.1% Triton, 0.1% sodium azide, 10 mM 
HEPES, 4% FCS, 150 mM NaCl). They were then incubated with the relevant 
antibody made up in permeabilisation buffer for 1 h on ice. Following recovery cells 
were resuspended in 200 µl of PBS and FACS analysis carried out.  
 
2.4.12 Statistical analysis 
In vitro experiments in this chapter were performed with a minimum of 3 replicates 
per group. Results were tested for statistical significance using an unpaired Student‟s 
t test with GraphPad Prism Version 5.0 software.  
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2.5 Results 
2.5.1 Bioinformatic validation that miR-31 targets mFoxp3 
Human miR-31 (hsa-miR-31) is known to silence human FOXP3
15
. Furthermore 
hsa-miR-31 and its mouse equivalent, mmu-miR-31, share the same sequence except 
that mmu-miR-31 has an extra “G” nucleotide at the 3‟ end. The location of this 
extra nucleotide was not expected to influence knockdown efficiency. Thus, the 
hypothesis was that mmu-miR-31 would function similarly in the mouse and silence 
mFOXP3.  
Before testing the hypothesis experimentally, the putative interaction 
between mmu-miR-31 and mFOXP3 was confirmed bioinformatically. The 
microRNA.org resource enabled searching under a given target mRNA, “FOXP3” in 
this case, filtered by species for mouse only. This returned a list of all putative 
miRNAs which may align to and silence mFOXP3. From here, individual miRNAs 
of interest were viewed in more detail, including sequence alignments and mirSVR 
score (figure 2.1). The perfect complemantarity within the seed region (nucleotides 
2-8 on the miRNA) coupled with the mirSVR score of -0.68 predicted a meaningful 
knockdown. These data were corroborated by the DIANA-microT algorithm which 
predicted alignment between mmu-miR-31 and mFOXP3 at the same site with a 
miTG score of 2. To put in context, the miTG score for hsa-miR-31 and human 
FOXP3 was 3.  
 Therefore, bioinformatically at least, miR-31 was predicted to silence 
mFOXP3.  
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Figure 2.1 Database analysis of microRNAs which target mFOXP3. Mouse miR-31 
(mmu-miR-31) was predicted as a putative RNAi mediator against mFOXP3. Shown is the 
proposed alignment of miR-31 within the 3‟UTR of the target mFOXP3 mRNA. Note the 
perfect complementarity within the seed region (nucleotide 2-8 on the microRNA). 
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2.5.2 Validation of miR-31 delivery and expression  
Efficacy of miR-31 in this assay mandated its over-expression in an in vitro system. 
Before examining the functionality of miR-31, successful delivery of the plasmid 
carrying miR-31 and appropriate intracellular processing were confirmed. This was 
achieved by detection of the mature miRNA by real time RT-PCR (figure 2.2). This 
experiment confirmed that miR-31 was over-expressed 54–fold compared with the 
empty backbone plasmid. 
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Figure 2.2 Detection of mature miR-31. Data extracted from RT-PCR using the ΔΔCT 
method showing the levels of mature miR-31 relative to an untransfected and a plasmid 
backbone sample. Levels were normalised against the RNU6B housekeeping gene, and the 
scale of over-expression represents the average of two independent experiments. 
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2.5.3 Assessment of miR-31 knockdown of mFOXP3 
From figure 2.2 it was clear that a large number of mature miR-31 duplexes were 
were produced and available within the cell. The next step was to determine if miR-
31 could silence mFOXP3. Parallel assessment of miR-31 against hFOXP3 acted as 
a positive control for the experiment as miR-31 has been previously published to 
silence hFOXP3 
15
. The same backbone plasmid without pre-microRNA-31 
sequence acted as a negative control. A commercially available miR reporter assay 
was employed. Commercially available luc-UTR constructs served as the source of 
the untranslated regions (UTRs) for the hFOXP3 and the mFOXP3 genes. These 
constructs express the 3‟UTR of the chosen target gene fused to the coding region of 
the Firefly luciferase gene. Successful silencing of the target mRNA (FOXP3) 
manifests as reduced luciferase protein expression with subsequent reduced 
luminescence. As seen in figure 2.3, miR-31 significantly silenced hFOXP3 
compared with pmiR-BB (p = 0.015). However, it had no effect on mFOXP3 (p = 
0.261). 
 This experiment demonstrated that miR-31 does not silence mFOXP3 and 
thus could not be expected to alter the TReg phenotype. 
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Figure 2.3 miR-31 does not silence mFOXP3. Luc-UTR constructs bearing the 3‟ UTR of 
human and mouse FOXP3 fused to the firefly luciferase gene were co-transfected with 
plasmids carrying pre-miR-31 or its backbone equivalent (pmiR-BB). 48 h later, HeLa cells 
were lysed and luminescence read using a luminometer. Human luc-UTR (FOXP3) is 
included as a positive control for the experiment. Data are represented as mean +/- SEM of n 
= 3 (** p = 0.015). 
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It was concluded from these results, that no endogenous miR effective 
against mFOXP3 was available or apparent. Therefore, it was necessary to design 
and test an alternative miR strategy. In order to test suitable inhibitory sequences, 
siRNAs were initially examined, with the ultimate aim of utilising the data generated 
to construct a DNA-based miR. 
 
2.5.4 Validation of siRNA delivery 
Prior to testing siRNA molecules, in vitro delivery of chemically synthesised 
siRNAs was first validated. siGLO
® 
was used to determine delivery efficiency by 
FACS analysis. Figure 2.4 shows that 74% (+/- 1%) of cells were fluorescent 
following siGLO
® 
transfection, which was significantly greater than the background 
level from untransfected samples (4% +/- 0.05%) (p < 0.001). 
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Figure 2.4 siRNA delivery to HeLa cells in vitro. A) Histograms from FACS analysis 
showing the number of cells positive (light grey) and negative (dark grey) for the 
fluorophore for an untransfected population and a population transfected with siGLO
®
. The 
histograms shown are representative of three independent replicates. B) Quantitative output 
for the number of transfected cells. Data are represented as mean +/- SEM of n = 3 (*** p < 
0.001).  
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2.5.5 Knockdown of a reporter gene (EGFP) 
Validation of the assay for in vitro assessment of RNAi was established by 
examining silencing of expression of the fluorescent reporter protein EGFP. This 
assay involved co-transfection of HeLa cells with a plasmid (pFOXP3) providing co-
expression of both EGFP and mFOXP3 (as a single mRNA transcript through an 
IRES sequence) and an siRNA targeting EGFP mRNA. For this experiment, the 
plasmid provides the EGFP target gene. 
A global picture of the silencing efficiency was obtained by looking at the 
percentage of cells that were EGFP
+ 
in the various samples (figure 2.5 A and B). 
Transfection of the target plasmid alone yielded 57% (+/- 0.7%) EGFP
+
 cells. Co-
transfection of an siRNA against EGFP resulted in a knockdown efficiency of 58% 
as evidenced by a reduction in the number of EGFP
+ 
cells to 24% (+/- 1.2%). This 
was statistically significant (p < 0.001). A scrambled, negative control siRNA did 
not reduce the number of EGFP
+ 
cells significantly (p = 0.124).  
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Figure 2.5 Knockdown of EGFP. A) Dot plots from FACS analysis where the numbers 
indicate the percentage of total cells above the line and hence positive for EGFP expression. 
Dot plots shown are representative of three independent replicates. B) Quantitative output 
for the number of EGFP
+ 
cells from three replicates presented as the mean +/- SEM (*** p < 
0.001). C) Histograms on the left showing the relative proportion of cells with negative, 
medium and high fluorescence intensity (P2, P3 and P4 respectively) which correlates with 
the level of EGFP expression. Each histogram is representative of three independent 
replicates. The graphs on the right represent the quantitative output from histograms from 
three independent replicates.  
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Data presented in Figure 2.5 A and B provide total number of cells positive 
or negative for the target protein (EGFP), and does not account for changes in level 
of intracellular expression within positive cells. Since partial knockdown may be 
sufficient to facilitate a phenotypic change in the cell, it is important to examine all 
reduction in gene expression. Stratifying the cells according to fluorescence intensity 
(negative, medium and high) overcomes this issue and accounts for partial 
knockdown. These data are shown in figure 2.5 C. Comparing a sample that received 
EGFP plasmid alone, with a sample that received both plasmid and an siRNA 
targeting EGFP, the percentage of cells with „high‟ fluorescence is reduced by 30% 
(+/- 0.5%; p < 0.001) from 32% to 2%. There was no significant change in the 
„medium‟ cell population (p = 0.592). This occurs against a backdrop of an increase 
in the number of negative cells by 30% (+/- 1.3%; p < 0.001) from 43% to 73%.  
This suggests that, following transfection of an siRNA targeting EGFP, cells that 
highly expressed EGFP now express the protein at an intermediate level, while those 
previously displaying medium expression are now negative for EGFP. 
In this experiment, the proficiency of the in vitro assay to assess RNAi was 
validated by knockdown of the reporter EGFP. 
 
2.5.6 siRNA Knockdown of mFOXP3 
Two 22-base pair chemically synthesised siRNAs (termed mimic #2 and mimic #4) 
were examined in an in vitro assay with mFOXP3-transfected HeLa cells. This assay 
involved co-transfection of HeLa cells with pFOXP3 and the siRNAs. For this 
experiment, the plasmid provided the mFOXP3 target gene. mFOXP3 expression 
was assessed via FACS with anti-mFOXP3 antibody labelling of cells. 
Transfection of the target plasmid alone yielded 47% (+/- 2.8%) 
mFOXP3
+cells. In terms of „absolute‟ silencing efficiency, where cells are either 
FOXP3 positive or negative, mimic #4 produced a superior knockdown efficiency at 
57% compared with 39% for mimic #2. The scrambled, negative control siRNA had 
an insignificant knockdown effect on mFOXP3 (p = 0.468). The knockdown 
efficiency achieved with both mimics was statistically significant (p < 0.003 for 
mimic #2 and p < 0.001 for mimic #4) and the difference in knockdown efficiency 
between the two mimics was statistically significant (p = 0.008) (figure 2.6 A and 
B). A concordant knockdown to that seen for mFOXP3 was observed by analysing 
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cells in terms of EGFP expression (data not shown). This validated the integrity of 
the IRES construct (see section 2.4.9 for further details).
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Figure 2.6 siRNA Knockdown of mFOXP3. A) Dot plots from FACS analysis where the 
numbers indicate the percentage of total cells above the line and hence positive for mFOXP3 
expression. Dot plots shown are representative of three independent replicates. B) 
Quantitative output for the number of mFOXP3
+
 cells from three replicates presented as 
mean +/- SEM (*** p < 0.001, ** p <0.003). C) Histograms showing the relative proportion 
of cells with negative, medium and high fluorescence intensity (P2, P3 and P4 respectively) 
which correlates with the level of mFOXP3 expression. Each histogram is representative of 
three independent replicates. D) The graph represents the quantitative output from 
histograms from three independent replicates. Only FOXP3 high cells (P4 in the histograms 
in C) are shown on the graph. 
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As per the knockdown of EGFP, any partial knockdown of mFOXP3 was 
potentially relevant as even a small reduction in expression of this crucial 
transcription factor could influence the suppressive capability ofTRegs. Again cell 
populations were stratified based on fluorescence intensity. Comparing a sample that 
received mFOXP3 plasmid alone with samples that also received mimic #2 or mimic 
#4 the percentage of cells with high fluorescence was reduced from 27% to 8% (p = 
0.001) and 4% (p < 0.001) respectively. No significant change was observed in cell 
populations with medium fluorescence (p = 0.82 for mimic #2 and p = 0.126 for 
mimic #4). This occurred against a backdrop of an increase in the number of 
negative cells from 49% to 63%(p = 0.005) and 72% (p < 0.001) respectively. 
Representative histograms for these data are shown in figure 2.6 C with quantitative 
output from three independent replicates shown.  As per the EGFP knockdown the 
data from this experiment suggests that, following transfection mimic #4 and mimic 
#2, cells that highly expressed mFOXP3 now express the protein at an intermediate 
level, while those previously displaying medium expression are now negative for 
mFOXP3 
This experiment was crucial to the progression of the overall aim, with two 
novel RNAi sequences against the target mFOXP3 identified and validated. 
 
2.5.7 Target-specificity of RNAi mediators against mFOXP3  
Aside from target knockdown efficiency, an important concern when designing an 
RNAi mediator is to minimise off-target effects. Thus mimic #2 and mimic #4 were 
tested against EGFP and knockdown efficiency was assessed (figure 2.7 A and B). 
Neither mimic (p = 0.051 for mimic #2 and p = 0.067 for mimic #4) nor the negative 
control siRNA (p = 0.124) yielded a statistically significant knockdown of EGFP 
when compared with a sample that received no siRNA (plasmid alone). As a positive 
control for the experiment, an siRNA against EGFP reduced the number of EGFP
+ 
cells from 56% to 26% (p < 0.001).    
 In this experiment mimic #2 and mimic #4 failed to silence an irrelevant 
target (EGFP) suggesting that these RNAi mediators are target specific.  
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Figure 2.7 Mimic # 2 and mimic # 4 are target-specific. A) Dot plots from FACS analysis 
where the numbers indicate the percentage of total cells above the line and hence positive for 
EGFP expression. Dot plots shown are representative of three independent replicates. B) 
Quantitative output for the number of EGFP
 +
 cells from three replicates presented as the 
mean +/- SEM (*** p < 0.001). 
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2.6 Discussion  
In this chapter endogenous miR-31 was shown to be incapable of silencing 
mFOXP3. This finding conflicted with the bioinformatic screen. Attention then 
switched to the design and testing of novel RNAi mediators against mFOXP3. 
Although designed as pre-microRNA constructs, the mature RNAi duplexes of 22 
bps were synthesised independently as siRNAs and tested in vitro. Proof of delivery 
for a fluorescent siRNA was first demonstrated followed by knockdown of a reporter 
gene. Together these steps validated the in vitro model system. Two candidate RNAi 
molecules were tested against our target gene (mFOXP3) and achieved varying 
degrees of knockdown. The candidate molecules were furthered tested against a non-
target gene. In the absence of knockdown, they were deemed to be target-specific. 
 
Rationale for testing miR-31; miR-31 has been shown to silence hFOXP3 
15
. The 
initial hypothesis for this study proposed that miR-31 might also silence mFOXP3. 
The potential benefits of working with a cross-species specific miRNA were many 
23
 
and clearly justified experimentation with miR-31 against mFOXP3; the value of the 
pre-clinical data would be greatly enhanced as the safety and efficacy data would be 
reconcilable with human data. If clinical translation of the compound was possible, 
the process would be greatly expedited and at much lower cost, as a single drug 
candidate would be conserved from the research stage through to patient 
administration. The potential for such cross-species reactivity represents a distinct 
advantage of RNAi therapeutics over small molecule and biological compounds 
24
. 
The sequence of mature miR-31 is conserved between the mouse and human 
species with the exception of an additional 3‟ “G” nucleotide on the mouse homolog. 
However, a miRNA profile of murine T cells did not highlight any distinction in 
miR-31 levels between TRegs and conventional CD4
+
 T cells 
13
. Furthermore, miRNA 
target specificity has been shown to fluctuate considerably between organisms due to 
diversity in RNAi pathways and variations in the components of RISC complexes 
16
. 
However, a bioinformatic screen using the miRanda-mirSVR methodology predicted 
that miR-31 would silence mFOXP3 (figure 2.1). This bioinformatic tool was 
deemed to be especially appropriate as the scoring algorithm had been generated 
based on miRNA transfection data in HeLa cells as per the planned experiments with 
miR-31 
16
. The mirSVR score of -0.6807 was substantially lower than the cutoff 
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score of -0.1 where the lower the score the greater the probability of meaningful 
downregulation; scores of -0.1 or lower have more than a 35% probability of a log 
expression change of at least -1 and better than 50% probability of a log expression 
change of at least -0.5. Moreover the mirSVR scores correlate linearly with the 
extent of downregulation 
16
. 
 
Limitations of bioinformatic algorithms; The bioinformatic prediction could not be 
validated at a practical level (figure 2.3) despite successful over-expression and 
detection of mature miR-31 (figure 2.2). This can most likely be attributed to 
generation of a false positive result by the miRanda-mirSVR methodology. Despite 
sequential improvements as newer algorithms have been developed, some limitations 
remain; the presence of non-specific sequence determinants that influence miRNA-
mediated regulation has been muted 
25
; RNA-binding proteins and motifs are known 
to interfere with miRNA regulation 
26,27
. Present algorithms are unable to factor 
these parameters into calculations 
16
. While a false positive readout was generated in 
this experiment perhaps a bigger concern would be false-negative outputs – most 
current target prediction methods do not consider miRNA target sites within the 
coding region of genes 
16
. However recent data from Argonaute-protein 
immunoprecipitations suggest that a significant proportion of target sites can be 
found in the coding regions of mRNAs 
28,29
.  
 
Use of siRNAs;Following on from the demonstration that miR-31 was unsuitable, 
two novel, alternative candidates were examined and validated, as chemically 
synthesised siRNAs rather than DNA-based constructs. siRNAs represent an 
invaluable tool for in vitro validation of RNAi mediators at a sequence level 
30
. Their 
small size (generally 22 bp) permits high transfection efficiency using routine 
chemical transfectants. The researcher need not be concerned with optimising 
parameters such as plasmid expression and intra-cellular processing. As such, 
siRNAs represent a more user-friendly method of exploiting RNAi in the early 
stages of a project. Upon successful validation of RNAi, the siRNA sequence can 
readily be transposed into DNA-based constructs (detailed in chapter 3). 
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Target specificity; While it is suggested in this chapter that the two candidate RNAi 
mediators are target-specific, by their failure to silence an irrelevant EGFP gene 
(figure 2.7) these data are not definitive. EGFP is not an endogenous gene and a 
more detailed analysis of the off-target effects would warrant gene expression 
profiling. This technology is expensive and would not be justified in the absence of 
any gross abnormality in the cell line used for these experiments. In any case off-
target effects in HeLa cells may not be recapitulated in the final target cell 
population of TRegs. 
 
Conclusion; In conclusion, the exploitation of RNAi as a therapeutic modality is still 
in its infancy, with currently no RNAi mediator in routine clinical use. RNAi 
therapeutics promise many benefits but given their potency, rigorous in vitro testing 
accompanied by cautious clinical development would seem prudent. Many of the 
obstacles, such as saturation toxicity, off-target effects, immune stimulation and 
delivery are slowly being overcome.  
In this chapter, a novel RNAi mediator against mFOXP3 was designed and 
tested. FOXP3, in its capacity as master regulator of TRegs, has taken on new-found 
significance as a target protein/gene in recent times in the field of cancer 
immunology and beyond. The intracellular localisation of this protein/transcription 
factor lends itself to manipulation by some form of gene therapy such as RNAi. The 
mouse homolog of FOXP3 was chosen as a target because it provided the potential 
for in vivo experimentation with the putative therapeutic. Such in vivo data would 
have far greater relevance in the context of anti-tumour immunity than any in vitro 
data derived from mixed-leukocyte reactions. The novel RNAi mediators against 
mFOXP3 did not silence a non-target gene suggesting that they are target-specific. 
The 22 bp duplexes utilised in this series of experiments provided a simple 
and efficient means to test the RNAi mediators at a sequence level. However 
progressing these siRNAs in their present format to pre-clinical studies and beyond 
would be very challenging (reviewed in section 1.2.3). A non-viral vector would be 
required with a resulting drop in delivery efficiency and due to the inherent 
vulnerability of the siRNAs in vivo repeated administration would likely be required. 
Therefore, subsequent chapters focus on development of optimal methods for 
delivery of the sequences validated here. 
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Chapter 3:  
Lentivirus as a vector for artificial miRNAs 
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3.1 Abstract 
The aim of this study was to develop an in vivo delivery strategy for the RNAi 
mediator developed in Chapter 2. Artificial miRNAs offer many advantages over 
siRNAs, including the capacity for delivery by viral vectors. Lentiviral vectors offer 
many desirable features for gene therapy. They mediate high level, long-term 
expression of the transgene and are lowly immunogenic. Thus, in this chapter the 
objective was to embed the validated siRNA (mimic #4) from chapter 2 within an 
artificial miRNA cassette and incorporate this into a lentiviral system.  
Functional validation of a lentiviral-mediated artificial miRNA knockdown 
was achieved against mFOXP3 in vitro. Lentiviral-mediated gene delivery to a 
growing B16OVA melanoma tumour was verified using a Firefly luciferase (FLuc) 
reporter gene construct. The optimal time to target TRegs within this tumour model 
was identified, and B16OVA tumour-bearing mice were intra-tumourally (i.t.) 
administered lentiviral vector carrying the artificial miRNA. The cytokine and 
cellular immune responses to treatment were examined but no therapeutic benefit 
was detected. 
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3.2 Introduction 
FOXP3 is recognised as a master regulator of TRegs
1,2
 with a profound effect on their 
functionality. This prompted the hypothesis that sustained RNA interference would 
be necessary to functionally inactivate TRegs for a period of sufficient duration to 
permit development of an altered immune phenotype within the tumour. This 
mindset encouraged the employment of a DNA-based RNAi mediator delivered via a 
viral vector; ideally an integrating virus for persistence within the cell. Lentiviral 
vectors boast many desirable attributes; they are capable of high level, long-term 
expression of the transgene due to integration into the genome; they are capable of 
transducing non-dividing cells and relative to other viral vectors, are lowly 
immunogenic 
3,4
. 
In this study the preferred mediator for RNAi was either a miRNA or an 
shRNA. Within the context of the proposed therapeutic strategy an siRNA-based 
approach was deemed unsuitable; delivery via a non-viral vector would be necessary 
which would undermine delivery efficiency; the short in vivo half-life of siRNAs 
would require repeat administrations, adding a further layer of complexity in terms 
of optimising posology. In contrast a DNA-based RNAi platform would overcome 
these issues as the benefits of a lentiviral vector could be harnessed, namely high 
transduction capability and transgene integration. Furthermore a miRNA, in 
particular an artificial miRNA, promised distinct advantages over an shRNA; more 
potent knockdown of the target gene could be expected as embedding the validated 
siRNA from chapter 1 in the well characterised miR-155 backbone would lead to 
more efficient handling by the RNAi processing machinery.  Moreover the risk of 
saturating toxicity would be lower as an artificial miRNA would be less likely to 
overload the RNAi processing machinery 
5
.  
While combining a lentiviral vector with an artificial miRNA seemed like an 
ideal strategy, some technical concerns have been reported with this combination 
(reviewed in
6
). For example, although the RNAi mediator used in this study was 
bioinformatically screened for off-target effects, no mediator is solely functional 
against the target gene, and it cannot be ruled out that the miRNA sequence could 
interfere with genes in the 293T producer cells. Self targeting, whereby the miRNA 
transcript is expressed within the producer cells and then elicits RNAi by targeting 
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the homologous sequences present in the LV vector genome, is also possible. 
Although no direct evidence exists for this occurrence with miRNAs, self-targeting 
has been demonstrated for shRNAs 
7
. Given the looser structure of miRNAs (the 
presence of mismatches) relative to shRNAs, self targeting would seem a legitimate 
concern. Taken en masse, any RNAi activity mediated by the miRNA of interest in 
the producer cells is undesirable and could undermine lentiviral vector production. 
There is also the possibility of the miRNA-containing vector genome being 
recognised by Drosha following transcription in the producer cell, leading to its 
destruction. Increased lentiviral titers secondary to Drosha silencing in the producer 
cells support this theory 
8,9
. Genetic instability in the lentiviral particles as a result of 
repeat sequences in the artificial miRNA can also be an issue, and duplications and 
deletions have been found during transduction of target cells 
10,11
. Promoter 
interference is also worth considering – if the promoter driving the transgene is 
significantly stronger than the promoter driving the full-length vector RNA, 
abundant transgene but very little vector genome expression manifests 
12,13
. 
Despite these hypothetical concerns about production of lentiviral particles 
carrying a miRNA, they are unlikely to be significantly relevant if high titre 
production is achieved, as no significant impact on subsequent delivery or 
knockdown efficiency would be expected. 
The focus of this chapter was the development of a DNA-based version of 
the siRNA validated in the previous chapter. A secondary goal was to incorporate the 
DNA-based version in a suitable viral vector. 
 
3.3 Study Aim 
The aim of this study was to incorporate RNAi mediators into a lentiviral-based 
system capable of delivery in vitro and in vivo. 
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3.4 Materials & Methods 
3.4.1 Design and testing of new SCR siRNA 
A 21 nucleotide sequence was chosen at random and a 3‟ “G” derived from the 
native miR-155 sequence (see below) was added. The sequence was modified 
according to Invitrogen‟s guidelines (www.invitrogen.com/rnai): runs of greater than 
3 identical nucleotides were avoided and the “GC” content was kept in the range of 
30-50% - this ensured that any knockdown failure could be attributed to the 
nucleotide composition and not any thermodynamic stability issues. The 22 
nucleotide sequence was bioinformatically assessed against mFOXP3 using the 
TargetScan
TM
 software and also run through the Basic Local Alignment Search Tool 
(BLAST) to confirm the absence of significant homology to any other genes 
14
. The 
reverse complement was generated, yielding a 22 base pair (bp) duplex. This siRNA 
(designated miR scr) was synthesised by Qiagen and tested in vitro against mFOXP3 
as previously described (section 2.4.9). The miR scr guide strand had the following 
sequence; 5‟ ACGTTCGATTATATCGATCGTG 3‟ 
3.4.2 Incorporating siRNA sequences into pre-microRNA cassettes  
The 22 bp duplexes of mimic #4 and miR scr were incorporated into pre-microRNA 
scaffolds (Invitrogen) as shown in figure 3.1 and as described; a 5‟ overhang 
(TGCT) was added to the functional siRNA strand (mimic #4 or miR scr) which was 
then merged with the 3‟ terminal loop sequence (optimised by Invitrogen); 
nucleotides 1-8 and 11-21 of the passenger siRNA strand were added to yield a 64 
bp single strand top oligo (panel A). The bottom oligo was designed as the reverse 
complement and both single stranded oligos were synthesised by Invitrogen. The 
oligos were annealed and ligated into the pcDNA6.2-GW/EmGFP-miR plasmid 
backbone (Invitrogen) (panel B). Successful insertion of the double stranded oligos 
was confirmed by Msc I restriction digest (which only digests within the terminal 
loop) and sequencing (Eurofins MWG Operon). 
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Figure 3.1 Incorporating siRNA sequences into pre-microRNA cassettes. A) Shows how 
the siRNAs (mimic # 4 and miR scr) were converted into single strand oligos with a hairpin 
loop. B) Shows a simpler representation of the single strand oligo in A together with its 
complementary bottom strand. The two single strand oligos were annealed and ligated into 
the pre-microRNA expression cassette generated from native miR-155. Further details are 
provided in the text. Figure adapted from Invitrogen‟s BLOCK-iT™ Pol II miR RNAi 
Expression Vector Kit manual. 
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3.4.3 Cloning pre-microRNA cassettes and lentiviral vector production 
To facilitate lentiviral vector production the pre-microRNA expression cassettes with 
their EmGFP reporter genes were transferred to a lentiviral production plasmid. Each 
EmGFP-pre-microRNA cassette was amplified by PCR using the same 5' SpeI and 3' 
EcoRI primers. The PCR products were cleaned-up by column purification 
(Promega) and digested with SpeI and EcoRI. They were then cloned into the pRRL-
sin-cPPT-CMV-MCS lentiviral production plasmid that had been digested with the 
same enzymes. This generated pRRL-303-Lenti-miR scr and pRRL-303-Lenti-miR 
4. 
 Lentivirus vectors (designated Lenti miR 4 and Lenti miR scr) were 
generated at the UCLA Vector Core by transient co-transfection of 293T cells as 
described previously, with slight modifications 
15
. Briefly, 100 mm dishes of non 
confluent 293T cells were co-transfected with 6.5 μg of pMDLg/pRRE (encoding 
HIV gag-pol), 3.5 μg of pMDG (encoding the VSV-G envelope),  2.5 ug of pRSV–
REV (encoding HIV rev) and 10 μg of the relevant pRRL-303 plasmid, by the 
calcium phosphate co-precipitation method 
16,17
. The plasmid vectors were kindly 
provided by Dr Luigi Naldini (University of Torino, Italy). Next day, the medium 
was adjusted to make a final concentration of 10 mM sodium butyrate and the cells 
were incubated for 8 h to obtain high-titer virus production as previously described 
18
. After the 8 h incubation, cells were washed and incubated in fresh medium 
without sodium butyrate. Conditioned medium was harvested 16 h later, passed 
through 0.45 μm filters and concentrated by ultracentrifugation (figure 3.2). 
Viral titer was determined by assessing viral p24 antigen concentration by 
ELISA (Alliance® HIV-I p24 ELISA Kit, Perkin Elmer) and expressed as μg of p24 
equivalent units per milliliter. P24 values were related to a previously generated 
infectious titre standard curve. This standard curve was established by production of 
reporter particles by substituting the pRRL-303 plasmid with the reporter pLentiLox-
DsRed plasmid
19
. Infectious titer was then determined by infection of 293T cells 
with serial dilutions of the concentrated virus preparation, followed by FACS 
analysis of DsRed expression 48 h later using an EPICS-XL flow cytometer 
(Beckman Coulter). 
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Figure 3.2 Schematic of lentiviral vector production. Shown are the relevant portions of 
the four plasmids (and the quantity of each plasmid per plate) used to generate VSV-G 
pseudotyped lenti miR 4 and lenti miR scr particles (top). These plasmids were co-
transfected into 293T cells by the calcium co-precipitation method. Sodium butyrate was 
utilised to achieve high titer production. 293T cell media was passed through a 0.45 μm 
filter and the particles were concentrated by ultracentrifugation. Following titration lentiviral 
particles were tested on HeLa cells in culture or in vivo. Further details are provided in the 
text. 
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3.4.4 Lentiviral vector experiments on HeLa cells  
1x10
5
 HeLa cells were seeded per well of a 24-well plate in 1 ml media and grown to 
approximately 80% confluency. Lentiviral particles were thawed, diluted in serum 
free media and the appropriate multiplicity of infection (MOI) added per well in a 
100 µl volume. For knockdown experiments pFOXP3 was transfected 6 h later as 
previously described (section 2.4.5). FACS analysis was carried out directly for GFP 
expression or following permeabilisation and staining with an anti-mFOXP3 
antibody as previously described. 
 
3.4.5 Tumour induction & monitoring 
7 week old female C57 Bl/6 mice were anaesthetised and their right flanks shaved. 
1x10
6 
B16OVA cells in a 200 µl volume were injected subcutaneously into the right 
flank of each mouse. Tumour volume was determined from measurements of the 
tumour in two dimensions using a callipers and the formula V=ab
2π/6, where a 
is the longest diameter of the tumour and b is the longest diameter 
perpendicular to diameter a. Measurements were taken on alternate days from when 
the tumour first emerged until death of the animal. They were also taken 
immediately prior to culling the animal for TReg quantification. 
 
3.4.6 In vivo administration of lentiviral vector 
9 days post tumour induction (based on the TReg infiltration data) lentiviral particles 
were administered directly into the tumour. Three different injection sites were used 
to deliver a total dose of 5x10
7
 infectious units in a 100µl volume using a 32 gauge 
needle. For the proof of delivery experiment lenti-luc2 particles were used. Lenti 
miR 4 particles and control, lenti miR scr particles, were used for the treatment 
experiment.  
 
3.4.7 Whole animal imaging  
Mice were anaesthetised, re-shaved around the tumour site and injected with 200 µl 
luciferin solution (3mg/ml) i.t. and a further 200 µl into the peritoneal cavity. Five 
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mins waiting was observed before mice were imaged on an IVIS imager (Perkin 
Elmer).  
 
3.4.8 Processing of tumour samples for FACS analysis 
The entire tumour was recovered and divided into equal and representative portions 
for FACS and cytokine analysis. The samples for FACS were processed into a single 
cell suspension as follows; the tumour mass was incubated in 1ml collagenase 
(Sigma) and dispase (Sigma) buffer (3 mg/ml of each) at 37
0
C in a shaking incubator 
for 10 mins. The sample was then mixed further by pipetting through 10 ml and then 
5 ml pipettes, before passing through a mesh filter in a physical extrusion technique. 
The cells were pelleted by centrifugation (1500 rpm for 5mins at 4
0
C), washed twice 
in PBS and resuspended in 2mls red cell lysis buffer (Sigma) with 5 minutes 
incubation at room temperature. 30 mls media with serum was added to stop the lysis 
process. Cells were recovered by centrifugation again, washed once in PBS and 
counted – both viable and non-viable. 1x106 viable cells were aliquoted per sample 
to be analysed and cells were fixed and stained as previously described (section 
2.4.11). 
 
3.4.9 Quantifying TReg infiltration and T cell subsets 
Tumours were harvested and processed into a single cell suspension as above. The 
following antibodies were used for staining; CD4-PerCP Cy5.5 (clone RM4-5), 
CD8-APC H7 (clone 53-6.7) (both 0.2 µg/test from Biolegend); CD25-APC (clone 
PC61.5) (0.1 µg/test, eBioscience) and FOXP3-PE (clone FJK-16a) (0.5 µg/test, 
eBioscience). For quantification of TReg infiltration cells were gated first on viability 
and then distinguished based on CD4 or CD8 positivity and analysed in terms of 
CD25 and FOXP3 expression. This gave the following two populations of TRegs; 
CD4
+
, CD25
+
, FOXP3
high
 and CD8
+
, CD25
+
, FOXP3
high
 and the following 
populations of activated CD4
+
 helper T cells (CD4
+
, CD25
+
, FOXP3
low
) and 
activated CD8
+
 cytotoxic T cells (CD8
+
, CD25
+
, FOXP3
low
).  For determining T cell 
subsets post lentiviral vector administration cells were gated first on viability and 
then stratified according to the level of FOXP3 expression. Using this stratification 
cells were then analysed in terms of CD25 and either CD4 or CD8 expression. 
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3.4.10 Analysis of in vivo cytokine profile 
A representative portion of tumour (approximately one third) was harvested from 
animals, flash frozen and stored at -80
0
C. Cytokine analysis was performed on a 
mouse pro-inflammatory multi-plex plate (Meso Scale Discovery) as per the 
manufacturer‟s instructions. Seven cytokines were assayed for: Interferon (IFN) γ, 
Interleukin (IL) 12 (p70 subunit), IL-1β, IL-6, mKC, IL-10 and tumour necrosis 
factor (TNF) α.  
The following preparatory work was performed on tumour samples; samples 
were thawed on ice and a 300 mg specimen was isolated. The appropriate volume of 
homogenisation buffer (PBS with protease inhibitor cocktail [Roche] and 10% FCS) 
was added to each specimen to yield a concentration of 100 mg of tissue per ml and 
a uniform solution was achieved using a tissue homogeniser. 500 µl of this solution 
was centrifuged at 1000g and the supernatant recovered.  
The cytokine assay was run as follows; 25µl of Blocker D-B (containing 
blocker and stabilisation agents) was added to each well, the plate was sealed and 
placed on a plate shaker for 30 min. Following incubation, the plate was washed (x1) 
in PBS + 0.05% Tween (Sigma) and blotted on tissue paper. Each sample 
supernatant was diluted 1 in 20 and 50 µl (equivalent to 250 µg of tissue) added per 
well. The standards were diluted to create a standard curve, as per protocol, in the 
homogenisation buffer and 50 µl was added to each well of the 96-well MSD plate. 
The plate was sealed and placed on a plate shaker for 1.5-2 h at 800rpm. The 
detection antibody solution mix (1µg/ml), from kit, was added to each well 
(25µl/well). The plate was sealed, covered with tinfoil, and placed on a plate shaker 
for 1.5 h. Following incubation, the plate was washed (x3) in PBS + 0.05% Tween 
(Sigma) and blotted on tissue paper. MSD Read buffer (2X), from kit, was added to 
each well (150µl/well) using reverse pipetting to prevent bubbles. The plate was read 
using an electro-chemiluminescent multiplex system Sector 2400 imager (Meso 
Scale Discovery). This system has a CCD camera that measures the output signal 
from the wells in units of counts of light. Using the standard curve (signal versus 
concentration [pg/ml]) the concentration of analyte in the unknown samples was 
derived from the output signals from the samples with known levels of the analyte of 
interest.  
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3.4.11 Statistical analysis 
In vitro experiments were performed with a minimum of 3 replicates per group. In 
vivo experiments were performed with a minimum of 3 mice per group. Results were 
tested for significance using an unpaired Student‟s t test with GraphPad Prism 
Version 5.0 software.  
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3.5 Results 
3.5.1 Development of a scrambled siRNA for DNA-based construct 
Although the negative control siRNA tested in chapter 2 fulfilled its function in 
validating the specificity of the test siRNA against mFOXP3, its sequence was 
proprietary and did not lend itself to incorporation into a plasmid construct. Thus, a 
new scrambled siRNA sequence (miR scr) was designed and examined in a 
mFOXP3 expression assay as before.  
Results are displayed in figure 3.3. miR scr had a statistically greater effect 
on the number of FOXP3
+
 cells than Neg siRNA (p = 0.01). However the 
knockdown efficiency induced by the test RNAi mediator (mimic #4) on FOXP3
+
 
cells of 45% was still significantly greater than that induced by miR scr (17%). This 
difference which represented genuine RNA interference equated to 28% (+/- 1.8%, p 
< 0.001) and provided the confidence to go forward and incorporate both duplexes 
into lentiviral constructs. 
In conclusion, a novel negative control RNAi molecule amenable to 
incorporation into a DNA-based construct was generated here and validated for the 
purpose of testing the experimental RNAi therapeutic. 
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Figure 3.3 mFOXP3 expression assay with new scrambled siRNA. A) Dot plots from 
FACS analysis representing the percentage of FOXP3
+
 cells following transfection of 
pFOXP3 and various siRNA duplexes into HeLa cells. The dot plots shown are 
representative of three independent experiments.  B) Quantitative output for the data shown 
in A. Data are represented as mean +/- SEM of n = 3. (*** p < 0.001). 
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3.5.2 Optimisation of lentiviral vector expression in vitro 
The data above and in chapter 2 confirmed that the mimic #4 sequence was capable 
of silencing mFOXP3. To facilitate in vivo therapy, delivery of the RNAi mediator 
DNA would be required. In this series of experiments, we sought to optimise the 
parameters required to achieve maximum lentiviral vector-based delivery and 
expression in vitro and thus induce maximal knockdown efficiency with the test 
miR. A GFP-encoding version of the lentiviral vector was employed for in vitro 
assays to examine the kinetics of transgene expression post transduction. 
The time at which maximum expression was achieved post transduction was 
first determined. An arbitrary MOI of 10 was chosen and the average GFP brightness 
per cell (mean fluorescence intensity [MFI]) quantified at different time points. 
Results are displayed in figure 3.4. Within the limitations of this assay, MFI was 
observed to be highest at 72 h post transduction, although not significantly higher 
than at 48 h (p = 0.168). Consequently 72 h was chosen as the time of maximum 
expression for all further in vitro experiments. 
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Figure 3.4 Determination of the time for maximal lentiviral expression in vitro. HeLa 
cells were transduced in culture with lentiviral particles carrying a GFP transgene at an MOI 
of 10. FACS analysis was carried out at the designated time points post-transduction. A) 
Histograms plotting the mean fluorescence intensity (MFI) against the number of cells. 
Histograms are representative of three independent experiments. B) Quantitative output from 
three replicates presented as the mean +/- SEM. 
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The optimal MOI for lentiviral vector on HeLa cells was then determined. This 
information would help achieve transduction of the maximum number of cells and 
hence the best knockdown possible. A range of MOIs from 5 to 20 was tested. 
Results are displayed in figure 3.5. An MOI of 20 was found to provide the highest 
transduction as evidenced by GFP expression by FACS. No reduction in cell 
viability (as measured by FACS analysis using propidium iodide) was observed with 
increasing MOI (data not shown). Although not statistically superior to an MOI of 
15 (p = 0.439), an MOI of 20 was used for future in vitro experiments.  
The above two experiments identified the optimal parameters for in vitro 
lentiviral vector transduction with the goal of facilitating maximum knockdown 
efficiency in subsequent assays. 
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Figure 3.5 Determination of optimal MOI for lentiviral transduction of HeLa cells in 
vitro. HeLa cells were transduced in culture with lentiviral particles carrying a GFP 
transgene at various MOI. The transduction efficiency as indicated by the number of GFP
+ 
cells was determined by FACS at 72 h. A) Dot plots from FACS analysis representing the 
percentage of GFP positive cells. The dot plots shown are representative of three 
independent replicates. B) Quantitative output from three replicates presented as the mean 
+/- SEM. 
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3.5.3 Lentiviral vector-mediated RNAi silencing of mFOXP3 
The validated lentiviral vector system was utilised for delivery of DNA cassettes 
corresponding to miR 4 (Lenti miR 4) or miR scr (Lenti miR scr) in in vitro assays. 
The effect of transduction of these constructs on mFOXP3 expression was examined 
by FACS in in vitro assays. Results are displayed in figure 3.6. A global picture of 
silencing efficiency can be obtained by looking at the percentage of cells that were 
mFOXP3 positive in the various samples (figure 3.6 A & B). Lenti-miR 4 
significantly reduced the number of FOXP3
+
 cells compared with lenti miR scr (11% 
+/- 1.5%, p < 0.002) and an untransduced control (8.4% +/- 1.4%, p = 0.004).  
However as outlined in Chapter 2, assessment of knockdown efficiency in 
terms of positive or negative cells may not reveal intracellular reductions in 
expression. Partial knockdown may be overlooked, although it may be sufficient for 
a phenotypic change in the cell. Thus, the FOXP3 status of cells was stratified 
according to fluorescence intensity (negative, medium and high) (figure 3.6 C). The 
graphs show a reduction in the number of highly positive FOXP3 cells following 
lenti miR4 transduction in comparison with lenti miR scr (5.8% +/- 1.8%,p = 0.033). 
The reduction in the number of cells highly expressing FOXP3 is accounted for by 
increases in the number of cells with medium expression (1.5% +/- 4%) and no 
expression at all (4% +/- 5.4%), although neither increase is statistically significant 
(p= 0.745 and p = 0.479 respectively). This suggests that, following lenti miR 4 
transduction, cells that highly expressed FOXP3 now express the protein at an 
intermediate level, while those previously displaying medium expression are now 
negative for FOXP3. 
This experiment validated lentiviral vector as an in vitro delivery vehicle for 
artificial miRNAs and confirmed that the mimic #4 sequence mediates RNAi against 
mFOXP3. 
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Figure 3.6 Effects on FOXP3 expression following transduction with lentiviral vector- 
microRNA particles in vitro. HeLa cells were transduced in culture with lentiviral particles 
carrying miR scr or miR 4 at an MOI of 20. 6 h later, cells were transfected with pFOXP3. 
After 72 h, cells were analysed for mFOXP3 expression by FACS. A) Dot plots representing 
the percentage of FOXP3
+
 cells. The dot plots shown are representative of three independent 
replicates. B) Quantitative output from three replicates presented as the mean +/- SEM. (** 
indicates p < 0.005). C) A more detailed analysis of the changes in mFOXP3 expression 
following lentiviral vector-mediated RNAi. Histograms (left panel) show the relative 
proportion of cells with negative, medium and high fluorescence intensity (P2, P3, P4 
respectively) which correlates with the level of mFOXP3 expression. Each histogram is 
representative of three independent replicates. The graphs represent the quantitative output 
from three replicates presented as the mean +/- SEM. 
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3.5.4 Lentiviral vector gene delivery in vivo 
Before attempting RNAi in vivo the first step was to confirm lentiviral vector-
mediated gene delivery to murine tumours. Reporter lentiviral particles carrying the 
luc2 gene were injected directly into s.c. B16OVA tumours. After four days, animals 
were imaged by IVIS whole body luminescence imaging. A 2 log-fold increase in 
luminescence could be detected specifically in tumours, compared with untreated 
control mice. Given the broad host range of the lentiviral vector employed, and the 
heterogenous nature of cell types within tumours, all cell types (T cells, other 
immune cells, tumour cells, fibroblasts etc) were expected to be transduced. While 
the specific cell types within the tumour which were transduced was not examined 
here, this experiment confirmed the ability of i.t. injection of the lentivirus particles 
to mediate in vivo transduction and expression of their transgene. 
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Figure 3.7 Lentiviral vector transduction in vivo. Murine xenograft tumours (flank) were 
i.t. injected with lentiviral particles carrying the luc2 transgene or PBS. Four days later, mice 
were subjected to whole body imaging. Bioluminescence is presented as a pseudocolour 
scale (right-hand side): red, the highest photon flux; blue, the lowest photon flux. 
Luminescence was detected specifically in the tumour region. A quantitative readout is also 
supplied below the image.  
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3.5.5 Determination of the optimal time to target intra-tumoural TRegs 
As a forerunner to in vivo experimentation with miR particles, the optimal time for 
tumour treatment was examined. Since intra-tumoural TReg numbers differ at various 
stages of xenograft growth, the aim was to establish the optimum therapeutic 
window to manipulate TRegs within the context of a growing tumour and so maximise 
therapeutic response. The ideal setting would require TReg infiltration prior to 
treatment but not too late in the course of the disease to ensure that tumour immune 
escape had not already taken place. 
In the absence of a non-terminal assay to determine TReg infiltration numbers, 
a reference curve of TReg number versus tumour volume for the s.c. B16OVA 
xenograft model was generated (figure 3.8). 
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Figure 3.8 Temporal analysis of intra-tumoural TReg numbers in B16OVA tumours. 
CD4
+
 and CD8
+ 
TRegs are graphed independently. TReg numbers as a percentage of total viable 
tumour cells were established by FACS analysis at various time points post induction of 
B16OVA tumours. These data were plotted against the average tumour volume for mice 
culled at that time point and the time post tumour induction. TReg numbers are plotted as the 
mean of 5 mice per time point +/- SEM. 
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A similar pattern was observed with CD4
+
 and CD8
+
TRegs albeit CD8
+
TRegs were 
generally present at a lower level (range 0.1 to 1.3% versus 0.7 to 6.6%). While 
tumour volume increased over time, the relative proportion of TRegs varied widely 
throughout the course of xenograft growth. Following an initial peak of TReg 
infiltration, numbers then declined followed by a trend towards increasing number 
again at the terminal stages of the disease.  
Since tumour volume could readily be established without the need to 
sacrifice the animal, this curve permitted estimation of the number of TRegs within a 
given tumour at a given time and hence at what tumour volume to treat. Based on the 
curve the optimal time to treat was determined to be at or before the tumour volume 
reached 0.1 cm
3
or day 8/9 post tumour induction. Identification of the optimal time 
at which to manipulate TRegs within the growing tumour provided the best chance of 
therapeutic success. 
 
3.5.6 The effect of Lenti miR 4 treatment on tumour cytokine profile 
Following identification of the optimal time to manipulate TRegs within the growing 
tumour mice were then treated with lentiviral particles carrying miR 4. Untreated 
tumour-bearing mice and mice treated with lenti miR scr served as controls. The 
hypothesis was that, following therapeutic intervention, the first detectable alteration 
would be a change in cytokine profile. 9 days post tumour induction (based on the 
TReg infiltration data) lentiviral particles were administered i.t. 4 days later all mice 
were culled at a single time point. Tumours were harvested and processed for 
cytokine analysis. The content of interferon-γ, IL-12p70, IL-1β, IL-6, mKC, IL-10 
and TNF-α was determined for each experimental tumour. Levels were quantified in 
supernatant derived from tumour homogenate using mouse pro-inflammatory 
multiplex plates. Results are displayed in figure 3.9. With the exception of a 
significant reduction in IL-1β levels (p = 0.029), administration of lenti miR 4 failed 
to invoke a globally significant change in cytokine profile relative to control animals. 
Indeed this reduction in IL-1β is contrary to the expected outcome – if mFOXP3 
knockdown had been successful one would expect a pro-inflammatory response 
which might be evidenced by an increase in IL-1β levels. Of note lenti miR scr failed 
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to invoke any detectable, significant change in cytokine profile compared with 
untreated animals. This is suggestive of the low immunogenicity of the vector itself. 
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Figure 3.9 The intra-tumoural cytokine profile following lenti miR 4 treatment 
C57 Bl/6 mice bearing s.c. B16OVA tumours were treated with lenti miR 4 or lenti miR scr. 
The cytokine profile of tumours 4 days post treatment was determined using a mouse pro-
inflammatory multiplex plate. Levels are shown only for cytokines above the limit of 
detection and expressed as the mean +/- SEM for three mice per group. Statistics compare 
the two lentiviral treatment groups where one group received miR 4 and the other received 
miR scr. * indicates p = 0.029. Sample in this context refers to a representative portion of 
each tumour corresponding to 250 µg of tissue. 
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3.5.7 Lenti miR 4 treatment effects on T cell populations 
Had there been a cytokine change as a result of functional inhibition of TRegs a 
decrease in the number of detectable TRegs along with a concomitant increase in 
immune effector populations (e.g. CD8
+
 cytotoxic T cells) would be expected 
20
. 
Nonetheless, both these T cell subsets were characterised by FACS analysis (figure 
3.10). However, as expected, no distinction in their relative abundance could be 
detected. The cytokine and T cell profiles presented confirm that further optimisation 
of the putative therapeutic and/or the experimental design are required to achieve a 
therapeutic response. 
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Figure 3.10 Intra-tumoural T cell subsets following lenti miR treatment. The relative 
abundance of different T cell subsets in tumour samples was determined by FACS analysis. 
Representative T cell populations from a mouse treated with lenti miR scr and a mouse 
treated with lenti miR 4 are compared from groups of 3 mice. Cells were stratified according 
to FOXP3 expression (left) and then analysed in terms of CD25 and either CD4 or CD8 
expression (right). P1 identifies CD4
+
, CD25
High
, FOXP3
High
 cells and represents CD4
+ 
TRegs. 
P3 identifies CD8
+
, CD25
High
, FOXP3
Low
 cells and represents CD8
+
 cytotoxic T cells. 
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3.6 Discussion  
In this chapter the goal was to advance our validated RNAi mediator from an 
experimental tool towards an in vivo therapy by combining it with a lentiviral vector 
system. This clinically relevant vector was demonstrated to be capable of delivery 
and induction of gene silencing in an in vitro system. Moreover, transduction was 
validated in an in vivo tumour model. The optimum stage in tumour progression at 
which to intervene with this and other similar therapeutic approaches was identified. 
However, within the limitations of the experimental model, no therapeutic benefit 
could be demonstrated following lentiviral delivery of an artificial miRNA targeting 
mFOXP3 in a pilot study. Further modifications of the therapeutic such as cell-
specific delivery capability coupled with improvements in experimental design 
should enhance the likelihood of success.  
 
Limitations of in vitro experimental setup: mFOXP3 was successfully silenced 
using a lentivirus vector to deliver an artificial miRNA in an in vitro system (figure 
3.6). However the knockdown efficiency was only 37% with lenti miR 4 in contrast 
to 57% with mimic #4 delivered with Lipofectamine
® 
(figure 2.6). This could in part 
be explained by the poor transduction efficiency achieved with the lentiviral particles 
(48% - figure 3.5) in contrast to the 70 % efficiency achieved with siRNA delivered 
using Lipofectamine
® 
(figure 2.4). 
The poor knockdown efficiency could be further explained by the 
experimental setup for the in vitro knockdown assay (figure 3.6). In the absence of a 
cell line that stably expressed mFOXP3 it was necessary to transfect cells with a 
plasmid carrying the target gene and also transduce cells with lentivirus carrying the 
relevant miR. The transduction and transfection of the same cells in vitro is not an 
ideal system, as one process likely interferes with the other and it requires a 
compromise between optimal conditions for both processes to succeed; for lentivirus 
transduction the optimal protocol involved seeding the cells 24 h in advance of 
transduction with maximum expression achieved after 72 h (figure 3.4); in contrast, 
maximum expression was achieved 48 h post transfection with Turbofect
®
, again 
allowing a 24 hour window after seeding (data not shown).  
 We attempted to combine these protocols without modification (transduction 
followed by transfection 24 hours later), but this proved unsatisfactory due to the 
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inability to transfect overly-confluent cells 48 h post seeding. Overall, cell viability 
was not significantly reduced however. We compromised by proceeding with 
transfection 6 h rather than 24 h post transduction. This improved transfection 
efficiency albeit not to the levels achieved under optimal conditions; transfection 
alone, under optimal conditions reached 47% of cells (figure 2.6) while transfection 
under the modified conditions and in the presence of lentivirus reached only 25.6% 
of cells (figure 3.6). Generation of HeLa cells stably expressing the miRNAs of 
interest using the lentiviral particles may have circumvented this problem as the 
optimal transfection protocol could have been followed.  
The above notwithstanding, the experimental strategy served to permit 
validation of the optimal miR from the various hypothetical sequences outlined in 
Chapter 2. 
 
In vivo transduction: Lentiviral transduction in vivo was confirmed using the luc2 
reporter gene and whole body imaging (figure 3.7). This assay did not provide any 
information as to which particular cell types within the tumour had been transduced 
however. Efforts were made to characterise which cell types had been transduced by 
FACS analysis through antibody detection of the delivered luciferase protein and a 
panel of cell-specific markers (data not shown). The absence of a robust, high 
affinity antibody against the luciferase protein made this work unachieveable 
however. Thus, we can only speculate as to what cells received lentimiR 4; Given 
that the lentiviral particles had been pseudotyped with VSV-G one would expect 
quite a broad, indiscriminate tropism
21
.  
 
miR activity: The effects of miR 4 expression within non-target (i.e. non-TReg) cells 
is largely unpredictable, but is likely to be heavily influenced by the level of FOXP3 
expression within a given cell type. Worthy of note, is that all human cancer cell 
lines tested in one study expressed detectable levels of FOXP3 
22
. It is hypothesised 
that cells expressing high levels of FOXP3 would be most responsive to miR4 over-
expression, but that FOXP3 knockdown may result in widely varying phenotypes for 
different cell types. Of concern would be the possibility that FOXP3 knockdown in 
cancer cells may be detrimental – recent reports suggest that FOXP3 acts as a tumour 
suppressor gene in breast 
23,24
 and prostate cancer
25
.  
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Limitations of xenograft model: From figure 3.8 the optimal time to treat was 
determined to be at or before the tumour volume reached 0.1 cm
3
. In practical terms, 
this related to tumour dimensions of approximately 0.6 cm x 0.6 cm. While it was 
possible to measure tumour volumes smaller than this, no samples were taken to 
determine TReg infiltration numbers as tumours were too small for FACS processing. 
It could be concluded that a day or two prior to the tumour volume reaching 0.1 cm
3 
(Day 8 or 9 post tumour induction) there were sufficient TRegs in situ for treatment 
and tumour immune evasion had not yet occurred. Intervention at this 
early/intermediate stage of disease progression is consistent with a previous study 
using diphtheria toxin to deplete TRegs in transgenic DEREG (depletion of regulatory 
T cells) mice
20
. This study also confirmed that intervention at a later time point in the 
disease had no effect on tumour volumes. Based on this, it was deduced that 
following the initial peak in TReg number within the s.c. B16OVA tumour model, 
immune control has been circumvented and therapies aimed at abrogating the 
suppressive component of the immune system would be insufficient to surmount 
anergy.  
 
Suggested reasons for therapeutic failure: Despite validation of in vivo 
transduction and optimisation of the time to target TRegs within the B16OVA tumour 
model, no therapeutic benefit could be detected at a cytokine or cellular level 
(figures 3.9 and 3.10). A number of explanations for the apparent failure of the 
therapy in vivo can be proposed; 
 
i) The experimental setup only included one sampling point – 4 days post 
lentiviral delivery directly to the tumour. Based on the whole body imaging data 
(figure 3.7) it is likely that the therapeutic artificial miRNA was expressed and most 
likely processed into the mature miR at this stage. However, it is unclear if an 
appropriate window of time was allowed for a response to FOXP3 silencing to 
manifest as an altered cytokine profile. Perhaps more pronounced alterations in 
individual cytokine levels may have been detectable earlier than day 4. The time lag 
for a cytokine response to translate into a cellular immune response is also difficult 
to predict and thus cellular changes may also have been missed by the single 
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sampling time point. Larger-scale trials including multiple sampling time points 
were beyond the practicalities of this thesis work. Future work might also look 
beyond lymphocytes and include a full immune cell profile of the tumour 
microenvironment. 
 
ii) The suitability of the tumour model may also need to be revisited. The 
B16OVA melanoma model was chosen as it represents an antigenically defined 
tumour. Thus any immune response raised against the tumour would be directed 
predominantly against a single antigen (the OVA peptide) and more readily 
detectable. However, the B16 tumour represents an aggressive model whose growth 
rate quickly outstrips its neovascularisation. This leads to a solid, vascularised outer 
tumour surrounding highly necrotic more central regions. Consequently distribution 
of lentiviral particles within the tumour and cytokine secretion throughout the 
tumour mass are highly variable and unpredictable. 
 
iii) As outlined above, it is unclear which particular cell types within the tumour 
mass were transduced. The potential exists for FOXP3 knockdown in non-TReg cells 
to nullify any potential therapeutic benefit. It is more likely that an insufficient 
number of TRegs were transduced to achieve a detectable alteration in cytokines. 
Targeted lentiviral transduction of T cells or more specifically TRegs would be one 
solution; such targeted particles promise improved efficiency of delivery to TRegs 
while simultaneously reducing off-target effects through their enhanced selectivity. 
A number of versatile platforms exist to redirect lentiviral particles (reviewed in 
section 1.3.3). Moreover the literature provides robust examples of lentivirus 
targeted to T cell surface receptors; Wang et al., have targeted the CD3 receptor 
26
 
while the Chen lab have demonstrated receptor-specific delivery via CD4 
27
. Perhaps 
the most appropriate surface receptor for targeting TRegs would be CD25 as it is 
constitutively expressed at a high level but only expressed on other T cell subsets 
following activation by antigen. Support for this receptor target comes from the 
myriad of TReg depletion studies using antibodies directed against CD25 (reviewed in 
28
). 
 
   
164 
 
iv) It is possible that the RNAi mediator was not potent enough i.e. that the level 
of FOXP3 knockdown within each cell was not sufficient to alter the TReg phenotype. 
While this was not determined for the in vivo experiment, the in vitro data would 
suggest that following lenti miR 4 delivery up to 15% of cells retain a medium level 
of FOXP3 expression (figure 3.6). It is unclear if such a level of FOXP3 expression 
can maintain the suppressive nature of TRegs. That said, if the knockdown achieved in 
vitro were to be recapitulated in vivo (with approximately 80% FOXP3 negative 
TRegs) one could predict that any immunosuppressive threshold had been overcome 
and an anti-tumour immune response would soon follow. 
 
Conclusion Conceptually the idea of treating cancer by manipulating immune 
cells (especially suppressive immune cells) is relatively novel 
29,30
. Immune-based 
therapies promise significant advantages over existing treatment modalities – 
through the generation of immunological memory distant secondaries and disease 
reoccurrences can be eradicated. The altered immune microenvironment that exists 
and indeed is fostered within a developing tumour, affords a therapeutic niche over 
the unflustered systemic immune system. In this chapter, we sought to exploit this 
niche - we present an exciting therapeutic strategy to harness the immune system to 
fight cancer by combining lentiviral vectors with an artificial miRNA. We developed 
a novel RNAi mediator against mFOXP3 but further improvements in delivery 
efficiency and specificity may be warranted. 
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Chapter 4: 
Tumour-associated macrophage targeting 
with a bacterial vector 
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4.1 Abstract 
The majority of human and mouse solid tumours feature an abundant macrophage 
population. However, despite the direct tumouricidal ability of macrophages and 
their ability to mobilise anti-tumoural immune responses through antigen 
presentation, a lack of these activities within tumours is apparent. The primary 
reason suggested for this phenomenon is the tumour-driven polarisation of 
macrophages to an M2-like phenotype, which is pro-tumourigenic. Thus, efforts to 
re-educate or re-programme the abundant tumour-associated macrophages (TAMs) 
to an anti-tumour M1 phenotype would seem meritorious, and has recently been 
validated in preclinical studies. 
NFκB signalling is central to maintaining the M2 phenotype. Inhibition of 
this transcription factor has been shown to re-educate TAMs. Targeting of IKK2, the 
major activator of NFκB, has been shown to induce significant antitumour responses 
preclinically. To date, only ex vivo transfection strategies related to this have been 
explored, and while validating this therapeutic target, possess only limited potential 
for clinical translation. This study sought to develop a more universally applicable 
strategy that could modify TAMs in situ, involving TAM-specific transfection in 
vivo.  
It was hypothesised that intra-tumoural non-invasive bacteria would serve as 
effective and specific delivery agents to TAMs. A non-pathogenic E. coli strain 
carrying a plasmid for mammalian cell expression of an IKK2 dominant negative 
protein (IKK2-DN) was designed and generated. The ability of this vector to mediate 
gene delivery to macrophages was validated in vitro in a human macrophage cell line 
using FACS analysis. I.t. administration of the therapeutic vector to growing s.c. 
tumours was examined in in vivo murine trials. TAM transfection was demonstrated 
by FACS. Cytokine profile analyses of tumours demonstrated induction of intra-
tumoural pro-inflammatory cytokines following treatment (compared with controls), 
suggesting re-education of M2 TAMs. 
This study demonstrates the utility of non-invasive bacteria as a novel class 
of TAM-specific gene delivery vector, as well as the potential for in vivo targeting of 
the NFκB pathway to re-programme TAMs, thereby switching their phenotype from 
pro- to anti-tumour. 
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4.2 Introduction 
TAMs generally follow an “M2” phenotype and play a detrimental role in cancer 
pathophysiology (section 1.1.3 above). They are found in distinct 
microenvironments within the tumour where they are co-opted by the presence or 
absence of various locally-derived signals for tumour gain; areas of invasion where 
they promote cancer cell motility, stromal and perivascular regions where they 
encourage metastasis, and in hypoxic regions where they stimulate angiogenesis 
1
. 
Moreover, TAMs resident within hypoxic tumour regions have been shown to 
increase production of matrix metalloproteinase-7 
2
. This protein cleaves Fas ligand 
on tumour cells rendering them less sensitive to chemotherapy and immune-
mediated cellular cytotoxicity 
3,4
. The behaviour of M2 macrophages within a 
growing tumour is totally at odds with that of M1 macrophages that are capable of 
tumour cell lysis, antigen presentation and stimulation of anti-tumour T and natural 
killer cell responses 
1
. Thus, re-programming macrophages to an M1 phenotype 
represented a justifiable therapeutic endeavour. 
Recent evidence from Hagemann et al suggested that the NFκB pathway was 
central to macrophage phenotype and that manipulation of this pathway could re-
programme macrophages 
5
. Activation of NFκB is regulated by the inhibitor of 
kappa B (IκB) kinase (IKK) complex of which the β-kinase (IKKβ or IKK2) is 
dominant. Following phosphorylation, IKK2 then phosphorylates IκB which is then 
degraded in the proteosome. The p65/p50 NFκB heterodimer is released, enabling 
translocation to the nucleus and inflammatory gene transcription 
6
. This signalling 
cascade can be blocked by introduction of a kinase-deficient, dominant negative 
IKK2 protein (IKK2-DN)
7,8
. This decoy protein competes with the unmodified, 
endogenous protein for binding to IκB. When IKK2-DN binds to its target, it is 
unable to phosphorylate it and the pathway is halted. In the absence of a robust 
protein delivery platform, the most robust means of delivering IKK2-DN is at a 
nucleic acid level via a genetic construct. 
Introduction of IKK2-DN into TAMs ex vivo followed by transfer of the 
modified macrophages has been shown to be effective in inducing anti-tumour 
responses.
5
. However such ex vivo manipulation lacks clinical translatability. Thus, 
we sought to combine IKK2-DN with a vector capable of in situ manipulation of 
   
171 
 
macrophages. Given the widespread expression of NFκB in different cell types a 
degree of selective delivery is required to mitigate off-target effects. 
The concept of bacteria-mediated gene therapy is not novel, and bacteria are 
known to localise to solid tumours following systemic administration
9,10
. 
Traditionally, invasive species of bacteria are used to non-specifically invade host 
tumour cells for „hand-over‟ of plasmid DNA for host cell expression of a 
therapeutic. This process (termed „Bactofection‟) is also used in vaccination 
strategies for various diseases, most commonly with oral administration of bacteria 
for the purpose of transfecting mucosal phagocytic cells to induce antigen 
presentation and antigen immune induction. 
We hypothesised that, in the context of intra-tumoural bacteria, use of non-
invasive bacteria would permit specific transfection of phagocytic cells, representing 
a novel strategy for cell type-specific targeting of tumour-related immune cells. The 
use of non-invasive bacteria promised to restrict the cell types that received IKK2-
DN to phagocytic cells such as macrophages.  
 
4.3 Study Aim 
The aim of this study was to assess the potential of MG1655, a non-invasive E. coli 
strain, to mediate bacterial gene therapy to tumour-associated macrophages. A 
second, dependent aim was to re-educate tumour-associated macrophages by 
inhibition of the NFκB pathway through non-invasive bacterial delivery of IKK2-
DN. 
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4.4 Materials & Methods 
4.4.1 THP-1 cell culture 
THP-1 cells were maintained in RPMI 1640 medium (Sigma-Aldrich) supplemented 
with 10% v/v foetal bovine serum (Sigma-Aldrich) and 2mM L-glutamine in the 
absence of antibiotics in a 37
0
C incubator with 5% CO2. 
 
4.4.2 Differentiation of THP-1 monocytes 
THP-1 cells were differentiated using a protocol modified from that previously 
published by Takashiba et al 
11
. Briefly 2x10
5
 cells were seeded per well of a 24-well 
plate in 1 ml media. PMA (eBioscience) diluted in DMSO was added to a final 
concentration of 200nM. Cell adherence and a spreading morphology were 
confirmed using a light microscope. After 24 h the media was changed and cells 
were allowed to recover for 48 h before further experimentation.  
 
4.4.3 Generation of bacterial vectors 
E.coli K12 MG1655 was used in all experiments (UCC culture collection). For in 
vitro work a GFP plasmid (pMAX-GFP, Amaxa, USA) under the control of a 
eukaryotic promoter was introduced into this strain by electro-transformation. 
For optimal transfection efficiency, hlyA-expressing bacteria are commonly 
employed; the hlyA gene derived from Listeria monocytogenes encodes the pore-
forming listeriolysin O protein, which facilitates phagosome escape, and has been 
previously shown to significantly increase bacterial vector mediated transfection 
efficiency
12
.For all in vivo work, a hlyA-expressing E. coli MG1655 strain (referred 
to as E. coli hereafter) was employed; MG1655 was transformed with a hlyA plasmid 
(pNZ44 - generated by Dr. Joanne Cummins, Cork Cancer Research Centre). 
E. coli was transformed with the therapeutic plasmid carrying a kinase-
negative mutant of IKK2 (IKK2-DN) – a kind gift from Dr. Rainer de Martin7. 
GFP and IKK2-DN genes were driven by eukaryotic promoters. Presence of 
the hlyA and therapeutic plasmid in the bacteria was confirmed by colony PCR to 
detect the hlyA and ampicillin resistance genes respectively.  
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4.4.4 Preparation of bacteria for in vitro and in vivo gene delivery 
The appropriate bacterial stock was inoculated into 10 ml LB-broth with antibiotic 
selection and grown overnight (~16 h) at 37
o
C, shaking at 200 rpm. The optical 
density of the culture was measured at a wavelength of 600 nm (OD600) and the 
culture then diluted to an OD600 = 0.1. The culture was grown for a further 2-3 h at 
37
o
C, shaking at 200 rpm and the bacteria harvested when the OD600 reached 0.8-1.0. 
1ml of the culture was then pelleted by centrifugation (13500 rpm for 1 min), the 
pellet was washed twice in PBS and resuspended in 1ml PBS. The concentration of 
this solution had previously been determined to be approximately 1x10
9
 CFU/ml. 
This stock solution was then diluted in PBS to the appropriate concentration.  
 
4.4.5 Bacterial gene delivery to differentiated THP-1 cells 
Bacteria carrying pMAX-GFP were prepared as above and added directly to the 
differentiated THP-1 cells at different multiplicities of infection (MOI). In all 
experiments, cells and bacteria were co-incubated overnight for 16 h. 
The efficacy of gene delivery was indicated by the number of GFP
+
 cells as 
determined by FACS analysis. FACS was performed as previously outlined (section 
2.4.11) with some modifications to the cell preparation steps; the adherence of the 
cells to the plate was broken by incubating in PBS with 5mM EDTA for 10-20 mins 
and pipetting up and down vigorously.  Cells were resuspended in PBS with 10% 
FBS to prevent clumping.  
The time window after bacterial exposure and before FACS analysis was 
deemed an important parameter for maximal detection of GFP expression. Thus, two 
different time windows were explored; in one strand of the experiment, the culture 
media was changed following overnight incubation with the bacteria and the cells 
were rested for 8 h prior to analysis. In a second strand of the experiment, cells were 
rested for 24 h before analysis. In this latter experiment, extracellular bacteria were 
killed with gentamicin (20mg/ml for 2 h) in an effort to preserve the viability of the 
macrophage cells. 
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4.4.6 Tumour induction and bacterial delivery in vivo 
6 week old female Balb/C mice (an immuno-competent strain) were anaesthetised 
and their right flanks shaved. The minimum tumourigenic dose (1x10
5
 cells) were 
injected s.c. into the right flank to induce the mouse CT26 colon tumour model. 18 
days post tumour induction mice were injected intra-tumourally at three different 
sites with a total dose of 1x10
6
 CFU of bacteria in a 100µl volume using a 32 gauge 
needle.  
 
4.4.7 Monitoring bacteria within a growing tumour 
1x10
6
 CFU of E. coli MG1655 with an integrated lux cassette (driven by a bacterial 
promoter) were injected into growing CT26 tumours in a 100µl volume using a 32 
gauge needle. At various time points mice were anaesthetised and subjected to whole 
body imaging using an IVIS imaging system (Perkin Elmer). 
 
4.4.8 Detection of gene delivery  
The therapeutic IKK2-DN protein was FLAG-tagged which permitted detection with 
an antibody and FACS analysis to determine which cells had been reached. A single 
cell suspension was derived from the tumour as outlined previously (section 3.4.8) 
and intracellular FACS staining carried out as per section 2.4.11. The following 
antibodies and test concentrations were used; F4/80-PE (clone BM8) (eBioscience, 
0.2 µg/test), anti-CD68-PerCP/Cy5.5 (clone FA-11) (Biolegend, 0.25 µg/test) and 
anti-FLAG Alexa Fluor 647 (Cell signalling, 1 in 450 dilution). 
 
4.4.9 Assessing cytokine profile  
As per section 3.4.10. 
 
4.4.10 Monitoring tumour progression 
As per section 3.4.5. 
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4.4.11 Statistical analysis 
As per section 3.4.11.
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4.5 Results 
4.5.1 E. coli MG1655 mediates gene delivery to macrophages in vitro 
To demonstrate proof of principle for non-invasive bacterial gene delivery to 
macrophages in vitro, the human THP-1 monocyte cell line was differentiated into 
macrophages and exposed to a bacterial strain carrying a plasmid encoding GFP 
under the control of a eukaryotic promoter. Transfection was assessed by FACS 
analysis for detection of GFP
+
 cells. 
Results shown in figure 4.1 demonstrate close to 100% transfection 
efficiency on viable cells following bacterial exposure at an MOI of 2.5 to 10, 
regardless of the time window between bacterial exposure and FACS analysis (see 
Materials and Methods 4.4.5 above). Cytotoxicity was clearly detectable under a 
light microscope at higher MOIs of 20 and 30 (data not shown) and, despite gating 
on viable cells, transfection efficiency was diminished by 90% (figure 4.1 A).  
A longer time window of 24 h after bacterial exposure and before FACS 
analysis resulted in greater macrophage cell death (data not shown).In an attempt to 
reduce macrophage cell death caused by bacterial replication, an antibiotic strategy 
for elimination of live bacteria was assessed. However, the use of gentamicin in this 
context was ineffective and did not influence the number of dying macrophages (data 
not shown). It is likely that cell death pathways had already been engaged in the 
macrophage cells.  
Overall, these data demonstrated the ability of this non-invasive bacterial 
vector to mediate efficient transfection of macrophages. 
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Figure 4.1 Bacterial-mediated transfection in vitro. The THP-1 monocyte cell line was 
differentiated into a macrophage-like phenotype and exposed to E.coli MG1655 carrying a 
GFP plasmid at different multiplicities of infection. Macrophages were allowed to recover 
for 8 h (A) or 24 h with gentamicin treatment (B). FACS analysis on viable cells was used to 
determine the number of GFP
+
 cells. Data presented are representative of three independent 
replicates.  
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4.5.2 Analysis of intra-tumoural viable bacterial vector in vivo 
Prior to initiating murine therapeutic trials, the fate of bacterial vector following i.t. 
injection to s.c. tumour xenografts was examined. It would be expected that a portion 
of the administered bacteria would i) be scavenged by phagocytic cells within the 
tumour, ii) leave the tumour and disseminate throughout the animal and/or iii) 
colonise the tumour microenvironment. 
To provide data towards answering these questions, 1 x10
6
 CFU MG1655 
carrying the lux cassette were injected into s.c. CT26 tumours in mice and monitored 
in vivo using whole animal imaging (figure 4.2). Since in this case expression of the 
lux reporter cassette was driven by a bacterial promoter, luminescence was indicative 
of live bacteria, rather than transfected cells. Thus detection of luminescence did not 
indicate whether the bacteria were intra- or extra-cellular. Figure 4.2 indicates that 
administered bacteria specifically colonised the tumour over time and continued to 
survive/grow within this microenvironment. This indicated that not all administered 
bacteria were phagocytosed. (Transfection was examined in subsequent 
experiments). No bacterial luminescence was detected elsewhere in the body, 
suggesting no significant spread of the vector. The reduction in luminescence 
detected at day one was interpreted as initial death of bacteria post injection. 
Thereafter bacterial replication commenced and luminescence increased accordingly. 
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Figure 4.2 Fate of i.t. administered bacteria in mice. 1x10
6
 MG1655 bacteria carrying the 
lux cassette were administered directly into growing CT26 tumours. Viable, luminescent 
bacteria were detected at various time points specifically in the tumour using whole body 
imaging. Bioluminescence is presented as a pseudocolour scale (top, right): red, the highest 
photon flux; blue, the lowest photon flux. A) Average luminescence in p/sec/cm
2
/sr is shown 
in parentheses. An untreated, tumour-bearing animal was imaged at each time point and is 
shown as a control. B) Graphical representation of tumour luminescence over time plotted as 
the mean +/- SEM for three mice. 
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4.5.3 Gene Delivery in vivo 
To provide evidence of gene delivery in vivo, bacteria bearing a plasmid encoding a 
FLAG-tagged protein under the control of a mammalian promoter were i.t. 
administered to s.c. CT26 tumours. FLAG expression was possible only following 
uptake of the bacteria by a mammalian cell and detection of FLAG by FACS was 
taken to be indicative of hand-over of the plasmid-borne gene from bacterial vector 
to, and expression by host mammalian cells. The cell type transfected was examined 
using antibody markers specific for macrophages.  
Tumours were harvested two days post treatment and a single cell suspension 
generated. Cells were labelled with appropriate antibodies. FACS analysis is 
displayed in figure 4.3. The TAM population was selected for analysis through 
gating on both CD68 and F4/80. Having gated on double positive macrophages the 
number that were FLAG
+
 (transfected) cells was determined. Compared with the 
control animal where the bacteria did not carry FLAG plasmid, approximately 20% 
of TAMs were FLAG
+ 
(66 versus 46.4) (figure 4.3A, right). Further characterisation 
of bacteria as in vivo gene therapy vectors might involve assessment of their 
capability to recruit phagocytic cells to the tumour. This extra information could be 
readily extracted from the above experimental setup by inclusion of a third group 
which did not receive any bacteria. 
As the goal was to specifically transfect TAMs it was also important to 
determine how selective the bacteria were as a delivery vector. For this, all cells 
were gated in terms of FLAG positivity (figure 4.3B, left) and then analysed through 
macrophage markers (figure 4.3B, right). Within the confines of this pilot study 17% 
of all cells in the tumour were deemed to be transfected by the bacteria. Of these, 
20% were definitely macrophages (stained double positive) while another 10% (Q1 
and Q4) could also be of macrophage origin. 68% of FLAG
+
 cells (Q3) were not 
positive for either macrophage marker however. The FLAG 
+
 cells were detected at 
day two only. No FLAG
+
 cells could be detected at day four or beyond (figure 4.3 
and data not shown). 
This experiment demonstrated the ability of non-invasive bacteria to transfect 
TAMs in vivo and provided further information as to the cell-specificity of this 
delivery strategy. 
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Figure 4.3 Bacterial-mediated gene delivery in vivo. E.coli +/- FLAG-tagged plasmid 
were i.t. administered directly to CT26 tumours. Two days later, tumours were harvested and 
individual cells analysed for TAM transfection by FACS detection of FLAG. A) % FLAG
+
 
TAM: CD68
+
F4/80
+
 TAMs (left) were gated on FLAG positivity (right). B) % FLAG
+ 
which are TAM; FLAG
+
 cells (left) were gated on macrophage markers (CD68 and F4/80) 
(right). Each panel shows data from a single representative animal. 
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4.5.4 Influence of in vivo therapeutic gene delivery on intra-tumoural 
cytokine profiles 
Confident that the bacteria were capable of transfecting 20% of TAMs in the tumour, 
it was then examined if the therapeutic strategy could alter the immune phenotype 
within the tumour. E.coli +/- the IKK2-DN encoding plasmid, or PBS was i.t. 
injected to growing CT26 tumours. The cytokine profile within the tumour was 
assessed at three time points post treatment. Results are displayed in figure 4.4.  
Greatest differences overall were observed four days post treatment, and 
statistics for this time point are displayed in figure 4.4 (right panel). At day four, a 
significant change in cytokine levels could be attributed to the IKK2-DN gene. 
Cytokine changes invoked within the tumour involved significantly increased 
(p<0.05) IL-12, IL-1β, IL-6 and mKC, which is consistent with a pro-inflammatory 
response. 
The possibility that administration of E.coli without the IKK2-DN gene could 
also induce a change in cytokine profile was also explored (figure 4.4.). The effect of 
the bacterial vector alone was assessed by comparing the E.coli treatment group with 
mice that received PBS. The cytokine levels in the bacterial vector group varied 
widely across the different time points. For clarity each cytokine was interpreted 
individually; for IFN-γ the decrease at day 4 and the increase at day 7 were 
insignificant (p = 0.091 and p = 0.145 respectively). For IL-12p70 the decrease at 
day 7 was not significant (p = 0.234). The increase seen at day 7 for IL-1β was not 
significant (p = 0.102).  
The increases in IL-6 levels between PBS and E.coli groups at day 2 and day 
7 were not statistically significant (p = 0.245 and p = 0.05 respectively). Notably 
however, the further increases seen in IL-6 at these time points due to the IKK2-DN 
plasmid were not significant either (p = 0.509 and p = 0.796 respectively) and thus 
the change in IL-6 was attributed solely to the vector. This contrasts with IL-6 levels 
on day 4 where an increase can be attributed directly to the IKK2-DN plasmid (see 
above). 
The increases in mKC (PBS compared with E.coli) at day 2 and day 7 were 
statistically significant (p = 0.033 and p = 0.036 respectively). However inclusion of 
the IKK2-DN plasmid (PBS compared with E.coli + IKK2-DN) was not significant 
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at day 2 (p = 0.135) but significant at day 7 (p = 0.027). however on closer 
inspection the change attributable to IKK2-DN compared with the vector alone at 
day 7 was not significant however (p = 0.731). Therefore the changes in mKC at day 
2 and day 7 were attributed solely to the vector. This contrasts with mKC levels on 
day 4 where an increase can be attributed directly to the IKK2-DN plasmid (see 
above). The increase in mKC due to the bacterial vector alone on day 4 was not 
significant (p = 0.114).  
Overall, these data demonstrate that, with the exception of an increase in 
mKC at day 2 and day 7, the bacterial vector had a minimal effect on the intra-
tumoural cytokine profile. In contrast the bacterial vector carrying IKK2-DN 
induced a significant change in the cytokine profile (p < 0.05) within the tumour.  
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Figure 4.4 Cytokine profile following bacterial delivery of IKK2-DN. Balb/c mice 
bearing s.c. CT26 tumours were treated with PBS, E.coli or E.coli + IKK2-DN plasmid. The 
cytokine profile within the tumour was determined using a mouse pro-inflammatory 
multiplex plate. Levels are expressed as the mean +/- SEM for 3 mice per group. The left 
panel displays individual cytokine profiles at three distinct time points post bacterial 
administration. The right panel focuses on day four where the greatest change in cytokine 
levels was detected. Statistics compare the two bacterial treated groups where one group 
received the therapeutic IKK2-DN gene and the other did not. *indicates p< 0.05. 
**indicates p< 0.005. Sample in this context refers to a representative portion of each 
tumour corresponding to 250 µg of tissue. 
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4.5.5 Influence of in vivo therapeutic gene delivery on tumour growth 
To determine if this immune response translated to a gross tumour growth response, 
tumour volume was monitored for 14 days following bacterial administration. No 
change in tumour volume could be detected between the different groups. At any 
time point a significant difference in average tumour volume could not be detected 
between PBS and E. coli groups (p > 0.257) or between E. coli and IKK2-DN groups 
(p > 0.327) (figure 4.5).  
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Figure 4.5 The effect of NFκB pathway modulation on tumour growth. Balb/c mice 
bearing s.c. CT26 tumours were treated with PBS, E.coli or E.coli carrying an IKK2 
dominant negative plasmid. Tumour volumes were determined at various time points and 
expressed as the mean +/- SEM (n=3 mice per group).  
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4.6 Discussion  
 
In this study proof of principle was demonstrated for the use of non-invasive bacteria 
as gene delivery vectors to immune cells. Delivery capability was initially validated 
in vitro using a differentiated human monocyte cell line and this could be replicated 
in vivo using a subcutaneous tumour model. Evidence was also supplied of an 
enhanced anti-tumour immune response secondary to bacterial delivery of a 
therapeutic gene – this response can most likely be attributed to an altered 
macrophage phenotype due to manipulation of the NFkB pathway. It is anticipated 
that further improvements to this therapeutic approach will pave the way for reduced 
cancer morbidity and extended survival in pre-clinical models and beyond. 
 
Bacterial vector colonises the tumour; The hypothesis that non-invasive bacteria 
could be used as gene delivery vehicles to reach phagocytic cells was tested. Proof of 
principle was demonstrated in vitro but before in vivo validation the behaviour of 
non-invasive and non-pathogenic bacteria following intra-tumoural injection was 
characterised. It was important to know if the bacteria would survive in this 
environment and if so would they colonise? Figure 4.2 confirmed that the bacteria 
colonised the tumour. This represented an important issue in designing the 
therapeutic protocol; colonisation implied that a steady supply of the bacteria and 
hence the therapeutic would be available to phagocytic cells in the tumour. This 
suggested that a single bacterial administration would be sufficient and that re-
treatment would not be required. That said whole animal imaging did not provide 
any information as to which regions of the tumour (e.g. viable or non-viable) had 
been colonised. This represents an important question for further development of a 
therapeutic protocol (see below). Such a question could be readily answered using 
immuno-histochemical techniques.  
 
TAM modulation in situ; The work in this study is predicated upon a previous study 
where the phenotype of macrophages was manipulated ex vivo by two different 
methods
5
; bone marrow-derived macrophages (BMDMs) were harvested from mice 
carrying a “floxed” IKK2 allele and transduced with adenovirus carrying a Cre 
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recombinase to generate IKK2-null macrophages. Alternatively BMDMs or TAMs 
were infected with adenovirus carrying a dominant-negative inhibitor of IKK2 
(IKK2-DN). The therapeutic potential of NFκB manipulation in macrophages was 
demonstrated in the ability to induce regression of existing tumours. However their 
approach depended on ex vivo transduction of sorted macrophages as no in vivo cell-
specific delivery mechanism was furthered. Recovery of TAMs from the majority of 
patient tumours is not feasible but interestingly the same therapeutic benefit could be 
achieved using syngeneic bone marrow-derived macrophages (BMDMs). It is 
important to note that IKK2 targeting in BMDMs most likely did not represent re-
education as these macrophages are unlikely to be polarised – rather IKK2 targeting 
prevents their polarisation when they reach the tumour. That said, autologous 
transplants of ex-vivo-modified BMDMs are laborious and technically-demanding 
and may not be financially feasible.  
Hence a strategy to reprogramme TAMs from an M2 to an M1 phenotype in 
situ was devised. This strategy was successful to a certain extent, although only 20% 
of TAMs were reached. The reason for this relatively low transfection efficiency of 
the target population may rest in the dissimilar localisation patterns of macrophages 
and bacteria within the tumour; although still a contentious topic, bacteria are 
thought to localise to hypoxic regions (reviewed in section 1.3.4); macrophages on 
the other hand are widely disseminated throughout the tumour mass although TAMs 
have been found within the hypoxic regions of a wide array of human tumours and 
experimental models 
1
. However if the bacteria localise only to hypoxic regions the 
remaining non-hypoxic macrophages will remain untransfected. 
 
Selectivity of delivery strategy; Perhaps of greater concern than the low transfection 
of macrophages is the knowledge that of the 17% of FLAG
+
 cells only 20% were 
macrophages. Enumerating a further 10% as macrophages due to non-concordance 
between the CD68 and F4/80 markers 70% of the cells transfected can still be 
defined as non-target cells (figure 4.3B). This could be anticipated however; 
choosing a non-invasive strain of bacteria was predicted to substantially restrict 
expression of the transgene. Only phagocytic cells which scavenged the bacteria 
would receive the transgene and large populations of tumour cells and lymphocytes 
for example would be exempt. However no means to limit phagocytosis or 
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expression to one particular phagocytic cell type were included. Other phagocytes 
such as dendritic cells are predicted to constitute the majority of the remaining 70% 
of FLAG
+
 cells. How these other phagocytes respond to NFκB pathway modulation 
remains to be fully elucidated. In the broader sense however it should be noted that 
reaching these other non-target phagocytic cells may be beneficial in the context of a 
non-specific activation the immune system within the tumour microenvironment.  
 
Interpretation of the cytokine response; Regardless of the cellular origin, the 
cytokine profile achieved of increased IL-12, IL-1β, IL-6 and mKC was consistent 
with a pro-inflammatory phenotype and could be expected to invoke an anti-tumour 
immune response. IL-12 provokes a T helper 1 immune response and is known to 
increase the proliferation and cytotoxicity of T and natural killer cells 
13
. Indeed 
over-expression of IL-12 from macrophages introduced with human prostate cancer 
cells into mice enhanced MHC expression in TAMs with subsequent increased T cell 
infiltrate and anti-tumour immune response 
14
. The IL-1 cytokines, of which IL-1β 
greatly predominates, upregulate adhesion molecules on vascular endothelial cells 
and stimulate production of chemotactic cytokines such as IL-8 
15
. This aids in the 
attachment of lymphocytes to the endothelium where they extravasate and migrate 
into the tumour mass. IL-1β is also a significant stimulator of IL-6 production by 
other cells. Although IL-6 is considered a T-helper 2 cytokine it can be involved in 
tumour rejection by augmenting eosinophil function and promoting B cell antibody 
production
16
. mKC, also known as CXCL1, is thought to play a role in 
tumourigenesis and tumour progression
17
. Thus the elevated levels are difficult to 
rationalise in the context of increased levels of the other anti-tumour cytokines. 
Taken together, this cytokine milieu would be expected to promote tumour 
regression. Indeed induction of a similar pro-inflammatory cytokine response (IL-
12
high 
and IL-10
low) invoked solely by modulation of the NFκB pathway in 
macrophages inhibited tumour growth as detected by luminescence in an ID8-luc 
ovarian model 
5
. This benefit could not be rationalised by the transient elevation in 
nitric oxide production and compelling evidence was advanced to support an IL-12-
mediated increase in natural killer cell recruitment.  
Demonstration of reduced IL-10 (or indeed TNF-α) levels within the tumour 
following IKK2-DN delivery would further support a change in immune response. 
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However, even in the untreated animals IL-10 was below the level of detection (0.3 
pg/µl). Therapeutic success would be expected to further reduce IL-10 levels 
rendering it more difficult to detect IL-10 in treated animals. Inclusion and detection 
of spiked controls (purified IL-10 protein with tumour homogenate) in the assay 
protocol rules out the possibility of anything in the tumour homogenate masking and 
hence blocking the detection of IL-10. Thus the inability to detect IL-10 was not 
attributable to a technical issue with the assay. Rather it would seem the levels were 
genuinely low within the tumour. Indeed levels lower than 0.3 pg/µl could be 
deemed inconsequential in terms of the global immune response.  
 
Limitations of this experimental strategy; While inhibition of tumour growth was 
observed in the aforementioned study, no change in tumour growth was detected in 
this study. Explanations for this include the different tumour models employed, the 
different strategies for monitoring therapeutic responses and the persistence of the 
different therapeutic strategies investigated; 
i) This study used the CT26 s.c. xenograft model which displays a rapid 
growth rate, providing only a short window of opportunity for therapeutic 
intervention and monitoring of responses (< 2 weeks). This is in stark contrast to the 
slow growing ID8 model employed by Hagemann et al where this window stretches 
to nearly 8 weeks. 
ii) While an altered cytokine profile was detected tumour volume was the 
only parameter employed to assess the consequences of this in terms of a global 
tumour response. This parameter represents a poor indicator of cell viability as live 
and dying/metabolically inactive cells are measured indiscriminately. FACS analysis 
of apoptotic markers would be useful to indicate if the therapeutic strategy had 
invoked cell death. Alternatively measurements of tumour density such as those 
undertaken clinically by MRI may provide evidence of therapeutic success at a 
whole tumour level. Furthermore an expanded study, incorporating a survival curve 
may generate further evidence of therapeutic benefit. Moreover tumour volume was 
determined rather subjectively using a callipers to measure externally in two 
dimensions. This approach does not account for subtle changes in tumour depth. 
In contrast Hagemann et al used the ID8-luc ovarian cancer model where 
tumour progression/regression was indicated by changes in luminescence. Non-
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viable cells were omitted as they were incapable of expressing the luciferase gene 
necessary for light and hence the resolution was likely far superior. Indeed with the 
advent of newer, more powerful optical imaging technologies as few as 3 
luminescent cells can be detected in the live mouse 
18
. In the absence of a 
luminescent CT26 model, the intervening steps in the therapeutic response (between 
cytokine changes and a macroscopic tumour response) could be followed; as 
reported an IL-12-driven increase in natural killer cell recruitment could be detected 
by FACS 
5
.  
iii) Hagemann et al introduced genetically manipulated macrophages into the 
tumour microenvironment. One could reasonably expect that large numbers of these 
macrophages would remain viable and this is borne out by the cytokine profile which 
is still skewed towards an M1 phenotype 14 days later. This sustained alteration in 
the cytokine balance is likely to lead to the recruitment of other immune cells (such 
as natural killer cells) with a subsequent macroscopic tumour response (as observed). 
In contrast bacteria were directly administered to the tumour microenvironment to be 
scavenged by phagocytic cells in this study. Although the bacteria colonised the 
tumour (figure 4.2) expression of the therapeutic plasmid was short-lived following 
delivery in this fashion as the FLAG-tagged protein could be detected in 
macrophages at day 2 but not day 4 after bacterial administration. This is supported 
by the cytokine data, where, allowing for a time lag between IKK2-DN expression 
and a cytokine response, a pro-inflammatory response could be detected at day 4 but 
had subsided by day 7. Thus the transient interruption of NFκB signalling and 
cytokine alteration may have been insufficient to induce a global tumour response. It 
is also likely that manipulation of just 20% of TAMs was insufficient to achieve a 
global tumour response.  
The transient expression of the FLAG-tagged IKK2-DN protein and short-
term cytokine alteration appears to contradict the colonisation data. However this 
phenomenon may be rationalised by the contrasting localisation patterns of the 
bacteria and TAMs – TAMs are predominantly found within viable, well-
vascularised compartments while the bacteria are thought to prefer hypoxic regions 
in the tumour. The bacteria and TAMs may well have been co-localised in a viable 
region following initial intra-tumoural introduction of the bacteria and this would 
explain the initial FLAG expression and detection. However it is likely that the 
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bacteria did not survive long term and/or were scavenged by phagocytic cells in 
these viable regions and their number was significantly depleted. In contrast bacteria 
within hypoxic regions thrived and were unhindered by phagocytic cells such as 
macrophages. It is these bacteria that are likely represented by the colonisation data 
at later time points (e.g. day 5 in figure 4.2).  
 
Therapeutic improvements; Improvement upon this therapeutic approach could be 
attempted from many angles. Although not justified based on the colonisation 
evidence one way of dealing with the transient nature of the intervention would be to 
retreat perhaps two or three days later with the hope of targeting viable tumour 
regions and maintaining the altered cytokine profile. As alluded to earlier, the 
indiscriminate delivery to many phagocytic cell types could prove problematic – this 
could be overcome by use of a macrophage-specific promoter such as the proximal 
part of the CD68 promoter 
19
. Increasing the potency with which the therapy blocks 
the NFκB signalling pathway could enhance the pro-inflammatory response and 
hence the disease outcome. Potency might be improved by use of an RNAi mediator 
against IKK2 for example. 
 
Conclusion; In summary, the concept presented in this study represents a paradigm 
shift in the approach to gene therapy. Since its inception as an experimental therapy, 
gene therapy has exclusively focused on delivery vectors as active agents and 
explored methodologies to enhance both their efficacy and specificity of delivery to 
target cells 
20
. Although the vector employed in this study has the capability to 
actively seek out the target organ, once within the hypoxic tumour 
microenvironment, it can be viewed as a passive delivery agent, prey waiting to be 
scavenged by predatory phagocytic cells. The stereotypical vector-target cell 
interaction is reversed with the target cell instigating the engagement. The immune 
response to a bacterial infection is hijacked for therapeutic gain. To our 
knowledge,this is the first employment of non-invasive bacteria for gene delivery to 
cells within tumours. A credible path for clinical translation of therapeutics targeting 
NFκB signalling in macrophages is offered. Moreover the data presented here 
support this gene therapy approach for macrophage manipulation in cancer, yet the 
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approach could easily be extended to other settings such as infectious disease or 
autoimmune conditions. 
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Chapter 5: 
Conclusions and Future Directions 
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Overall, the work presented here describes two novel approaches to abrogating the 
tumour-induced immune suppression that constrains the immune response to a 
tumour. The work can be subdivided based on the target cell population - regulatory 
T cells or tumour-associated macrophages; 
 
1) Targeting regulatory T cells 
 An in vitro mFOXP3 expression assay was developed and optimised 
 An endogenous miRNA (miR-31) wasinvestigated as a potential RNAi 
mediator against mFOXP3 and confirmed to be incapable of silencing this 
target, in contrast to its human homologue 
 Novel RNAi mediators were designed and tested, and two candidates were 
confirmed to significantly silence mFOXP3 
 The best candidate RNAi mediator, in addition to a novel, validated 
scrambled siRNA, were embedded within DNA-based artificial miRNA 
cassettes 
 The artificial miRNA cassettes were incorporated into lentiviral vector 
particles 
 Lentiviral vector gene delivery parameters were optimised in vitro 
 Lentiviral-mediated artificial miRNA knockdown was achieved against 
mFOXP3 in vitro 
 Lentiviral-mediated gene delivery to a growing B16OVA tumour was 
established using an FLuc reporter gene construct 
 The optimal time to target TRegs within this tumour model was identified 
 Mice were treated intra-tumourally with lentiviral vector carrying the 
artificial miRNA and therapeutic responses analysed. However, no 
significant therapeutic response was observed. 
 
2) Targeting tumour-associated macrophages 
 Non-invasive bacteria were shown to mediate „spontaneous‟ gene delivery to 
macrophages in vitro 
 Following intra-tumoural injection, non-invasive bacteria were confirmed to 
colonise the tumour 
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 In vivo transfection of tumour-associated macrophages by non-invasive 
bacteria was established and the selectivity of this delivery strategy 
investigated 
 A pro-inflammatory cytokine response was invoked within the tumour 
following bacterial delivery of a gene targeting the NFκB pathway suggesting 
„re-education‟ oftumour-associated macrophages 
 
The outputs from this project provide much justification for continuation of this 
work. With regard the Treg targeting approach, while no therapeutic response was 
observed within the limitations of the model utilised, the data generated suggest 
value in the strategy. The RNAi mediator identified was shown to be highly effective 
in vitro, and it was successfully incorporated into a robust artificial miRNA system. 
This system minimises any potential issues with intra-cellular processing by the 
endogenous RNAi machinery. ,It seems likely that the success of the putative 
therapeutic in vivo was undermined at the delivery stage, in terms of insufficient 
numbers of transduced target cells. Future work might involve utilisation of 
modified or indeed alternative vector systems. The artificial miRNA system confers 
flexibility such that the RNAi mediator can readily be incorporated into most vector 
systems. The future deployment of a targeted lentiviral vector system would improve 
both the efficiency and specificity with which the RNAi mediator is delivered to the 
target, regulatory T cell population and would seem especially justified. 
 
Similarly, the targeting of tumour-associated macrophagesfor therapeutic benefit 
appears very promising. The use of non-invasive bacteria as a delivery vector to 
reach this population represents a novel concept in gene therapy whereby the vector 
is passive rather than active. Proof of delivery was demonstrated and an 
immunological response was identified following delivery of a validated therapeutic 
gene. Thus, future work would involve refinements to this therapeutic strategy; other 
bacterial strains could be explored with a view to improving delivery efficiency, a 
more potent therapeutic could be employed, while incorporation of a macrophage-
specific promoter would improve selectivity of gene expression. Any future work 
would benefit from a more sensitive in vivo tumour model such as the ovarian ID8-
luc2 model, which features an abundance of TAM. While a cytokine response was 
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readily detectable using the CT26 tumour model, macroscopic tumour improvements 
were difficult to discern. A more sensitive model would better guide therapy 
optimisation. Moreover, the advent of transgenic “reporter mice” coupled to 
improvements in optical imaging technology promise more powerful in vivo models 
of cancer and its treatment. Of relevance to this work is the emergence of NFκB 
reporter mice. Adoptive transfer of sorted macrophages from these mice to “non-
reporter” animals with growing ID8-luc2 tumours would provide aformidable tool 
for assessment of the therapeutic response at both the gene (NFκB) and macroscopic 
tumour level (luminescence) simultaneously. 
 
Another future project might involve combining aspects of both therapeutic 
strategies explored in this thesis. The recent identification of a population of 
FOXP3
+
 macrophages within the tumour microenvironment presents this 
opportunity. Although the contribution of this population to the dynamic interplay 
between cancer and the immune system is still being characterised, it is suggested 
that silencing FOXP3 expression would also be beneficial. Thus combining the 
validated RNAi mediator with the bacterial vector system would seem rational.  
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